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ABSTRACT 
 
New Diazo Reagents and Applications of β-Lactones for Synthesis and Biological 
Evaluation of Natural Products. (December 2011) 
Supakarn Chamni, B.S., Thammasat University 
Chair of Advisory Committee: Prof. Daniel Romo 
 
Natural products are essential tools for basic cellular studies leading to the 
identification of medically relevant protein targets and the discovery of potential 
therapeutic agents. We have developed a set of second-generation diazo reagents with 
small steric footprints, namely an α-trifluoroethyl (HTFB) diazo reagent, for 
simultaneous arming and SAR studies of bioactive natural products. The Rh(II)-
catalyzed O−H insertions of several alcohol-containing natural products, including the 
potent translation inhibitor lactimidomycin, are investigated and useful reactivity and 
both chemo- and site- (chemosite) selectivities are observed. The α-trifluoroethyl diazo 
reagents (HTFB) shows clear differences in the IL-2 reporter assay with FK506 
derivatives and provides greater retention of biological activity in a hMetAP2 
proliferation assay of fumagillol derivatives compared to the first generation p-
bromophenyl diazo reagent (HBPA). The synthetic utilities of the new α-trifluoroethyl 
diazo reagent (HTFB) provide a great new tool for basic cellular studies facilitating the 
discovery of new drug candidates for human disease. 
 iv 
Furthermore, we are interested in methodologies for β-lactone synthesis and 
transformations. In this study, we demonstrated synthetic versatilities of β-lactones for 
the synthesis of β-lactam congeners of orlistat as fatty acid synthase inhibitors via SnCl4-
promoted tandem Mukaiyama aldol-lactonization (TMAL) reaction and a one-pot, mild 
conversion of β-lactones to β-lactams. The inhibitory activities of the derived β-lactam 
derivatives are determined in a biochemical fluorogenic assay using recombinant FAS-
TE, and the micro-molar range FAS-TE inhibitory activities were observed.  
Additionally, we pursued synthetic studies toward the total synthesis of 
spongiolactone, which is a unique β-lactone-containing marine diterpenoid, isolated 
from the marine sponge Spongionella gracilis. This natural product bears a unique 
tricyclic β-lactone core possessing four contiguous stereogenic centers and an additional 
stereogenic quaternary carbon on a cyclohexyl appendage. We completed the total 
synthesis of 6,15-bis-epi-spongiolactone by employing an intramolecular nucleophile-
catalyzed aldol-lactonization (NCAL) process as the key step to construct the fused 
tricyclic β-lactone core. Importantly, we developed a double diastereoselective and, for 
the first time, a kinetic resolution via the NCAL process that enables an enantioselective 
strategy to the tricyclic β-lactone core of (+)-spongiolactone. 
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 1 
CHAPTER I 
 
INTRODUCTION TO METHODS FOR NATURAL PRODUCT 
DERIVATIZATION  
 
Over the past 50 years, the discovery and the study of novel natural products 
produced from diverse living terrestrial and marine organisms has had a profound impact 
on human health.1 Indeed, natural products are an immense source of chemical 
diversity.2 These complex molecules are capable of interacting with numerous human 
cellular proteins and typically have intrinsic cell permeability.3 As a result, many natural 
products or natural product-inspired small molecules are currently in clinical use as 
antibiotics, antitumor agents, immunosuppressants, antiviral drugs, and enzyme 
inhibitors.4 For example, Taxol isolated from the Pacific Yew tree, is currently used 
clinically for the treatment of ovarian and breast cancers.5 Furthermore, natural products 
have a rich history as tools for basic cellular studies leading to the discovery of potential 
cellular targets for intervention of human diseases6 and in this way contain enormous 
information content that should be fully exploited.  
Gaining an understanding of the detailed mode of action of biologically active 
natural products, including the identification of putative protein targets, continues to be a 
highly useful strategy for the discovery of human therapeutics.7 These studies are greatly 
facilitated by detailed structure-activity relationship (SAR) studies and the synthesis of  
____________ 
This dissertation follows the style of the Bioorganic and Medicinal Chemistry Letters. 
 2 
cellular probes derived from a particular natural product of interest. The choices of 
derivatization strategies normally depend on the reactive functional group on natural 
products. These cellular probes, which typically contain a functional group for in vitro or 
in vivo attachment of reporter tags such as biotin or a fluorophore, continue to be of great 
importance for such studies.8   
 
1.1. Basic Technology of Cellular Probe 
According to activity-based protein profiling (ABPP) fundamentals, pioneered by 
Carvatt and Bogyo,9 the bioactive natural product probe typically consists of three 
elements (Figure 1.1); (i) a reactive group, (ii) a linker region, and (iii) a reporter tag. 
 
Reporter 
tag
Linker
Reactive
group
Natural product
Epoxide, Sulfonate
Michael acceptor
Peptides
Polyethylene glycol
Alkyl
Biotin
Fluorophore
Radiolabel  
Figure 1.1. Bioactive natural product probe. 
 
 The reactive group also referred, as a ‘warhead’ is the most important piece of 
the probe design. It is designed to covalently link the probe to the active site of enzyme. 
                                                
  The first two paragraphs on page 1 and 2 were reprinted with permission from “Diazo 
Reagents with Small Steric Footprints for Simultaneous Arming/SAR Studies of 
Alcohol-Containing Natural Products via O–H Insertion” by Chamni, S.; Dang, Y.; He, 
Q-L.; Bhat, S.; Liu, J. O.; Romo, D. ACS Chem. Biol. 2011, ASAP. Copyright 2011, 
American Chemical Society. See Appendix B. 
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In our study, the reactive group is a bioactive natural product. The linker region is a 
short hydrophilic polyethylene glycol chain that bridges the reactive group and the 
marker (tag) together. This element can be used to control the probe specificity such as 
solubility and prevent steric hindrance between the reactive group and the reporter tag. 
The tag element is useful for identification or purification such as fluorophore, biotin 
and radioactive tag. This part also includes the latent analytical handles such as alkynes 
or azides.  
 
1.2. Methods for Natural Product Derivatization Leading to Cellular Probe 
Synthesis 
Synthetic strategies toward the preparation of natural product probes normally 
involves the two-step connection of the reactive group and the reporter tag to the linker, 
which can be done in different synthetic sequences in both in vitro or in vivo 
experiments. The most efficient strategy for tag attachment is Sharpless-Hüisgen 
cycloaddition of the tethered alkyne and azide to deriver a triazole linker (Figure 1.2).10  
 
NN
N
N3
Reactive group
Linker
Alkyne
Azide
Linker Reporter tag
CuSO4, H2O
Reducing agent
Ligand
in vitro or in vivo
Reactive group
Reporter tag
Triazole
 
Figure 1.2. Tag attachment via Sharpless-Hüisgen cycloaddition. 
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 For the past several years, many methods for natural product derivatization for 
cellular probe synthesis have been continuously developed, including the development 
of synthetic methodology to bridge reactive groups to linkers and the development of 
fluorescent and photoreactive reporter tags. In general, amide and carbamate formations 
are the common derivatization strategies for alcohol- and acid-containing natural 
products due to their stability in living cells and practical synthesis (Scheme1.1).11  
 
Scheme 1.1 
N
N
O
HO
CN
O H
N
O
O
O
H
N
O
S
NHHN
O
OH O
O
O
OH
OH
O
O
H
N
O
O
NHO
N
BN
F
F
Quinocarmycin probe (1.1)
Pladienolide probe (1.2)
 
 
Several synthetic methodologies have been developed for natural product 
derivatization for linker and tag attachment to deliver natural product conjugates 
featuring highly retention of biological activity. Carreira and coworkers12 reported the 
preparation of amphotericin B probe for biochemical study of mammalian membrane by 
employing reductive amination of aldehyde and amine to obtain a new piperazine linker 
in good yield with highly chemoselectivity. This protocol required mild condition, which 
could be applied to sensitive functional groups such as hemi-acetal, carboxylic acid and 
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ester. It also showed excellent functional group tolerance toward alcohols and olefins 
(Scheme 1.2).  
 
Scheme 1.2 
O
Me
HO O
O
O
HO
N Me
OHN
O
FmocHN
Me
Me
O OH OH
OH
OH OH
OH
CO2H
OH
N
O
FmocHN
O
O NaCNBH3, HCl,13 h; 75%
Amphotericin B, DMF
1.3
1.4
 
 
Chemical inducers of protein dimerization (CIDs) are the powerful molecular 
tools for probing diverse biological processes. CIDs can be used to identify protein 
targets of natural products by activating gene expression in living yeast cells. In 2004, 
Peterson and Muddana13 developed a two-step synthesis of a highly active, and cell-
permeable CID of estrone utilizing oxime formation to functionalize the ketone moiety 
for linker and tag attachment. This method resulted (O-carboxymethyl)oxime linker in 
quantitative yield with the tolerance of unprotected alcohol (Scheme 1.3).  
 
Scheme 1.3 
Me OH
O
HO
Me OH
N
HO
O
OH
O
1.5 1.6
H2NOCH2CO2H!HCl
pyridine; 99%
 
 6 
Additionally, metal-mediated coupling reactions have shown the versatility 
toward the derivatization of sensitive and complex natural compounds. Forsyth and 
coworkers14 reported the preparation of phorboxazoles derivatives to elucidate the 
intracellular processing and targeting of the potent cytostatic/apoptotic anticancer drug. 
A Sonogashira coupling was employed to couple the terminal alkyne 33-O-Me-45,46-
dehydrobromophorboxazole A (MDHBPA, 1.7) and a terminal vinyl iodide derivative of 
the blue fluorescent dye N,N,-dimethyl-7-aminocoumarin (DMC, 1.8) to provide the 
phorboxazoles-fluorescence probe (1.9) in high yield (Scheme 1.4). 
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Olefin metathesis also played a role in natural product derivatization and 
bioactive probe synthesis. Myers and co-workers15 prepared a dansyl probe of (−)-ent-
avrainvillamide (1.12) to validate the targeting of nucleophosmin using a clever 
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mutagenesis strategy. They employed olefin metathesis to conjugate (−)-ent-
avrainvillamide (1.11) with biotin 1.10. The Grubbs second-generation catalyst was used 
and excellent chemo- and site selectivity were observed. Only the terminal olefin of 1.11 
reacted in good yield (Scheme 1.5).  
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One of the biggest challenges for preparing molecular probes is designing the 
probe’s elements. Choosing suitable linkers and reporter tags facilitates the interaction 
between natural products and specific protein receptors, while exhibiting minimal 
indiscriminate bio-reactivity and allows easy visualization, identification and 
purification of the target enzyme. In 2007, Mizui and co-workers16 developed a dual 
crosslinking-affinity probe of pladienolide B as a goal for utilizing photoaffinity labeling 
and affinity chromatography to verify protein targets in the immunoprecipitation 
experiments of tumor cells (Scheme 1.6). This probe (1.13) was 645-fold less active than 
pladienolide B but enabled an immunoblotting experiment with streptavidin-horseradish 
peroxidase and resulted in the identification of a single protein band.  
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OH O
O
O
OH
OH
O
O
H
N
NH
O
O
CF3
N N
N
N
O
S
H
N
HN
O
1.13
Biotin for affinity
chromatograghy
Diazirine for photocrosslinking
 
 
In the Romo group, we have begun the studies toward the development of natural 
product derivatization methodologies as the goal to develop mild and versatile strategies 
to functionalize bioactive natural products and prepare natural product probes to 
facilitate the structure-activity relationship (SAR) studies leading to the discovery of 
drug candidates. We have developed a couple synthetic methods for mild and 
monofunctionalization derivatization of natural products, based on natural product’s 
functionalities. Our first publication in this area was report in 2007.17 We described mild 
and monofunctionalization of alcohol-containing natural product via Rh(II) mediated 
O−H insertion with new p-bromophenyl diazoacetate (Scheme 1.7). Several 
commercially available natural products and derivatives were functionalized under the 
reported conditions to achieve the corresponding monoether (1.16 and 1.17) in high 
chemoselectivity with good yield.  
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Regarding to the successful establishing scope of mild and 
monofunctionalization derivatization, this research has been further explored and 
currently is an ongoing research area in the Romo group. In 2010, we reported another 
mild and monofunctionalization derivatization of arene containing natural products via 
In(OTf)3 catalyzed iodination.18 The facile tag attachment via variety of metal-mediated 
coupling reactions highlighted the advantage of this protocol (Scheme 1.8). The 
regioselectivity was governed by electronic and steric property of substrates. This 
method provided iodobenzene products in nearly quantitative yield. 
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In 2009, White and co-workers19 reported the development of a use of brønsted 
base such as N,N-diisopropylethylamine for oxidative, Pd(II)/sulfoxide-catalyzed, 
intermolecular C−H allylic amination. This methodology was utilized in the late-stage 
oxidation of estrone ((+)-1.21 and (+)-1.22) and cedrene ((−)-1.25) derivatives yielding 
the excellent chemoselectivity toward inactivated terminal olefin in the presence of free 
alcohol and produced a linear allylic sulfonamide in excellent yield (Scheme 1.9).  
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Fluorescence tags have been studied for almost 40 years, since Wieland reported 
the labeling of phalloidin by fluorescein isothiocyanate in 1967.20 Since then, fluorescent 
modifications have continuously emerged as an important tool in the study of natural 
product biology. In 2006, La Clair and his collaborators21 established a central strategy 
for converting natural products into fluorescent probes by labeling a diverse set of 
natural products with a single dye. By this means, the number of variables displayed 
within a collection of natural product probes is reduced by the use of single label and a 
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common set of linkers. As a result, biological data collected from the refined set of 
probes are homogenized.  
Coumarin (1.27) was chosen as a central dye for these studies regarding to its 
lack of biological activity and good photophysical properties. A set of coumarin 
derivatives was developed with variety of labeling functional groups to enable 
derivatization the diverse set of bioactive natural products via several derivatization 
methodologies (Scheme 1.10).  
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Coumarin labels not only simplifies chromatographic purification but also extend 
the detection limit. This allows synthetic operations with micrograms of materials and 
they can be used for live-cell imaging. Additionally, these fluorescent probes provided 
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reliable retention of natural product’s biological activities and gave details of mechanism 
of action of natural products leading to drug discovery from natural products. 
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CHAPTER II 
 
NEW DIAZO REAGENTS WITH SMALL STERIC FOOTPRINTS FOR 
SIMULTANEOUS ARMING AND STRUCTURE-ACTIVITY RELATIONSHIP 
STUDIES OF ALCOHOL-CONTAINING NATURAL PRODUCTS*    
 
2.1. Introduction 
Natural products and their derivatives have had a long invaluable history as a 
source of therapeutic agents. Regarding to their structural complexity and interesting 
biological activity, natural products continue to play a significant role as a tool for 
protein target discovery and understanding of cellular pathways. Several of bioactive 
natural products have been used in clinical trial and distributed in the market such as 
FK506 and orlistat. Numerous of them are currently developed to treat cancer, resistant 
bacteria and viruses, and immunosuppressive disorders.  
In general, following the isolation and purification process, the newly discovered 
natural products are subjected to a large number of spectroscopic techniques to fully 
characterize and completely assign stereo structures, which is a time consuming process. 
The structure elucidation process causes a significantly delay of the basic cellular studies 
to determine the relevant protein targets, which is an essential knowledge for further 
                                                
  *Reprinted with permission from “Diazo Reagents with Small Steric Footprints for 
Simultaneous Arming/SAR Studies of Alcohol-Containing Natural Products via O–H 
Insertion” by Chamni, S.; Dang, Y.; He, Q-L.; Bhat, S.; Liu, J. O.; Romo, D. ACS Chem. 
Biol. 2011, ASAP. Copyright 2011, American Chemical Society. See Appendix B. 
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synthetic and biomedical research. Additionally, natural product derivatization protocols 
are typically a formidable approach because a limit quantity of natural products, lack of 
selectivity and requiring a mild-monofunctionalization reaction.  
Many approaches have been developed for preparation of natural product 
derivatives to afford the novel and unique sites for tag attachment without losing 
bioactivities.22 These processes require multi-step syntheses, which are both challenging 
and time-consuming. Alternatively, random derivatization techniques such as a photo-
cross-linking of natural products to an affinity matrix have been developed. However, 
they cannot rely on any information related to the site of attachment, the retention of 
bioactivity, and potential design problems in the case of failure to identify the targets.23 
Furthermore, the possibility of natural products degradation, for example by UV 
irradiation, must be considered. 
 
2.1.1. Simultaneous Arming and Structure-Activity Relationship (SAR) Studies of 
Natural Products for Chemical Proteomics  
Natural products are often challenging to functionalize in chemo- and site 
(“chemosite”)24 selective manner because of their structural complexity, dense 
functionality, and limited quantities. We aim to develop a set of chemo- and both site 
selective and non-site selective reactions that can enable simultaneous arming by 
attachment of an appropriate functional group (i.e., an alkyne) at various sites on a 
natural product to provide the diverse set of natural product derivatives, which is an 
important feature for SAR studies (Figure 2.1).  
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Figure 2.1. General strategy for simultaneous arming and structure-activity relationship 
studies (SAR) of natural products for chemical genetics. 
 
 
We are interested in the strategy that relies on metal catalysis, which can 
facilitate the variation of chemosite selectivity based on catalyst/natural product 
interaction. In Phase I, substrate and/or reagent control leads to an initial chemoselective 
but site nonselective reaction to obtain various natural product derivatives (derivatives 
A, B, and C) from mismatched case. Subsequent separation by robust and versatile 
methods, such as preparative HPLC and LC-MS, deliver the natural product derivatives for 
the initial SAR studies to determine the most appropriate site for tag attachment, which 
provides the greatest retaining bioactivity. In Phase II, the goal is to selectively synthesize 
natural product derivative that shows the greatest retaining biological activity (Figure 2.1, 
derivative A) by substrate and reagent control. This matched case leads to a chemosite 
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selective process to afford only derivative A. In Phase III, subsequent conjugation with 
reporter tag (i.e., biotin) typically by ‘Click’ reaction gives rise natural product probes 
for SAR studies by protein assays and affinity chromatography experiments. 
 
2.1.2. Derivatization of Alcohol-Containing Natural Products via Chemo- and Site 
Selective Rh(II)-Catalyzed O−H Insertions 
According to two natural product databases, Dictionary of Natural Product 
(DNP, Chapman & Hall) and Bioactive Natural Product Database (BNPD, Szenzor), 
alcohols are one of the most prevalent functional groups found in natural compounds.25 
However, not all alcohols presented in natural products are crucial for biological activity 
and thus can serve as site for derivatization. To date, there are many approaches for 
direct derivatization of alcohol containing natural product.26 However, the reported 
conditions are typically guided by the knowledge of reactivity and stability of natural 
products. Additionally, these reactions are conducted under predominantly acidic or 
basic conditions, which are harsh for many natural products. In contrast, O−H insertions 
normally take place under mild and neutral conditions, and the diazo ester reagents are 
stable and easy to prepare. Therefore, O−H insertion proves to be a versatile method for 
derivatization of alcohol containing natural products. 
In the Romo group, we have developed a strategy that enables simultaneous 
arming and SAR studies for alcohol-containing natural products involving both chemo- 
and site selective (“chemosite” selective) and site non-selective O−H insertion reactions 
with rhodium carbenoids derived from alkynyl diazoacetates.17 In this strategy, the 
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arming process leads to natural product alkyne-derivatives that are equipped for 
subsequent conjugation to various tags via Sharpless-Hüisgen cycloaddition (Figure 2.2). 
In this way, the arming step requires only the knowledge of basic functional group 
presented in natural products, which diminishes the time between natural product 
isolation and cellular protein receptor isolation. Moreover, metal mediated reaction as 
Rh(II)-catalyzed O−H insertion is readily performed on small scale and provides a mild 
and mono-functionalization with high chemo- and site selectivity and potentially some 
degree of site non-selectivity to obtain the greatest number of derivatives for initial SAR 
studies. This method can be applied to a diverse set of alcohol-containing natural 
products for simultaneous arming and SAR studies that also enable subsequent bioactive 
probe synthesis for chemical genetics. 
 
Rh(II) catalyst
OH
OH
OH
OH
Bioactive polyol
natural product
Bioactive natural product 
alkynyl ether derivative
R
N2
O
O
OH Insertion
Simultaneous
Arming & SAR
Studies
N N
N
TAG
Cu(I) catalyst
Sharpless-Hüisgen
Cycloaddition
Natural product probe
O
O
R
OH
O
OH
OH
Tag
Conjugation
N3 O
O
OH
O
OH
OH TAG
R
 
Figure 2.2. Two-step O−H Insertion/Sharpless-Hüisgen cycloaddition sequence for 
preparation of alcohol-containing natural product probes. 
 
 
2.1.3. Rh(II)-Mediated O−H Insertion: Mechanism and Carbene Type  
  Rh(II)-catalyzed O−H insertions were introduced by Tessié and co-workers in 
197327 and referenced as the most efficient metal-mediated reactions for the 
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decomposition of α-diazo carbonyl compound. Today, the synthesis and rhodium- 
mediated O−H insertion reactions of a wide range of diazo compounds are well 
documented and have become a standard procedure for organic synthesis.28 Three 
possible mechanisms have been proposed related to a concerted mechanism, the 
protonation of a carbene to generate carbocation intermediate, and nucleophilic attack on 
the electrophilic carbene to form a ylide followed by hydrogen transfer (Figure 2.3).  
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Figure 2.3. Three possible mechanisms of O-H insertion. (a) Concerted mechanism, (b) 
Protonation of carbene to generate carbocation intermediate, (c) Nucleophilic attack on 
the electrophilic carbene to form a ylide followed by hydrogen transfer. 
 
 
However, the detail mechanisms of the C−O bond formation derived from the 
carbene insertion into the O−H bond are not fully understood. There is no direct 
experimental evidence to determine the O−H insertion mechanism. Although the 
concerted pathway (Figure 2.3a) cannot be completely excluded, it was likely that most 
O−H insertion reactions of carbenes proceed by one of the stepwise processes (Figure 
2.3b or 2.3c). Until 2007, Han and co-workers29 explained the plausible insertion 
mechanism of Rh(II)-methylene carbene into the O−H bond of alcohols, except phenol30 
by the analysis of the energy barriers using B3LYP functional both in gas phase and in 
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CH2Cl2. They observed that the energy barrier associated with a concerted mechanism 
was higher than that of stepwise mechanism. Therefore, they concluded that the insertion 
of rhodium carbenoid into O−H bond of methanol and ethanol is more likely a stepwise 
mechanism, while the concerted mechanism is preferred for the O−H insertion of 
phenols.  
A metal carbenoid is a reactive species derived from the decomposition of a 
diazo precursor. The O−H insertion reactivity and selectivity, including 
chemoselectivity, regioselectivity, and stereoselectivity normally depend on the metal 
carbene character, which is classified into three major groups according to the carbenoid 
substitutents; acceptor, acceptor/acceptor, and donor/acceptor (Figure 2.4).31 
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Figure 2.4. Classification of carbenoid intermediates. 
 
 
In general, reactivity of a particular carbene is governed by substituents and the 
metal. The terms “donor” and “acceptor” refer to electron donation or withdrawal 
through resonance effects, respectively. An acceptor group (EWD) generally increases 
electrophilicity and reactivity, whereas a donor group (EDG) increases stability and 
chemoselectivity.32 With regard to selectivity and reactivity of carbenoid in C−H 
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activation chemistry, the electrophilic carbenoids exhibit poor regio- and 
stereoselectivity and they are susceptible to other competing reactions such as carbenoid 
dimerization. However, the carbenoids with insufficient electrophilicity show a lack of 
reactivity. An electron-withdrawing substituent, typically a carbonyl moiety causes 
highly electrophilicity. The acceptor carbenoids, which derived from diazo compounds 
bearing a single electron-withdrawing substituent, are highly reactive metallocarbenoid 
species, which cause a high degree of carbene self-dimerization. The acceptor/acceptor 
carbenoids, derived from diazo compounds bearing two electron-withdrawing 
substituents, are highly stable compared to acceptor carbenoid precursors. In the 
presence of a second electron-withdrawing group, a highly active metal catalyst is 
required to decompose these diazo compounds. However, the derived metal carbenoid is 
highly reactive but less selective. The common side reactions for these carbenoids are 
carbene self-dimerization and hydride transfer to form zwitterionic intermediates.  
The donor/acceptor carbenoids contain a donor substituent, such as vinyl or aryl, 
which is capable of stabilizing the carbenoid through electron resonance. The 
donor/acceptor carbenoids are capable of undergoing highly chemoselective processes. 
As a result, the donor/acceptor carbenoids are often used in metal-catalyzed insertion 
research. 
 
2.2. Results and Discussion 
 In the Romo group, we previously described mild and versatile strategies for 
simultaneous arming (with a reactive functional group or array) and SAR studies that 
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facilitate mode of action studies of natural products.17,18 One such method involves 
chemosite selective and non-selective O−H insertions with rhodium carbenoids derived 
from hexynyl-α-p-bromophenyl diazoacetate (2.1, HBPA) as a donor/acceptor carbenoid 
precursor. The arming process leads to natural product derivatives that are equipped with 
tethered alkynes for subsequent conjugation to various tags via Sharpless-Hüisgen 
cycloaddition to generate cellular probes (Figure 2.5). The utility of this strategy was 
demonstrated with a panel of natural products including FK506. An FK506-HBPA-
biotin conjugate probe (2.2) was employed to successfully pull-down the entire 
‘immunosuppressive complex’ consisting of calcineurins A/B, calmodulin, and FKBP12.  
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Figure 2.5. Proof of principle affinity experiments with a novel FK506-HBPA-biotin 
conjugate obtained via O−H Insertion/Sharpless-Hüisgen cycloaddition leading to the 
pull-down of the entire “FK506 Immunosuppressive Complex”. 
 
 
2.2.1. Alteration of Chemosite Selectivity Using Chiral Rh(II) Catalysts 
The simultaneous arming and SAR studies of alcohol-containing natural products 
via Rh-catalyzed O−H insertions has provided a versatile tool for the mild and mono-
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functionalization derivatization of alcohol containing natural product with high 
chemosite selectivity. As a goal for obtaining the greatest number of derivatives for 
initial SAR studies, the development of the O−H insertions was performed by relying on 
a metal catalysis process. The use of rhodium catalysts bearing chiral ligands to enable a 
type of “double asymmetric synthesis”33 potentially leads to the variation of chemosite 
selectivity toward the O−H insertion of alcohol-containing natural products.  
In this study, Doyle’s rhodium(II) carboxamidate complexes (Figure 2.6) were 
interesting since they displayed outstanding enantioselectivity, regioselectivity and 
stereoselectivity.34 These carboxamidate catalysts consist of four classes of complexes: 
pyrrolidinones (Rh2(5S-MEPY)4), oxazolidinones (Rh2(4S-MEOX)4), imidazolidinones 
(Rh2(4S-MPPIM)4), and azetidinones (Rh2(4S-MEAZ)4). These catalysts have more 
structural rigidity than rhodium(II) carboxylates such as Rh2(OAc)4 and Rh2(esp)2 
(Figure 2.7) and include four bridging amine ligands around the dirhodium core with 
two oxygen and two nitrogen donor atoms bound to each rhodium in a cis-configuration. 
The chiral center of the enantio-pure ligands is positioned in such a manner that 
influences the approach of the substrate and the orientation of the carbene, thereby 
influencing regioselectivity as well as stereoselectivity. 
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Figure 2.6. Doyle’s rhodium chiral catalysts.  
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Figure 2.7. Rhodium (II) carboxylated catalysts. 
 
 
According to this idea, the experiments were preformed to demonstrate the 
potential of altering chemosite selectivity, while maintaining the mono-functionalization 
O−H insertion process. The commercially available chiral Rh(II) catalysts developed by 
Doyle35 were investigated for O−H insertions with gibberellic acid methyl ester (2.3) and 
brefeldin A (2.4). These two natural products served as the model substrates since they 
contain several potentially reactive sites for alteration of chemosite selectivity (Figure 
2.8). Gibberellic acid methyl ester (2.3) has an internal and a terminal disubstituted 
olefin and two sterically differentiated alcohols (secondary and tertiary alcohol), whereas 
brefeldin A (2.4) has the electronically differentiated olefins, and alcohols including α,β 
unsaturated ester, secondary alcohol and allylic alcohol.  
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Figure 2.8. Ideal substrates for alteration of chemosite selectivity study. 
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Exploring the variation of chemosite selectivity of O−H insertion of gibberellic 
acid methyl ester (2.3) with Rh(II) catalyst including achiral and chiral catalysts showed 
a significant difference in carbene reactivity (Table 2.1). In most case, O−H insertion 
occurred at the secondary alcohol of gibberellic acid methyl ester to obtain 2.5a as a 
major product and no reaction at the olefins leading to cyclopropanation adducts. 
Rh2(4S-MEAZ)4 (Table 2.1, entry 4) provided the highest yield of 2.5a (72%) and 
highest diastereoselectivity (dr, 1:2). However, its enantiomeric catalyst Rh2(4R-
MEAZ)4 (Table 2.1, entry 5) provided 2.5a only 35% yield. These results pointed out to 
the desired difference in molecular recognition between substrate and catalyst.  
Surprisingly, Rh2(esp)2, which is an achiral catalyst developed by Du Bois,36 was 
the only catalyst that provided the alteration of site selectivity (Table 2.1, entry 2). In 
this case, O−H insertion at the tertiary alcohol of gibberellic acid methyl ester (2.3) was 
observed along with O−H insertion at the secondary alcohol in 1:1 ratio (dr, 1:1). Both 
diastereomers were separable and obtained in moderate yield. Employing enantiomers of 
Rh2(4S-MEPY)4, Rh2(4R-MEPY)4, and Rh2(4S-MPPIM)4 (Table 2.1, entries 6, 7 and 9) 
produced only HBPA dimerization with no observation of O−H insertion products. 
Interestingly, O−H insertion with Rh(esp)2 at low temperatures (−78 oC) also caused 
self-dimerization of HBPA and precluded O−H insertion with gibberellic acid methyl 
ester (2.3).  
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Table 2.1. Alteration of chemosite selectivity employing Rh(II) chiral catalysts process 
with gibberellic acid methyl ester (2.3). 
 
gibberellic acid
 methyl ester (2.3)
RO O
O
OH
H
Me
OMeO
HO O
O
OR
H
Me
OMeO
HO O
O
OH
H
Me
OMeO
Br
O
O
N2
HBPA (2.1)
2 equiv
5% mol Rh cat., CH2Cl2, r.t., 1h
+
2.5a 2.5b
Dietherification (2.5c)  
 
Entry 
Rhodium 
Catalyst 
Reaction 
Condition 
2.5a:2.5ba %Yieldb drc 
1 Rh2(OAc)4 23 oC, 1 h >95:5 62% 2.5a 1:1 
2 Rh2(esp)2 23 oC, 30 min 
∼50:50 
 
35% 2.5a 
28% 2.5b 1:1 
3 Rh2(esp)2 
−78 oC, 1 h 
then 23 oC, 1 h 
Obtained only 
HBPA dimer 
NDe ND 
4 Rh2(4S-MEAZ)4 23 oC, 30 min >95:5 72% 2.5a 1:2 
5 Rh2(4R-MEAZ)4 23 oC, 30 min >95:5 35% 2.5a 1:1 
6 Rh2(4S-MEPY)4 23 oC, 6 h 
Obtained only 
HBPA dimerd 
ND ND 
7 Rh2(4R-MEPY)4 23 oC, 6 h 
Obtained only 
HBPA dimerd 
ND ND 
8 Rh2(4S-MEOX)4 23 oC, 30 min >95:5 35% 2.5a 1:1 
9 Rh2(4S-MPPIM)4 23 oC, 6 h 
Obtained only 
HBPA dimerd 
ND ND 
aRatios were determined by 1H-NMR (500 MHz) and no dietherification was observed. bYields refer to 
isolated yields. cDiastereomeric ratios (dr) of 2.5a at ether α-carbon were determined by 1H-NMR (500 
MHz). dReaction was slowly proceeded. eND refers to not determined. 
 
 
Investigating chemosite selectivity of O−H insertion of brefeldin A (2.4) was 
performed in the same strategy as gibberellic acid methyl ester (Table 2.2). The pairs of 
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enantiomeric catalysts (Table 2.2, entries 3-8) were studied along with achiral Rh(II) 
carboxylates (Table 2.2, entries 1 and 2). In this study, we observed only O−H insertion 
of the secondary alcohol of brefeldin A, no cyclopropanation at the olefins and no 
dietherification (2.6c). Rh2(OAc)4 (Table 2.2, entry 1) provided the highest yield of 2.6a 
(62%) with dr, 1:1.  
 
Table 2.2. Alteration of chemosite selectivity employing Rh(II) chiral catalysts with 
brefeldin A (2.4). 
 
Br
O
O
N2
HBPA (2.1)
2 equiv
5% mol Rh cat., CH2Cl2, 23 oC, 1h
Dietherification (2.6c)
O
O
H
HO
HO
H
Brefeldin A (2.4)
O
O
H
HO
RO
H +
O
O
H
RO
HO
H
2.6a 2.6b
 
 
Entry Rhodium  
Catalyst 
2.6a:2.6ba % yield of 
2.6ab 
drc 
1 Rh2(OAc)4 >95:5 62%  1:1 
2 Rh2(esp)2 >95:5 24%  >19:1 
3 Rh2(4S-MEAZ)4 >95:5 29%  1:1 
4 Rh2(4R-MEAZ)4 >95:5 23%  1:1 
5 Rh2(4S-MEPY)4 Obtained only HBPA dimerd NDe ND 
6 Rh2(4R-MEPY)4 Obtained only HBPA dimerd ND ND 
7 Rh2(4S-MEOX)4 >95:5 28% 1:1 
8 Rh2(4S-MPPIM)4 Obtained only HBPA dimerd ND ND 
aRatios were determined by 1H-NMR (500 MHz) and no dietherification was observed. bYields refer 
to isolated yields. cDiastereomeric ratios of 2.6a at ether α-carbon were determined by 1H-NMR 
(500 MHz). dReaction was slowly proceeded. eND refers to not determined. 
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Interestingly, an unexpected diastereoselective O−H insertion was observed 
when Rh2(esp)2 was used (Table 2.2, entry 2). This catalyst gave low yield of 2.6a (24%) 
but showed an excellent diastereoselectivity (dr, >19:1). Use of chiral Rh(II) 
carboxamidates (Table 2.2, entries 3, 4 and 7) significantly lowered the yield of O−H 
insertion products (2.6a) comparing to Rh2(OAc)4 (23-29% vs. 62% isolated yield, 
respectively). In this case, the enantiomeric catalysts Rh2(4S-MEAZ)4 and Rh2(4R-
MEAZ)4 (Table 2.2, entries 3 and 4) provided the same reactivity leading to the low 
yield of 2.6a (29% and 23%, respectively) and similar diastereoselectivity (dr, 1:1) was 
observed. Employing both enantiomers Rh2(4S-MEPY)4 and Rh2(4R-MEPY)4, and 
Rh2(4S-MPPIM)4 (Table 2.2, entries 5, 6 and 8) produced only HBPA dimerization and 
no O−H insertion products were observed. These results were similar to O−H insertion 
of gibberellic acid methyl ester, which were described previously.  
Regarding to the results we observed from Tables 2.1 and 2.2, we concluded the 
idea of altering site selectivity by chiral catalysts via a type of “double asymmetric 
synthesis” that each natural product has specific shape-shape interactions or specific 
“shape fit” with particular metal carbenoids. Therefore, the overall shape interaction and 
reactivity of catalyst are more important than chirality’s of the catalyst itself. 
 
2.2.2. Development of Second Generation Diazo Reagents 
In our initial study, the first generation of diazo reagents, 5-hexynyl-(α-4-
bromophenyl) diazoacetate (HBPA, 2.1) was applied to the Rh(II)-promoted O−H 
insertion of various types of alcohol-containing natural products.17 However, the large 
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steric size of the p-bromophenyl group and its close proximity to the point of attachment 
to the natural product was a potential liability for retaining bioactivity and subsequent 
affinity chromatography experiments. We thus sought to develop sterically smaller diazo 
reagents with similar or better reactivity to the p-bromophenyl substituted reagent 
(HBPA) that potentially improve the retention of bioactivity.  
Herein, we describe the development of an α-trifluoroethyl (HTFB) substituted 
carbenoid precursor (2.7) that leads to a greatly reduced steric footprint yet provides 
similar reactivities, including chemosite selectivities, as the previously described p-
bromophenyl reagent 2.1 (Figure 2.9). Importantly, the α-trifluoroethyl (HTFB) 
substituted conjugates may offer greater utility for identifying cellular receptors of 
bioactive natural products due to their smaller steric size. We therefore set out to study 
the α-trifluoroethyl (2.7a), α-trifluoromethyl (2.7b), and α-cyano (2.7c) diazo reagents 
that possess different substituents with varied steric sizes and electron withdrawing 
potential, which would also alter the reactivity of the derived rhodium carbenoids 
(Figure 2.9). While the proposed diazo reagents would lead to acceptor/acceptor 
carbenoids,37 the fluorinated hex-5-ynyl 2-diazo-4,4,4-trifluorobutanoate (2.7a, HTFB) 
and hex-5-ynyl 2-diazo-3,3,3-trifluoropropanoate (2.7b) have the added advantage of 
enabling 19F-NMR analysis of crude natural product derivatization reactions. 
In contrast, the hex-5-ynyl 2-cyano-2-diazoacetate (2.7c) was expected to 
provide a highly reactive metallocarbenoid species.38 Computational studies performed 
on Spartan ’08 v1.2.0 software at the level of theory: DFT-B3LYP/6-31++G(2df,2p) 
were used for calcutating molecular volumes. These results supported the significant 
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steric size difference based on calculated molecular volumes that could be expected 
between the derived natural product derivatives (cyano, 35.10 Å3; 1,1,1-trifluoroethyl: 
65.51 Å3; p-bromophenyl: 117.02 Å3). In addition, the hex-5-ynyl 2-(4-p-azidophenyl)-
2-diazoacetate (2.7d)39 was prepared for its potential as a trifunctional linker for 
photoaffinity labeling of low affinity binding proteins40 and the derived carbenoid was 
expected to exhibit similar reactivity to the p-bromophenyl reagent 2.1.  
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Figure 2.9. Simultaneous arming/SAR studies via O–H insertion of polyol natural 
products using diazo reagents with varied steric footprints and subsequent tag 
conjugation. 
 
 
To enable studies of their reactivity, these new diazo reagents were successfully 
prepared on gram scale (~5 g) by esterification and subsequent base-promoted diazo 
transfer. We found that diazo reagents 2.7a (Scheme 2.1), 2.7c (Scheme 2.2), and 2.7d 
(Scheme 2.3) are stable at room temperature, and storable at -10 oC with no 
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decomposition after one year. However, the α-trifluoromethyl reagent 2.7b (Scheme 2.4) 
is highly unstable and decomposed at room temperature.  
 
Scheme 2.1 
O
O
N2
O
O
p-ABSA, DBU
CH3CN, 23 oC, 4h
2.7a (HTFB)
F3C
F3CO
O
F3C
OPh
O
Cl
TiCl4, Et3N, CH3CN
reflux, 30 min
91%
58%
OH
O
OH
EDCI.HCl, DMAP
CH2Cl2, 23 oC, 2h
F3C
92%
4,4,4-trifluorobutanoic acid (2.7a-1) hex-5-yn-1-yl 4,4,4-trifluorobutanoate (2.7a-2)
hex-5-yn-1-yl 2-benzoyl
4,4,4-trifluorobutanoate (2.7a-3)  
 
 
Scheme 2.2 
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Scheme 2.3 
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Scheme 2.4 
F3C
N2
O
O
2.7b
F3C
OH
O
OH
F3C
O
O
EDCI.HCl, DMAP,
CH2Cl2, 23 oC, 4h
83%
p-ABSA, DBU
CH3CN, 23 oC, 4h Unstable3,3,3-trifluoropropanoic 
acid (2.7b-1) hex-5-yn-1-yl 
3,3,3-trifluoropropanoate (2.7b-2)  
 
The reactivity of diazo reagents 2.7a, 2.7c, and 2.7d were initially studied with 
gibberellic acid methyl ester (2.3), which serves as an ideal substrate to study chemosite 
selectivity. Under the standard O–H insertion conditions with Rh2(OAc)4, diazo reagents 
2.7a and 2.7d exhibited similar stability and reactivity compared to the p-bromophenyl 
diazo 2.1 (Table 2.3, entry 1) providing monoethers 2.8a and 2.8d derived from O–H 
insertion with the more accessible secondary alcohol along with recovered ester 2.3 
(Table 2.2, entries 2 and 4). However, the more reactive α-cyano reagent 2.7c gave a 
complex mixture likely resulting from both O–H insertion and cyclopropanation41 with 
no recovery of starting material (Table 2.3, entry 3).  
Overall, the α-trifluoroethyl diazo reagent 2.7a provided the best results with 
regard to stability, reactivity, and selectivity of derived rhodium carbenoid compared to 
the p-bromophenyl diazo 2.1. With respect to catalysts, Rh2(esp)2 described by 
DuBois,36 gave optimal conversion to the monoether 2.7a (66%) and higher 
diastereoselectivity (dr, 4:1), however, this was accompanied by 25% of diether 2.10 
(Table 2.3, entry 5). Rh2(OAc)4 was the most chemosite selective catalyst favoring the 
less hindered and nucleophilic secondary alcohol at C3 (Table 2.3, entry 2). We next 
investigated various known chiral Rh(II) catalysts in conjunction with the α-
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trifluoroethyl diazo reagent 2.7a as a mean to alter chemosite selectivity of the O–H 
insertion. Several commercially available chiral rhodium catalysts including those of 
Davies42 and Doyle35 were investigated.  
 
Table 2.3. Comparison of reactivity and chemosite selectivity of novel diazo reagents 
2.7a, 2.7c-d with various Rh(II) catalysts. 
2.1: R = p-BrC6H4 (HBPA, ref.17), 2.7a: R = CH2CF3 (HTFB)
2.7b: R = CF3, 2.7c: R = CN, 2.6d: R = p-N3C6H4
HO O
OH
H
Me
OMeO
O O
OH
H
Me
OMeO
R
O
O
+
2.8a-dgibberellic acid
 methyl ester (2.3)
diether 2.10a-d
O O
3 13
HO O
O
O
H
Me
OMeO
R
O
O
3 13
2.9a-d
(3.0 equiv)
5 mol% Rh(II) catalyst
CH2Cl2, 23 oC, 1 h
4
4
R
N2
O
O
4
 
aData from ref. 17. bRatios were determined by 1H-NMR (500 MHz). cEthers 2.8-2.10 were detected by LC-MS but not 1H-NMR 
(500 MHz). dYields refer to isolated yields and numbers in parentheses refer to recovered starting material. eDiastereomeric 
ratios of 2.8 at ether α-carbon were determined by 1H-NMR (500 MHz). eND refers to not determined. 
 
 
Entr
y 
Diazo 
reagent Catalyst 
Monoether 
ratio 2.8:2.9
b
 
Diether 
2.10 
% 
Yield
d
 
dr 
(2.8)
e
 
1a 2.1 Rh2(OAc)4 >95:5 <5
 c
 55 (38) 1:1 
2 2.7a Rh2(OAc)4 95:5 <5
 c
 45 (32) 2:1 
3 2.7c Rh2(OAc)4 ND
f ND ND ND 
4 2.7d Rh2(OAc)4 70:30 0 57 (25) 1:1 
5 2.7a Rh2(esp)2 87:13 25 66 (7) 4:1 
6 2.7a Rh2(OCOCF3)4 50:50 0 28 (44) 2:1 
7 2.7a Rh2(4S-
MEAZ)4 
ND 0 <5
 c 
(74) ND 
8 2.7a Rh2(4R-
MEAZ)4 
ND 25 <5
 c 
(68) ND 
9 2.7a Rh2(4S-
MEOX)4 
50:50 0 41 (29) 1:1 
10 2.7a Rh2(S-DOSP)4 85:15 0 75 3:1 
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The use of chiral catalysts enables a type of ‘double diastereoselectivity’ that 
could in principle alter chemosite selectivity. Of the four chiral catalysts studied (Table 
2.3, entries 7-10), Rh2(S-DOSP)4 provided the highest yield of monoetherification (75%) 
of ester 2.3 with good diastereoselectivity (dr, 3:1) and a high degree of chemosite 
selectivity (Table 2.3, entry 10). However, Rh2(OCOCF3)4 and Rh2(MEOX)4, which are 
known to lead to more reactive carbenoids compared to Rh2(OAc)4, gave lower 
chemosite selectivity as expected. Thus, these catalysts are ideal for obtaining the 
greatest number of derivatives for initial SAR studies of a novel polyol natural product. 
The scope of this O–H insertion with the new trifluoroethyl diazo ester (2.7a) 
was assessed with several commercially available natural products and derivatives 
(Table 2.4). In general, O–H insertion with metallocarbenoid is governed by both steric 
and electronic effects.43 Despite the smaller steric size of the α-trifluoroethyl group, 
Rh2(OAc)4 catalyzed O–H insertions of diazo reagent 2.7a with the natural products 
showed similar chemosite selectivity compared to the p-bromophenyl reagent 2.1. These 
results suggested that the electronic effects play the predominant role for chemosite 
selectivity. 
Brefeldin A (2.4) presented two potentially reactive alcohols; however, the more 
accessible secondary alcohol (C13) was selectively alkylated over the more electron rich 
allylic alcohol (C1). Paclitaxel (2.11a) has two electronically and sterically distinct 
secondary alcohols and a tertiary alcohol. The more accessible secondary alcohol (C2’) 
was selectively derivatized with no reaction detected at the other alcohols or the amide 
N–H. To determine the reactivity of amines in comparison to alcohols, ephedrine 
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(2.12a), which bears a secondary alkyl amine and a secondary alcohol, was studied. As 
expected, the major adduct isolated was that derived from N–H insertion due to greater 
nucleophilicity; however, some bis-derivatization derived from both N–H and O–H 
insertion was also detected.  
 
Table 2.4. Scope of Rh2(OAc)4-catalyzed chemosite selective O–H insertion of HTFB 
(2.7a) with various natural products. 
 
monoetherification
HTFB (2.7a)
O
O
H
HO
RO
H
O
HO OBz
AcO O OH
O
OAc
H
O
OR
NH
Ph
Ph
O
RO
OMe
O
O
OH
OMe
O
HO
O
O
N
O
OMe
HN
O
OR O
O
O
O
2.4: R=H (brefeldin A)
2.4b/2.4b': R=HTFB (13-HTFB brefeldin A)
 (2.4b:2.4b', dr 1:1)a, 57(23)%b
2.11a: R=H (paclitaxel)
2.11b/2.11b': R=HTFB; 2'-HTFB paclitaxel
(2.11b:2.11b', dr 5:1), 49(20)%c
13
32
2'
2.14a: R=H (lactimidomycin)
2.14b/2.14b': R=HTFB (17-HTFB lactimidomycin)
(2.14b:2.14b', dr 1:1), ~15%e
2.13a: R=H (FK506)
2.13b/2.13b': R=HTFB (32-HTFB FK506)
(2.13b:2.13b', dr 7:1), 66(17)%c
17
NR
OH
2
2.12a: R=H ((!)-ephedrine)
2.12b/2.12b': R=HTFB (2-HTFB ephedrine)
(2.12b:2.12b', dr 1:1), 49(25)%
 NH & OH insertion,15%d
24
1
HTFB (2.7a), 5-hexynyl-
",","-trifluorobutanoate
R =
OH
OH
OH
OH
 5 mol% Rh2(OAc)4
CH2Cl2, 23 oC, 1 h
OH
O
OH
OH
CH2CF3
O
O
4
CF3CH2
N2
O
O
4
OR
OMe
O
O
6
2.15a: R=H (fumagillol)
2.15b/2.15b': R=HTFB; 6-HTFB fumagillol
(2.15b:2.15b', dr 7:1), 63(21)%
H
aDiastereomeric ratios (dr) were determined by 1H-NMR (500 MHz) and refer to the mixtures of 
diastereomers at the ether α-carbon. bValues refer to isolated yields and numbers in parentheses refer to 
recovered starting material. c6.0 equiv of HTFB (2.7a) was added via syringe pump over 2 h. 
dBifunctional derivatization involving both O–H and N–H insertion was detected by LC-MS. eRun on a 2 
mg-scale reaction therefore yield is approximate (microbalance) following purification by preparative 
HPLC with some unreacted lactimidomycin recovered. 
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In the case of FK506 (2.13a), O–H insertion led to chemosite selectivity at the 
more accessible cyclohexyl secondary alcohol (C32) in 66% yield and with good 
diastereoselectivity (dr, 7:1). No O–H insertion at the macrocyclic secondary alcohol 
(C24) or dietherification was observed. Previously, dietherification of FK506 was 
observed when HBPA (2.1) was added in one portion.17 Therefore, slow addition of 6 
equivalents of HTFB (2.7a) over 2 h, again prevented dietherification.  
Lactimidomycin (2.14a) is a macrocyclic natural product with a pendant 
cycloheximide that has gained much interest due to its potent inhibitory effect on 
eukaryotic translation and elongation properties leading to dramatic antitumor 
activities.44 However, lactimidomycin is highly acid and base sensitive which limits 
derivatization strategies. Thus, this became an excellent substrate for testing the 
mildness of this O–H insertion process. Use of HTFB (2.7a) provided ~15% yield of 
isolated, purified (preparative HPLC) ether 2.14b on a reaction scale of 2 mg at 50% 
conversion with some loss of material attributed to degradation during purification. The 
successful derivatization of such a sensitive natural product demonstrates the utility of 
the described derivatization strategy as it proceeds under essentially neutral conditions, 
works efficiently on small scale (∼1-2 mg), and allows for the recovery of unreacted 
starting material.  
Fumagillol (2.15a) is a natural product in fumagillin family, which is known to 
inhibit angiogenesis through irreversible inhibition of human type 2 methionine 
aminopeptidase (MetAP2).45 The O–H insertion of fumagillol employing HTFB 
provided ether 2.15b in good yield (63%) without cyclopropanation and epoxide 
 36 
decomposition.  
Overall, these results are consistent with chemoselectivities previously observed 
for O–H insertion with Rh(II)-carbenoids derived from HBPA (2.1) and while not all  
O–H environments were explored, the same reactivity patterns (primary alcohol ≈ 
secondary alkyl amine > secondary alkyl alcohol > secondary allylic alcohol ≥ aryl 
amine > phenolic alcohol > tertiary alkyl alcohol > indole and no reaction with N–H of 
amide or alkenes) would be expected based on observations to date. 
 
2.2.3. Proof of Principle Protein Assays and Affinity Experiments 
We were next interested in studying the effect of having sterically different α-
substituents leading to the retaining or improving of biological activities. Our studies 
focused on the effect of the α-trifluoroethyl substituent (HTFB) that displayed a smaller 
steric footprint in comparison with the bulky p-bromophenyl substituent (HBPA) on the 
ethers obtained from O–H insertion of natural products in the cellular assays and also 
affinity chromatography experiments with derived biotin conjugates.  
Lactimidomycin conjugates 2.14b/2.14bʹ′  and 2.16/2.16bʹ′  which derived from 
O–H insertion with the α-trifluoroethyl substituted diazo reagent (2.3a) and p-
bromophenyl substituted reagent (2.1) respectively (Scheme 2.5) were assayed in the in 
vitro translation assays performing in rabbit reticulocyte lysates (Promega Flexi RRL). 
Although, lactimidomycin (2.14a) was enabled to derivatize by mild and mono-
functionalization O–H insertion with first- and second-generation diazo reagents (2.1 
and 2.3a, respectively), we observed ~50% conversion and obtained low yield of 
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2.14b/2.14bʹ′  (15%) and 2.16b/2.16bʹ′  (13%) along with recovery of starting material 
(2.14a) by preparative HPLC separation.  
Unfortunately, the SAR studies of 2.14b/2.14bʹ′  and 2.16/2.16ʹ′  in cell-
proliferation and RNA translation of rabbit reticulocyte lysates assay showed a 
tremendous loss of inhibitory activity (Table 2.5). The lactimidomycin-HBPA 
derivatives 2.16/2.16ʹ′  showed lower inhibitory activity in cell-proliferation >1000-fold 
compared to lactimidomycin (IC50 >3000 and 2.8 nM, respectively).  
 
Scheme 2.5 
2.3a: R= CH2CF3 (HTFB)
2.1: R= p-BrC6H4 (HBPA)HN
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O
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O
O
O 17
2.14b/2.14b': R= CH2CF3 (15%)a
2.16/2.16': R= p-BrC6H4 (13%)aLactimidomycin (2.14a)  
aRun on a 2 mg-scale reaction followed by preparative HPLC purification that causes loss and 
decomposition of desired product therefore yield is approximate (microbalance). 
 
 
Table 2.5. IC50 values of lactimidomycin (2.14a) and derivatives 2.14b, 2.14bʹ′, and 
2.16/2.16ʹ′  for in vitro proliferation and translation of rabbit reticulocyte lysate assay. 
 
Compound IC50 proliferation (nM) 
IC50 in vitro translation 
(µM) 
Lactimidomycin (2.14a) 2.8 0.73 
2.14b NDa 98.2 
2.14bʹ′  ND 228.7 
2.16/2.16ʹ′  >3000 63.7 
aND = means not determined. 
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Unexpectedly, lactimidomycin-HBPA derivatives 2.16/2.16ʹ′  showed better 
inhibitory activity in the translation assay compared to lactimidomycin-HTFB 
derivatives 2.14b and 2.14bʹ′  (IC50 98.2, 228.7 and 63.7 µM, respectively). However, all 
resulted lactimidomycin derivatives exhibited lower inhibitory activity in RNA-
translation ~100-300 folds compared to lactimidomycin. Since, we know that hydroxyl 
group on lactimidomycin is not crucial for biological activity. We assumed that the loss 
of potency resulted from an interference of α-substituent that diminished natural product 
and protein target interaction. Additionally, the diastereomeric FK506-derived ethers 
2.13b/2.13bʹ′  and 2.18/2.18ʹ′  were prepared and purified by preparative TLC, which 
enable to separate each diastereomer. An FK506-HTFB-biotin probe (2.19) was 
prepared by Sharpless-Hüisgen cycloaddition of the major diastereomeric HTFB ether 
2.13b and commercially available biotin azide 2.17. The FK506-HBPA-biotin conjugate 
2.20 was also prepared in a similar fashion (Scheme 2.6).  
 
Scheme 2.6 
  CuSO4/ Na Ascorbate (1:10)
t-BuOH/H2O (1:1), 23 oC, 24 h
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2.18/2.18':  R= p-BrC6H4 (HBPA)
2.19: R= CH2CF3  (60%)b 
2.20: R= p-BrC6H4 (42%)
2.17
O
 
aEthers 2.13b and 2.18 are the major diastereomers and ethers 2.13bʹ′  and 2.18ʹ′  
are minor diastereomers. bBiotin probes 2.19 and 2.20 were derived from 
isolated 2.13b and 2.18 as single diastereomers, respectively. 
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In our previous study, the use of an FK506-HBPA-biotin probe (2.2) led to pull-
down of the entire immunosuppressive complex including FKBP12, calcineurin A/B, 
and calmodulin.17 In the IL-2 reporter assay, the FK506-HTFB derivatives 2.13b and 
2.13bʹ′ showed diminished inhibition of IL-2 production (~2-fold, IC50 15.9±2.8 and 
19.8±14.5 nM, respectively) compared to the FK506-HBPA derivatives 2.18 and 2.18ʹ′  
(IC50 10.2±3.8 and 7.3±0.6 nM, respectively) (Table 2.6). A similar trend was observed 
when the biotin conjugates were assayed in the IL-2 reporter assay with the FK506-
HTFB-biotin probe 2.19 showing a >4-fold decrease in IC50 value compared to the 
corresponding FK506-HBPA-biotin conjugate 2.20. 
 
Table 2.6. IC50 values for IL-2 inhibition of Jurkat T cells by the diastereomeric 
FK506/HTFB ethers (2.13b/2.13bʹ′) and FK506-HPBA ethers (2.18/2.18ʹ′) and biotin 
conjugates 2.19 and 2.20.  
  
Compound IC50 (nM)a 
2.13a 1.8±0.2 
2.13b 15.9±2.8 
2.13bʹ′  19.2±14.5 
2.18 10.2±3.8 
2.18ʹ′  7.3±0.6 
2.19 97.4±17.5 
2.20 27.9±10.6 
aStandard deviations provided for assays performed in triplicate. 
 
In the most dramatic demonstration of the impact of a smaller steric footprint, 
side by side comparison of the two FK506-biotin probes 2.19 and 2.20 showed that the 
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smaller α-trifluoroethyl conjugate only led to pull-down of FKBP12, while the p-
bromophenyl conjugate led once again to pull-down of the entire ternary complex 
containing both FKBP12 and calcineurin (Figure 2.10).  
 
 
Antibodies are abbreviated as: CnA, calcineurin A; CaM, calmodulin; FKBP12, FK506 
binding protein 12 (*means long time exposure). Red arrows indicate proteins that 
specifically bind to the FK506 probes including CnA, CaM, and FKBP12. 
 
Figure 2.10. Proof of principle affinity chromatography experiments with FK506-
HBPA-biotin conjugate (2.19) and FK506-HTFB-biotin conjugate (2.20). Conjugates 
were incubated with Jurkat T cell lysates with or without pre-incubation with FK506 
(left panel: silver staining of all retained proteins; right panel: Western blotting by 
indicated antibodies).  
 
These results demonstrated the profound effect of a smaller α-trifluoroethyl 
versus a larger p-bromophenyl substituent in pull-down experiments and is consistent 
with C32-aryl substituted FK506 derivatives, which were previously reported to increase 
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binding to calcineurin.46 This previous study also described the increased IL-2 inhibition 
by C32-aryl versus C32-trifluorethyl substituted FK506 derivatives proposed to be due 
to favorable π-π interactions with calcineurin. 
Fumagillol (2.15a, Table 2.4) is a natural product known to inhibit angiogenesis 
through irreversible inhibition of human methionine aminopeptidase type 2 (hMetAP2). 
The O−H insertions proceeded in good yield to provide HTFB-fumagillol 2.15b/2.15bʹ′ 
(63%) and HBPA-fumagillol 2.21/2.21ʹ′  (58%) without competing cyclopropanation or 
epoxide degradation (Scheme 2.7).  
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Previous SAR studies have shown that the structure of the C6-substituent can 
dramatically affect bioactivity.47 We thus set out to evaluate the difference between 
trifluoroethyl and p-bromophenyl-substituted fumagillol derivatives obtained from O−H 
insertion of the C6-alcohol of fumagillol. Docking experiments with HTFB- and HBPA-
fumagillol (2.15b/2.15bʹ′  and 2.21/2.21ʹ′) using the X-ray structure of hMetAP2 
suggested that the p-bromophenyl derivative (2.21/2.21ʹ′) would suffer from greater 
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unfavorable interactions upon binding to hMetAP2 compared to the α-trifluoroethyl 
derivative (2.15b/2.15bʹ′) (Figure 2.11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11 Side-by-side comparison of docked fumagillol-HBPA (2.21/2.21') and 
fumagillol-HTFB (2.15b/2.15b') and the crystal structure of fumagillin-bound hMetAP2. 
Cobalt atoms are shown in purple, His-231 (the residue forming the covalent linkage) is 
marked, and a 5Å zone around fumagillin is rendered as a Connolly surface. 
 
Based on molecular modeling and docking,48 both HTFB and HBPA derivatives 
of fumagillol (Figures 2.11a-c) appear to fit into hMetAP2's substrate binding pocket. 
However, the p-bromophenyl group of HBPA did not have as much conformational 
a) Structure of fumagillin bound hMetAP2 
(PDB ID: 1BOA). 
b) Putative structure of 2.15b/2.15b', 
sculpted from PDB ID: 1BOA. 
c) Putative structure of 2.21/2.21', 
sculpted from PDB ID: 1BOA. 
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flexibility as the α-trifluoroethyl of HTFB within the pocket. Furthermore, the p-
bromophenyl group might be a liability since the fumagillol-HBPA derivative 
(2.21/2.21ʹ′) would appear to require larger entrance into the binding pocket through the 
'exit tunnel'. Thus, the interaction of fumagillol with hMetAP2 was chosen as a second 
test system to test the differences that could result between p-bromophenyl and α-
trifluoroethyl derivatives, which possibly generalized the effect of α-substituent steric 
footprint for several natural products. 
The derived diastereomeric fumagillol ethers 2.15b/2.15b' and 2.21/2.21' were 
not readily separated; therefore, they were used as a mixture of diastereomers for in 
cellulo protein profiling (Scheme 2.8). Side-by-side assays with fuma-alkyne (2.22) and 
TNP470 (2.23) were performed for comparison. The affinity experiments with 
fumagillol-HTFB (2.15b/2.15bʹ′) led to greater pull-down of MetAP2 than that of 
fumagillol-HBPA (2.21/2.21ʹ′) (Figure 2.12). Consistent with these results, fumagillol-
HTFB 2.15b/2.15bʹ′  also showed greater inhibitory activity in a human umbilical vein 
endothelial Cells (HUVEC) proliferation assay compared to the fumagillol-HBPA 
derivatives 2.21/2.21ʹ′  (~5-fold decrease, IC50 115.3±35.4 and 568.2±215.1 nM, 
respectively).  
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Scheme 2.8 
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Figure 2.12. Affinity chromatography experiments with fumagillol derivatives 
2.15b/2.15bʹ′, 2.21/2.21ʹ′, 2.21 and 2.23. Click reactions to catch the fumagillol targets 
were performed in vivo using azide 2.24 to afford biotinylated fumagillol derivatives. 
The target of fumagillol was analyzed by blotting membrane with streptavidin 
horseradish peroxidase or antibody against hMetAP2. 
Lane 1: 10% input; Lane 2: DMSO; 
Lane 3: Fumagillol-alkyne (2.22) in 
competition with TNP470 (2.23); 
Lane 4: Fumagillol-alkyne (2.22); 
Lane 5: Fumagillol-HTFB (2.15b/ 
2.15bʹ′); Lane 6: Fumagillol-HBPA 
(2.21/2.21ʹ′). Bottom: Western 
blotting to confirm hMetAP2 (human 
methionine aminopeptidase type 2). 
The arrow points to MetAP2. 
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A similar trend was observed when 2.15b/2.15bʹ′ and 2.21/2.21ʹ′  were assayed in 
the MetAP2 enzymatic assay (Table 2.7). The fumagillol-HTFB 2.15b/2.15bʹ′  showed 
~4-fold increase in EC50 value compared to fumagillol-HBPA 2.21/2.21ʹ′  (EC50 
0.27±0.03 and 0.95±0.23 µM, respectively). Thus, the comparative results of both 
fumagillol and FK506-HBPA and HTFB alcohol derivatives highlighted the significance 
of the smaller steric footprint and demonstrate the utility of the novel α-trifluoroethyl 
diazo reagent 2.3a for natural product derivatization. 
 
Table 2.7. IC50 values in HUVEC cells and the EC50 values from hMetAP2 assay of 
fumagillol (2.15a), fumagillol-HTFB (2.15b/2.15bʹ′) and fumagillol-HBPA (2.21/2.21ʹ′).  
 
Compound IC50 Proliferation (nM)a 
EC50 MetAP2  
(µM)a 
2.15a ND 0.06±0.01 
2.15b/2.15bʹ′  115.3±35.4 0.27±0.03 
2.21/2.21ʹ′  568.2±215.1 0.95±0.23 
2.22 0.47±0.07 ND 
2.23 0.16±0.06 ND 
aStandard deviations provided for assays performed in triplicate. ND =  
not determined. hMetAP2 = human methionine aminopeptidase type 2. 
 
 
2.3. Conclusion 
In conclusion, the variation of chemo- and site selectivity of O−H insertion 
protocol for derivatization of alcohol-containing natural products was described by 
employing Rh(II) catalysts including achiral and chiral catalysts. The results suggest that 
each natural product has specific shape-shape interactions or specific “shape fit” with 
particular metal carbenoids. Therefore, the overall shape interaction and reactivity of 
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catalyst are more important than chirality of the catalyst itself. Furthermore, we have 
developed two new diazo reagents, the α-trifluoroethyl diazo reagent 2.3a (HTFB) and a 
p-azidophenyl diazo 2.3d reagent for simultaneous arming and SAR studies of bioactive 
natural products via O−H insertion. HTFB (2.3a) possesses a reduced steric footprint 
compared to the p-bromophenyl reagent (2.1) and enables the use of 19F-NMR to 
facilitate small-scale, crude derivatization reaction analysis. Furthermore, this reagent 
showed comparable reactivity and good chemosite selectivity compared to HBPA (2.1). 
The difference in steric footprint and binding affinity of an HTFB-FK506 derivative for 
FKBP12 was demonstrated by measurement of IC50 values in the IL-2 reporter assay; in 
addition, affinity chromatography experiments in side-by-side comparisons of FK506-
HTFB-biotin (2.19) and FK506-HBPA-biotin (2.20) led to dramatic differences in 
proteins captured. Furthermore, HTFB- and HBPA-fumagillol derivatives prepared by 
these methods also demonstrated the advantage of the α-trifluoroethyl substituent in 
terms of smaller steric footprint leading to increase the binding to hMetAP2. The p-
azidophenyl diazo reagent 2.3d should prove useful for photoaffinity experiments with 
low affinity natural product receptors. Further applications of these reagents to natural 
product derivatization and their subsequent use for receptor isolation are under active 
investigation. 
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CHAPTER III 
 
SYNTHESIS OF β-LACTAM CONGENERS OF ORLISTAT AS FATTY ACID 
SYNTHASE INHIBITORS*   
 
3.1. Introduction 
 In the past several decades, cancer research has continuously been an ongoing 
study due to its complicated metabolic pathway and uncontrolled tumor growth. Cancer 
has long been known as a malignant disorder in human diseases. Based on the 
GLOBOCAN, about 12.7 million cancer cases were reported and 7.6 million cancer 
patients died in 2008.49 Disordered intermediary metabolism in human cancer cell has 
been well documented50 since Warburg reported the first observation of high levels of 
anaerobic metabolism in cancer cells (known as the “Warburg effect”) in1924.51 
Increased anaerobic glycolysis has become an indication of the transformed phenotype 
of cancer cell lines, since the glycolytic pathway is an essential energy source for tumors 
(Figure 3.1).52 In the 1950s, Greenstein50 and Medes53 observed an elevated level of fatty 
acid synthesis in tumor tissue, which suggested affiliation between glycolytic pathway 
and fatty acid synthesis. However, little attention was given to endogenous fatty acid 
synthesis in human cancer cell lines. Thirty years later, Beaker54 described the de novo 
synthesis of fatty acids in tumor cells that could be a significant source of fatty acid for 
                                                
  *Reprinted with permission from “β-Lactam Congeners of Orlistat as Inhibitors of 
Fatty Acid Synthase” by Zhang, W.; Richardson, R. D.; Chamni, S.; Smith, J. W.; 
Romo, D. Bioorg. Med. Chem. Lett. 2008, 28, 2491-2494. Copyright 2008, Elsevier, See 
Appendix B. 
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tumor growth, despite having adequate nutritional lipid supply from outer sources. 
Recently, Kuhajda55 revealed the association between fatty acid synthesis towards poor 
prognosis in breast cancer and the inhibition of fatty acid synthesis effectively and 
selectively killing cancer cells. Regarding these observations, fatty acid synthesis has 
slowly emerged as a cancer chemoprevention and continues to be of significant interest 
in tumor biology.  
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Figure 3.1. Fatty acid synthesis and its functions in mammalian tissues. 
 
3.1.1. Structure and Function of Mammalian Fatty Acid Synthase 
 Fatty acid synthase (FAS) is a 272 kDa multi-complex enzyme that plays an 
essential role in fatty acid synthesis leading to the formation of palmitate, a 16-carbon 
saturated free fatty acid (Scheme 3.1).56 FAS can be found in all plants and animals and 
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it is classified into two principal classes. The FAS I is a single, large, multifunctional 
polypeptide that controls the formation of palmitic acid, while FAS II is the 
monofunctional enzyme that associates with FAS I to generate a range of lipids for 
mitochondria functions.57 The FAS I has recently been found to be an important target 
for oncology since it showed oncogenic activity58 and its inhibition effectively and 
selectively kill cancer cells, with low cytotoxicity to normal cells.59 
The structure of mammalian FAS consists of two identical multifunctional 
polypeptides, which contain 6 catalytic domains and 1 protein carrier that arrange in an 
intertwined, X-shaped, head-to-head homodimer with a buried surface area of 5400 Å2 
(Figure 3.2).60 
The two polypeptide-chains are associated with each other through hydrophobic 
interactions between the KR, ER and DH domains of the two subunits, which is located 
at the center of the FAS structure. Each domain adopts a coiled conformation that allows 
multiple intra- and inter-subunit interactions between the functional domains. The FAS 
structure can be divided into two portions involving the condensing portion (KS and 
MAT domains) and the β-carbon modifying portion (DH, ER, and KR domains). The N-
terminal domains are β-ketoacyl synthase (KS), malonyl/acetyltransferase (MAT), and 
dehydrogenase (DH), and the C-terminal domains are enoyl reductase (ER), β-ketoacyl 
reductase (KR), acyl carrier protein (ACP), and thioesterase (TE). 
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Figure 3.2. Structure and domain organization of fatty acid synthase (FAS). (a) 
Conventional dimeric model: head-to-tail organization, (b) Revised X-shaped dimeric 
model: head-to-head organization, (c) 3.2 Å crystal structure of fatty acid synthase 
(FAS). KS=ketoacyl synthase; MAT=malonyl/acetyltransferase; DH=dehydrogenase; 
ER=enoyl reductase; KR=ketoacyl reductase, ACP=acyl carrier protein; TE=thio-
esterase; The two non-enzymatic domains, ΦKR=pseudo-ketoreductase and 
ΦME=pseudo-methyltransferase.  
 
 
In normal tissues, more than 25 enzymes are involved in the metabolism of 
glucose to fatty acids. However, the fatty acid synthetic pathway conducted by FAS 
involves three crucial steps that happen respectively:61 (1) the condensation of malonyl-
CoA and acetyl-CoA catalyzed by MAT, (2) elongation, a 7-repeating cycle of reduction 
and dehydration to extend 2 carbons in each cycle, resulting in the elongating of the fatty 
acid chain catalyzed by KS, DH, ER, and KR, and (3) termination to release palmitate 
from ACP catalyzed by TE (Figure 3.3).  
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Figure 3.3. Synthesis of palmitic acid by fatty acid synthase. 
 
This process consumes 1 acetyl-CoA, 7 malonyl-CoA, 7 ATP, and 14 NADPH 
molecules to produce one molecule of palmitate. In highly lipogenic tissues such as 
liver, lactating breast and adipose tissue of well-nourished adults, the primary role of 
fatty acid synthesis is energy storage by converting excess carbohydrates to fatty acids, 
followed by esterification to store as triacylglycerol. Furthermore, fatty acid synthesis has 
specialized functions such as lactation to produce fatty acids that are easily digested by 
infant.  
 
3.1.2. Fatty Acid in Tumorigenesis and Fatty Acid Synthase Inhibitors 
 In normal human tissues, the down-regulation of FAS is normally observed 
because of sufficiently high levels of fat consumption.62 A number of studies have 
shown the over expression of FAS in tumor cells including carcinomas of the colon63, 
prostate,64 ovary,65 endometrium66 and breast.67 The de novo fatty acid synthesis of 
cancer cells results in palmitate, which is similar to the product from normal liver and 
lipogenic tissues, though FAS is up-regulated in cancer cells and the resulted palmitate is 
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predominantly incorporated into phospholipids, not triacylglycerol. Furthermore, fatty 
acid synthesis in tumor cells is transcriptionally generated either by hormones or 
oncogenes that are operated through kinase pathways, not by food consumption as 
occurring in normal lipogenic tissue. Additionally, the level of FAS can be detected in 
patient’s blood. The mechanism for FAS up-regulation in cancer cells has not yet been 
discovered. However, the over expression of FAS, resulting high levels of 
phospholipids, points to the sufficient energy for promoting tumor growth. This 
hypothesis has been supported particularly in breast and prostate cancer, where clinical 
studies found an association between FAS expression and cancer prognosis.68 
The inhibition of FAS has been studied by employing a diverse array of natural 
products as FAS inhibitors (Table 3.1). Each FAS inhibitor has a different inhibiting 
mechanism and inhibits different FAS domains.69 According to pharmacological studies, 
FAS inhibitors exhibit anticancer activity by blocking tumor cell proliferation, eliciting 
tumor cell death, and preventing tumor growth in animal models. Together, these details 
highlight FAS as a therapeutic target for diagnosis and prognosis of human cancer, and 
the studies of FAS inhibition potentially lead to new anticancer therapeutics and 
chemoprevention protocols.  
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Table 3.1. Fatty acid synthase (FAS) inhibitors and their protein targets. 
FAS Inhibitorsa FAS Domain targetsb 
Cerulenin KS 
C75 KS, ER and TE 
C93 KS 
Orlistat and β-lactone derivative TE 
5-(furan-2-ylmethylene) pyrimidine 2,4,6-trione TE 
Tea polyphenol (EGCG and ECG) KR 
EGCG hydrolytic product MAT 
Flavonoid KR 
Triclosan ER 
aSee Ref. 47d and references cited for details. bFatty acid domains: KS=ketoacyl synthase; 
MAT=malonyl/acetyltransferase; ER=enoyl reductase; KR=ketoacyl reductase; TE=thio-esterase.  
 
 
3.1.3. Orlistat, a Fatty Acid Synthase Inhibitor with Antitumor Activity 
Orlistat (Tetrahydrolipstatin) is one of the well-known FAS inhibitors as an 
antiobesity drug with potential antitumor activities. It is the first Food and Drug 
Administration (FDA)-approved, over-the-counter weight loss medication under the 
trade name ‘Xenical’ by Roche and ‘Alli’ by GlaxoSmithKline that is distributed to 
many countries including United States. This antiobesity drug primarily inhibits 
pancreatic and gastric lipases within the gastrointestinal (GI) tracts by blocking 
hydrolysis of triglycerides, thus no fatty acid uptake from diet.70 In 2004, orlistat was 
also found to inhibit the thioesterase domain (TE) of fatty acid synthase (FAS), which is 
an important enzyme for cancer growth.71 The FAS-TE mechanism of inhibition by 
orlistat involves a tight-binding, irreversible inhibition by formation of a new covalent 
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bond at the active site of serine via acylation by the β-lactone (Figure 3.4).72 
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Figure 3.4. Orlistat (3.1) and inhibition of FAS-TE mechanism. 
 
Regarding to the effective blocking of cellular FAS activity, orlistat induces 
endoplasmic reticulum stress and apogenesis in tumor cells, inhibits endothelial cell 
proliferation and angiogenesis.58 Several studies toward FAS inhibitors have shown an 
antitumor activity including prostate, breast, ovary, and melanoma cancer cells without 
adverse effects on normal cells. However, the clinical application of orlistat for 
systematic use in cancer chemotherapy is very limited due to poor solubility and oral 
bioavailability. Indeed, one important aspect of orlistat is observed in the determination 
of the orlistat-FAS-TE co-crystal structure59 to confirm the binding mode and inhibiting 
mechanism (Figure 3.5).  
The crystal structure displays the binding pocket in the FAS-TE domain that can 
be divided into three portions: a cavity that holds the N-formyl-L-leucine moiety of 
orlistat, the specificity channel where the 16-carbon palmitate core binds, and the short-
chain pocket that accommodates the hexanoyl tail. In FAS-TE active sites, orlistat exists 
in two forms: a serine adduct derived from a covalently bounded acyl-enzyme 
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intermediate (Figure 3.5a) and a hydrolyzed product derived for β-lactone hydrolysis by 
water yielding the hydroxy acid moiety (Figure 3.5b). These findings, together with 
molecular docking studies, provide useful information for structure-based drug design 
for drug development and SAR studies of orlistat and other orlistat-like analogues as 
promising anticancer therapeutics. 
 
 
 
Figure 3.5. Binding mode of orlistat in the TE domain of FAS. (a) a serine adduct 
intermediate, (b) a hydrolyzed product (gray ball and stick,) with superimposed serine 
intermediate (pink ball and stick) to show the shifts and changes in the hydrolyzed 
product.   
 
(a) 
(b) 
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3.1.4. Synthesis of β-Lactones via Tandem Mukaiyama Aldol-Lactonization 
(TMAL)  
β-Lactones is a versatile synthetic intermediates that can undergo a variety of 
transformations in stereospecific functionalization to achieve the key intermediates for 
various natural product syntheses.73 Several direct approaches leading to asymmetric 
synthesis of β-lactone have been reported74 including a highly diastereoselective route to 
racemic trans-3,4-disubstituted β-lactones based on a tandem Mukaiyama aldol-
lactonization (TMAL). In 1994, Hirai and co-workers reported the first example of β-
lactone formation via a Mukaiyama aldol-lactonization.75 The cis-β-lactone was 
produced in low yield from the reaction of p-nitrobenzaldehyde and thiopyridyl ketene 
acetal with ZnCl2 (Scheme 3.1). Building on Hirai’s protocol, the Romo group 
developed a diastereoselective β-lactone synthesis through a tandem Mukaiyama aldol-
lactonization (TMAL) to access both trans- and cis-β-lactone from various aliphatic 
aldehydes and thiopyridyl ketene acetals by employing ZnCl276 and SnCl477, respectively 
to achieve the desired-β-lactones in good to moderate yields with high 
diastereoselectivity (Scheme 3.2) 
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Scheme 3.2 
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Throughout the course of optimization, various parameters were studied 
including Lewis acids, substituents and silyl protecting groups on ketene acetals. Several 
important results were observed to enable highly efficient β-lactone formation via 
TMAL process.78 To date, ZnCl2 was the only Lewis acid that delivered trans-β-lactones 
(3.7). Regarding the substituent on the ketene acetal, the thiopyridine moiety was found 
to be crucial for β-lactone formation due to the coordination of zinc to sulfur and 
nitrogen atom on thiopyridine moiety assisting the formation of the zinc complex. 
Furthermore, the steric bulkiness of the silyl group of the ketene acetal played an 
important role in the outcome of the TMAL process. We found that less bulky silyl 
groups increased the yield of β-lactone products. The experimental evidence also 
suggested that the Mukaiyama aldol was the rate-limiting step because no typical aldol 
products were observed from the reaction. Based on our observations, we proposed a 
mechanism of ZnCl2-mediated TMAL reactions, which associated to the highly ordered, 
boat-like transition state arrangement leading to trans-β-lactones (Scheme 3.3). 
Considering the nature of thiopyridyl ketene acetal 3.6, the poor overlapping 
between sulfur atom and the adjacent carbon atom leads to a high degree of sp3 character 
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that facilitates the formation of a cyclic transition state arrangement. The sulfur atom has 
an available site to coordinate with zinc(II) and forms 4-membered, tetrahedral zinc(II) 
thiopyridyl chelate 3.6a (Scheme 3.3). Then, an aldehyde (3.5) chelates to zinc(II) and 
forms the diastereomeric trigonal bipyramidal zinc(II) complexes (Z)- and (E)-3.9a. The 
formation of a carbon-carbon bond leads to the intermediate (Z) and (E)-3.9b that adopts 
the boat-like transition stage arrangement, which then undergo facile transannular 
lactonization ((Z) and (E)-3.9c), followed by Zn−O bond dissociation to release the ring 
strain yielding silylated β-lactones (Z) and (E)-3.9d. Desilylation by the liberated 
chloride ion derived from 3.10b delivers trans-β-lactones 3.7.79 
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In the case of SnCl4-mediated tandem Mukaiyama aldol-lactonization (TMAL), 
SnCl4 is known to form a bidentate chelating with the 2-mercaptopyridine moiety of 
ketene acetal, which facilitates the formation of silylated ketene. Therefore, we proposed 
the [2+2] cycloaddtion mechanism between aldehyde and in situ generated silylated 
ketenes for SnCl4-mediated TMAL process to achieve cis-β-lactones (Scheme 3.4). 
Nucleophilic attack by aldehyde 3.5 to the highly activated ketene 3.12, followed by ring 
closure, delivers the silylated β-lactone intermediate (3.13). Subsequent desilylation by 
the liberated chloride ion yields cis-β-lactones 3.8.80  
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The ZnCl2 and SnCl4-mediated tandem Mukaiyama aldol-lactonization (TMAL) 
has been used to access a variety of racemic and optically active β-lactones including 
several natural products.81 
 
3.1.5. A Single-pot, Mild Conversion of β-Lactones to β-Lactams  
A β-lactam is a four-membered cyclic amide that is commonly found in several 
antibiotics such as penicillin and amoxicillin.82 This heterocycle has emerged as an 
important synthetic target and is employed as a versatile intermediate in synthesis.83 The 
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first synthetic β-lactam was reported by Staudinger in 1907 from the [2+2] cycloaddition 
of diphenylketene (3.15) and Schiff base 3.14 (derived from aniline and benzaldehyde) 
to yield β-lactam 3.16.84 
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 In the Romo’s group, we have developed several strategies for β-lactone 
transformation and extension of its utility in synthesis.85 Building on Miller’s protocol,86 
we reported an indirect route to optically active β-lactams via one-pot conversion of β-
lactones to β-lactams, involving β-lactone ring opening and intramolecular Mitsunobu 
cyclization.87 Acyl C−O ring opening of β-lactone 3.17 by hard-nucleophile such as O-
benzyloxyamine delivered β-hydroxy amide 3.18 followed by Mitsunobu cyclization to 
achieve the corresponding β-lactam 3.19 with inversion of configuration at the β-carbon. 
The cis-β-lactones resulted trans-β-lactams. In most cases, high diastereoselectivity of 
the derived β-lactams were observed. However, less satisfactory results were obtained 
when the α-carbon was substituted with heteroatom such as OBn and SiMe3. 
 
 
 
 
 61 
Scheme 3.6 
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3.1.6. Synthesis of β-Lactone Congeners of Orlistat and SAR Studies 
In previous synthetics studies toward FAS inhibitors, a variety of orlistat 
congeners were prepared using our ZnCl2-mediated tandem Mukaiyama aldol-
lactonization (TMAL) process as a key step (Scheme 3.7).81g,h,j  
 
Scheme 3.7 
Orlistat (3.1); R1 = C10H21, R2 = C6H13, R3 = CH2(CH3)2
Valilactone (3.1a); R1 = C5H11, R2 = C6H13, R3 = CH2(CH3)2
Panclicin D (3.1b); R1 = C7H15, R2 = C10H21, R3 = H
Lipstatin (3.1c); R1 = C5H11-(cis-CH=CH)-CH2-(cis-CH=CH)
                          R2 = C6H13, R3 = CH2(CH3)2
ZnCl2-promoted
TMAL
H
TBSO O
R1
S
OTBS
R2
N
3.21
3.1a-c
+R1
O
O
R2
O
R3 NHCHO
O 3.20
 
 
Comparative antagonistic activity of derived orlistat derivatives toward a 
recombinant form of FAS-TE was reported along with comparative activity-based 
profiling. Several novel β-lactone based orlistat analogs showed the improved potency 
toward FAS-TE inhibitor, an increased potency toward tumor cells, and greater selectivity 
for tumor cells over fibroblasts. However, the structural requirements for inhibition of 
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FAS-TE and factors for improving solubility, potency, and selectivity were delineated 
(Table 3.2).81j These results provided an important fundamental aspect for structure-
based design of β-lactones with optimal cytotoxicity profiles, and it has been suggested 
that the orlistat congeners can be optimized for use in preclinical drug design and 
clinical drug development in carcinomas treatment.  
 
Table 3.2. Orlistat congeners that displayed enhanced FAS-TE inhibitory but different 
cellular selectivity.a 
 
Entry O O
R2
O
R3 NHCHO
O
R1
 
FAS-TE 
IC50 (µM) 
MDA-MB-
231 
IC50 (µM) 
Hs58.Fs 
IC50 
(µM) 
1 R
1 = C10H21, R2 = C6H13  
R3 = (CH3)2CH2; (Orlistat) 
1.35 16.8 70.2 
2 R
1 = C4H9, R2 = C6H13 
R3 = (CH3)2CH2; (Valilactone) 
0.03 10.5 >100 
3 R1 = C10H21, R2 = C2H5, R3 = H 0.23 1.3 10.0 
4 R
1 = (CH=CH)CH2, R2 = C6H13 
R3 = (CH3)2CH2 
0.28 3.3 29.6 
5 R1 = C4H9, R2 = C6H13, R3 = H 0.10 48.0 52.2 
6 R
1 = C7H15(CH=CH)CH2 
R2 = C6H13, R3 = (CH3)2CH2 
0.12 >100 43.9 
7 R1 = C12H25, R2 = C6H13, R3 = H 0.21 26.9 37.3 
8 R
1 = C12H25, R2 = C6H13 
R3 = PhCH2 
0.29 >100 >100 
aMDA-MB-231 is the breast carcinoma cells and Hs58.Fs is the foreskin fibroblasts. These two cell 
lines were used to distinguish mechanism based cell death that elicited by inhibition of FAS from 
general cytotoxicity.  
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3.2. Results and Discussion 
As part of ongoing efforts to develop new β-lactone based transformations, we 
previously reported a mild, efficient two-step, one-pot method for conversion of β-
lactones to β-lactams based on the method of Miller.86 In conjunction with our ongoing 
SAR studies of orlistat targeting FAS-TE, we envisioned that conversion of the β-
lactone core to a β-lactam would lead to the discovery of a new class of FAS inhibitors 
with improved solubility and similar or greater potency and selectivity. 
Herein, we report the first synthesis of β-lactam derivatives of orlistat that exhibit 
inhibitory activity toward thioesterase domain of FAS. The synthetic strategy toward the 
synthesis of β-lactam congener of orlistat synthesis involved stereocomplementary 
SnCl4-promoted tandem Mukaiyama aldol-lactonization (TMAL) reaction leading to the 
cis-β-lactone. Subsequent conversion of the cis-β-lactone to the trans-β-lactam was 
performed via a one-pot β-lactone ring opening followed by intramolecular Mitsunobu 
reaction to obtain the desired β-lactam (Scheme 3.8).88 
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 The first target was β-lactam 3.24a, which directly mimics the stereochemistry 
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and substituent pattern of orlistat, except the shorter β-substituent. The aldehyde 3.22a 
was prepared from dianion alkylation89 of methyl acetoacetate (3.25) leading to 3.26. A 
stereogenic center was elaborated from asymmetric Noyori reduction90 to afford 
optically active β-hydroxy ester 3.27 followed by silylation and ester reduction to obtain 
enantiopure aldehyde 3.22a in good yield (Scheme 3.9).  
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The known ketene acetal 3.28 was prepared from thioesterification of octanoyl 
chloride (3.28a) and 2-mercaptopyridine (3.28b) to obtained thioester 3.28c. Subsequent 
stereoselective deprotonation91 followed by treatment with tert-butyldimethylsilyl 
chloride (TBSCl) afforded (E)-silyl ketene acetal selectively (Scheme 3.10).  
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The crucial sequences commenced with SnCl4-promoted TMAL reaction with 
aldehyde 3.22a and (E)-silyl ketene acetal 3.28 to predominantly deliver the desired cis-
β-lactone (+)-3.23a as a 6:1 mixture of syn/anti diastereomers (Scheme 3.11). Complete 
cis-selectivity of β-lactone core was verified by analysis of the coupling constant, which 
showed JHα,Hβ = 7.0 Hz corresponding to our previous report.77 The relative 
stereochemistry with respect to the δ-center was confirmed, based on our previous 
observations,74a,81h,81j and it was consistent with Evans’s 1,3-asymmetric induction 
model for Mukaiyama aldol addition of β-siloxy aldehyde.92 The facial selectivity via 
1,3-induction involved internal chelation between Lewis acid and both carbonyl and β-
oxygen substituent to deliver a conformationally locked, which promoted the 
nucleophilic-attack on the less hindered face leading to anti-adduct (+)-3.23a, respected 
to δ-siloxy group and β-lactone. 
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 Followed an application of a one-pot conversion of cis-β-lactone to trans-β-lactam 
by β-lactone ring opening with benzyloxy amine and intramolecular cyclization through 
Mitsunobu reaction leaded to the formation of β-lactam (−)-3.31 with preserved 
diastereoselectivity (Scheme 3.12). 
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Subsequent desilylation of (−)-3.31 yielded δ-hydroxy-β-lactam (−)-3.32. Finally, 
acylation with N-formyl-L-valine to mimic the ester side chain of orlistat, followed by 
SmI2-promoted reductive N−O bond cleavage of the N-benzyloxy-β-lactam yielded β-
lactam congener of orlistat (−)-3.24a in 9 steps with 8% overall yield (Scheme 3.13). 
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For SAR study, we also targeted the synthesis of β-lactam 3.24b bearing 
different amino acid in ester side chain (Scheme 3.14) by employing similar synthetic 
strategy as previously explained. The SnCl4-promoted TMAL reaction of the optically 
active aldehyde 3.22b and thiopyridyl ketene acetal 3.28 provided the cis-β-lactone (+)-
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3.23b with excellent diastereoselectivity (dr, 15:1). The one-pot conversion of the cis-β-
lactone (+)-3.23b to trans-β-lactam (−)-3.34 followed by desilylation afforded alcohol 
(−)-3.35. Subsequent acylation with N-formyl-glycine and reductive N−O bond cleavage 
by SmI2 completed the synthesis of β-lactam (−)-3.24b (dr, 15:1) in 14% overall yield. 
In addition, the enantiomeric series were also synthesized for SAR comparison 
employing RuBr2[(S)-BINAP] to prepare the enantiomer of aldehyde 3.22b to obtaining 
β-lactam (+)-3.24b in comparable yields. 
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The inhibitory activities of the derived orlistat β-lactam derivatives were 
determined by the biochemical fluorogenic assay using recombinant FAS-TE (Table 
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3.3). Not surprisingly, in general, the β-lactam derivatives exhibited lower FAS-TE 
inhibitory activity compared to orlistat (IC50 =1.35 µM) due to the greater stability of β-
lactam moiety toward nucleophilic attack by serine active site comparing to β-lactone. 
Most of N-benzyloxy β-lactam derivatives (3.32, 3.34, 3.36 and 3.37) showed only 
moderate inhibitory activity toward recombinant FAS-TE with IC50 in micromolar range 
(30-100 µM). Surprising exception was β-lactam (−)-3.35, which retained the N-
benzyloxy group, silyl ether and also shares the same absolute stereochemistry with 
orlistat. This derivative showed the highest inhibitory activity (IC50 = 8.6 µM) among all 
studied β-lactams. 
 
Table 3.3. Inhibitory properties of β-lactam derivatives of orlistat toward recombinant 
FAS-TE domain. 
 
Compound Complement Inhibition IC50 (µM) 
Compound Complement Inhibition IC50 (µM) 
(−)-3.24aa Inconclusive result (−)-3.35 8.6 
(−)-3.24bb No inhibition (+)-3.35 97.4 
(+)-3.24bb No inhibition (−)-3.36 86.8 
(−)-3.32 50.5 (+)-3.36 61.2 
(−)-3.33 67.6 (−)-3.37 68.9 
(−)-3.34 58.2 (+)-3.37 39.2 
a dr, 6:1. b dr, 15:1.  
 
Unfortunately, inhibitory study of β-lactam (−)-3.24a, having a shorter carbon 
side chain at the β-position, was inconclusive as it failed to exhibit a regular dose-
response in the fluorogenic assay. It is also highlighted that a shorter chain at the β-
position of the β-lactam relative to the β-lactone of orlistat, did not show significant 
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improvement in the inhibitory activity toward recombinant FAS-TE, while the 
improvement in the inhibitory activity was observed in β-lactone derivatives.81j 
Unexpectedly, neither β-lactam (+)-3.24b nor its enantiomer, which is structurally most 
similar to orlistat, showed inhibitory activity; however, this may be due to solubility 
which is also a problem found in SAR studies of orlistat.  
 
3.3. Conclusion 
Several β-lactam congeners of orlistat were successfully prepared for further 
structure-activity relationship studies (SAR) to evaluate the inhibitory toward 
thioesterase domain of FAS. The synthetic approach toward β-lactam congeners of 
orlistat involved SnCl4-mediated tandem Mukaiyama aldol-lactonization (TMAL) 
reaction and a one-pot conversion of the β-lactone to the β-lactam as the key steps to 
deliver the desired β-lactam target. The inhibitory activities of the derived β-lactam 
derivatives were evaluated against a recombinant form of FAS-TE. In general, these 
derivatives showed lower potency toward FAS-TE compared to their β-lactone analogs. 
However, the β-lactam (−)-3.35 possessing a N-benzyloxy-β-lactam was discovered to 
have a good potency (IC50 = 8.6 µM). This significant finding suggests that this class of 
compounds should be further investigated as the potential FAS inhibitors. 
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CHAPTER IV 
 
SYNTHETIC STUDY TOWARD THE TOTAL SYNTHESIS OF 
SPONGIOLACTONE 
 
4.1. Introduction 
Spongiolactone (4.1) is a marine diterpenoid natural product discovered by Sica 
and co-workers in 1986 from the extraction of Mediterranean sponge Spongionella 
gracilis which was found in Italy (Figure 4.1).93 This natural product displays a unique 
structure that resulted from a heavily rearrangement of spongian diterpene carbon 
skeleton (4.2). Indeed, spongiolactone has partial structural features resembling to the 
previously isolated gracilin diterpenes.94 This thus suggested that spongiolactone 
delivered from a similar precursor but though a different biosynthetic pathway.  
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Figure 4.1. Structure of spongiolactone (4.1) and spongian diterpene skeleton (4.2). 
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4.1.1. Structural Assignment, Features, and Biological Activity of Spongiolactone 
and Congeners 
As a part of the target re-isolation to accumulate large quantities of the new 
spongian diterpene family for a variety of biological assays, spongiolactone was isolated 
and its stereostructure was elucidated on the basis of chemical and physicochemical 
evidence. Regarding to spectroscopic data and chemical evidence reported by Sica,84 
spongiolactone was isolated as an optically active, colorless oil ([α]D +67.6, c 1.7, 
CHCl3) and the IR spectrum showed two carbonyl absorptions at 1830 and 1730 cm-1, 
which are characteristic absorption of β-lactone and ester functionalities, respectively. In 
addition, LiAlH4 reduction and subsequent acetylation of spongiolactone gave an 
expected triacetate 4.3 (Scheme 4.1).  
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The relative stereochemistry of spongiolactone was revealed based on extensive 
spin decouple experiments. The results that were obtained from NOE correlations fully 
corresponded to the proposed structure (Figure 4.2). However, considering the coupling 
constants of spongiolactone (4.1) and its reduced triacetate product (4.3) showed the 
equivocal relative stereochemistry by the unexpected low coupling constant of trans-
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protons on C14-C15 of 4.1 (J = 4.4 Hz) and identical coupling constants were observed 
from trans-protons on C14-C15 and cis-protons on C6-C15 of 4.3 (J = 8.0 Hz) (Table 
4.1). 
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Figure 4.2. The Nuclear Overhauser Effect (NOE) correlations of spongiolactone.84 
 
Table 4.1. 1H-NMR and coupling constant (J) data of contiguous stereogenic centers of 
spongiolactone (4.1) and triacetate 4.3.a   
 
Position δH (J) of 4.1 δH (J) of 4.3 
6 3.90 ddd (6.0, 11.0, 6.0) 2.51 m 
7 3.04 dd (16.0, 11.0) 2.66 dd (16.0, 6.0) 
2.80 bdd (16.5, 8.4) 
2.29 m 
14 2.42 dd (12.0, 4.4) 2.29 m 
15 4.77 dd (6.0, 4.4) 4.90 dd (8.0, 8.0) 
16 4.14 dd (11.0, 6.6) 4.04 dd (11.0, 6.6) 
4.13 dd (11.0, 4.4) 
3.98 dd (11.0, 6.2) 
 aδH values are recorded in ppm and J values are recorded in Hz. 
 
Considering all spectroscopic evidence, Sica and co-workers reported the 
complete structure of spongiolactone as an unusual tricyclic-β-lactone-containing 
diterpenoid possessing four contiguous stereogenic centers, a stereogenic quaternary 
carbon on the cyclohexyl appendage, and an isovaleric ester chain. However, the 
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absence of a single-crystal X-ray structure leaves the relative and absolute 
stereochemistry of this natural product still in question. 
In 2009, Jaspars and co-workers reported the discovery of a demethyl congener 
of spongiolactone, 3′-norspongiolactone (4.4), from the extract of marine sponge 
Spongionella porifera found in West Angaur, the Philippines (Figure 4.3).95 The 
spectroscopic data including COSY and HMBC correlations obtained for the diterpene 
moiety of 3′-norspongiolactone (4.4) were virtually identical to those reported for 
spongiolactone (4.1). The only difference between these two compounds was the 
presence of butyric ester instead of the isovaleric ester found in spongiolactone. 
Therefore, they assumed that the relative configurations of both compounds are 
identical, which was consistent with the observed 2D-NOESY data. Here again, the 
single-crystal X-ray structure of 3′-norspongiolactone was not obtained.  
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Figure 4.3. Structure of 3′-norspongiolactone (4.4).  
 
Interestingly, Jaspars and co-workers reported the biological activities of 3′-
norspongiolactone to show cytotoxicity against K562 human chronic myelogenous 
leukemia cells (IC50 12±1 µM), normal human peripheral blood mononuclear cells 
(PBMC; IC50 30±10 µM), and 60% EGF-R tyrosine kinase inhibitor. These results 
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suggested that 3′-norspongiolactone has moderate selectivity toward cancer cell lines 
compared to human normal cell lines. Due to this low selectivity, 3′-norspongiolactone 
may not be a good drug candidate for cancer therapy. Because of close structural 
similarities between spongiolactone and 3′-norspongiolactone, it can be inferred that 
their biological activities are resemble and points out that spongiolactone is likely toxic 
to both cancer and normal cell lines. 
Importantly, the relative stereochemistry of both spongiolactone and 3′-
norspongiolactone is still questionable, especially the stereochemistry of the contiguous 
stereogenic centers on C13-C14-C15. The ambiguous relative stereochemistry of the 
spongiolactone core was shown not only in the coupling constants reported by Sica 
(Table 4.1)93 and 2D-NOESY reported by Jaspars,95 but also observed from structural 
comparisons of spongiolactone and another spongian diterpenes (Figure 4.4).96 Most of 
these natural products show a similar cyclohexane baring a quaternary carbon moiety 
with an α-face proton on the carbon (C13) five atoms away from the quaternary carbon 
center (C10). These questions lead us to the primary goal for the total synthesis of 
spongiolactone to confirm its relative and absolute stereochemistry. 
Although the first isolation was reported nearly 25 years ago, the synthetic study 
toward spongiolactone has never been reported neither the biological activities nor the 
biosynthetic pathway. The presence of the β-lactone, in analogy to other β-lactone-
containing natural products, denotes to the acylating potential of this natural product 
toward cellular targets. Therefore, further bioactive probe synthesis and biological study 
may disclose modes of actions and protein targets of spongiolactone.  
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Figure 4.4. Structural comparison of spongiolactone (4.1) and spongian diterpenes. 
 
4.1.2. Intramolecular Nucleophile-Catalyzed Aldol-Lactonization (NCAL) Process 
β-Lactones have emerged as versatile synthetic intermediates due to their 
inherent reactivity derived from ring strain.73 As the masked aldehyde functionality, β-
lactones undergo a variety of transformations in stereospecific fashions and are 
employed as the key intermediates in many natural product syntheses. In recent years, 
several methodologies have been reported for the asymmetric synthesis of β-lactones 
and continue to be an active research area.74  
One of the first practical, catalytic asymmetric β-lactone syntheses was 
developed by Wynberg and co-workers in 1982 and its utility was demonstrated by the 
large-scale synthesis of optically active malic and citramalic acid.97 In this process, the 
highly reactive aldehyde 4.13 was treated with ketene 4.14 in the presence of cinchona 
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alkaloids, such as quinidine (4.16) and quinine (4.17), which were employed as the 
catalysts to deliver β-(trichloromethyl)-β-propiolactone 4.15a and 4.15b in good to 
moderate yields with excellent to moderate enantioselectivities (Scheme 4.2).  
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Although the utility of Wynberg β-lactone synthesis is well documented and 
stands as a benchmark for further development in this area, there are some limitations to 
this methodology including the need for a ketene generator and the requirement of 
highly activated aldehyde substrates (i.e., α-chlorinated). 
As part of our program to develop a concise, asymmetric route to β-lactones,85 
we described the development of a protocol that allowed the use of an in situ generated 
ketene that was delivered from acetyl chloride (4.19) and Hunig’s base providing a 
variety of optically active β-lactones in similar yields with excellent enantioselectivities 
compared to Wynberg’s protocol (Scheme 4.3). However, the highly electrophilic 
aldehydes remained a prerequisite for the preparation of β-lactones.  
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After extensive optimization to overcome the limitations of Wynberg β-lactone 
synthesis, we investigated the use of unactivated, non-α-chlorinated, aliphatic aldehydes 
in an asymmetric route to β-lactones and reported the initial development of an 
intramolecular nucleophile-catalyzed aldol-lactonization (NCAL) process of aldehyde 
acid that led to a variety of novel β-lactone-fused bicyclic systems.99 
In 2001, we reported the first example of an intramolecular, asymmetric NCAL 
reaction employing aldehyde acids as the advanced substrates. These aldehyde acids 
contained non-activated aldehydes and enabled in situ generation of ketene from 
carboxylic acids by utilizing acid activating reagent and Hünig’s base. The slow addition 
of aldehyde acid to the mixture of nucleophile (in this case O-acetyl quinidine and O-
acetyl quinine) and Mukaiyama’s reagent (acid activating agent) gave the bicyclic β-
lactones in excellent enantioselectivities (Scheme 4.4). 
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This method merges the catalytic, asymmetric β-lactones synthesis with 
carbocycle construction via organocatalysis. The optimization and exploration of the 
scope of the intramolecular nucleophile-catalyzed aldol-lactonization (NCAL) reaction 
lead to significant findings including the development of modified Mukaiyama’s 
reagents,100 investigation of nucleophiles as organic catalysts and the use of keto acids as 
the substrates for NCAL process (Scheme 4.5).101  
 
Scheme 4.5 
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Extension of these studies to keto acid substrates significantly expanded the 
scope of this process allowing access to bicyclic and tricyclic β-lactone systems that 
possess up to three stereocenters including a masked tertiary carbinol center and a 
reactive β-lactone moiety.  
After ambitious efforts to improve the NCAL process, the mechanism of the 
NCAL reaction was proposed (Scheme 4.6).101,102 This process involves two plausible 
mechanistic pathways that differ only in the two distinct reactive intermediates; the acyl 
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ammonium species (4.25) derived aldol-lactonization mechanism (Path A) and the 
ketene species (4.26) proceeding by a [2+2] cycloaddition mechanism (Path B).  
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Upon activation of the carboxylic acid by Mukaiyama’s reagent, elimination of 
the hydroxylated activating reagent would lead to ketene 4.26 that would undergo a 
[2+2] cyclization and deliver β-lactones 4.30. One other possible mechanistic pathway, 
which we believe to be the major route to catalytic, asymmetric β-lactones synthesis, is 
through the formation of an acyl ammonium species via nucleophile-promoted 
transacylation to obtain 4.25. The loss of nucleophile, which is in equilibrium with acyl 
ammonium 4.25, results in the formation of ketene (4.26) for [2+2] cyclization. On the 
other hand, subsequent deprotonation of the acyl ammonium leads to an ammonium 
enolate 2.27, which undergoes an intramolecular aldol reaction that is the stereochemical 
controlling and rate-determining step. Then, lactonization of 4.28 produces the 
tetrahedral intermediate 4.29 followed by regeneration of the nucleophile, which is 
employed as a catalyst in this process affords the bicyclic β-lactone 4.30. Because the 
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reaction is performed at room temperature, it appears reasonable to assume that either 
the highly reactive ketene intermediate is slowly generated, and thus only low 
concentrations are observed, or the acyl ammonium pathway is predominant. 
Furthermore, due to the ring stain, only cis-aldolate 4.27 would be expected to cyclize 
generating only the cis-β-lactone. In the case of the aldehyde acid, the mechanism 
assuredly involves an aldol-lactonization process due to the observed high level of 
asymmetric induction. Although the evidence is less conclusive when evaluating the 
keto acid, to date we believe that an aldol-lactonization mechanism is a major pathway 
toward organonucleophile-promoted bis-cyclization processes. 
Recently, we have developed the double diastereoselective, nucleophile-
catalyzed aldol-lactonization (NCAL) process for the synthesis of β-lactone fused 
carbocycles and β-lactone fused tetrahydrofuran using cinchona alkaloid catalysts with 
enantioenriched aldehyde acids to deliver good to excellent diastereoselectivity (Scheme 
4.7).103  
 
Scheme 4.7 
X
Y
O
OHO
O
X
Y
O
N n-Pr
Br OTf
10 mol % Nucleophile
i-Pr2NEt, CH2Cl2     
23 oC, 48 h
O
X
Y
O
+
n
H
R*
X, Y = O, CH2
n = 1, 2
n nR* R*
Nucleophile (X, Y = CH2)
Et3N ! dr = 1:1
O-TMS-Quinidine (4.20c)! dr > 19:1
O-TMS-Quinine (4.20d)! dr > 1:19
4.21b
4.31
4.32a 4.32b
 
 
 81 
Furthermore, we reported a significant advancement in the NCAL methodology 
with keto acids involving the use of Birman’s chiral cyclic isothiourea as the chiral 
nucleophile and p-toluenesulfonyl chloride as an activating agent (rather than 
Mukaiyama’s reagent) to achieve highly enantioselective bi- and tricyclic β-lactones 
(Scheme 4.8).104 
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The practical, catalytic, asymmetric NCAL process of aldehyde acids and keto 
acids has been developed and is an ongoing research area in the Romo group. 
Optimization and exploration of the scope of asymmetric processes including 
applications to heterocycles and natural product syntheses are currently underway. The 
utility of catalytic, asymmetric NCAL process has recently been demonstrated in the 
total synthesis of (−)-salinosporamide A,105 (−)-curcumalactone A.106 
 
4.1.3. Previous Studies Toward the Total Synthesis of Spongiolactone 
 In the Romo group, we have been targeting β-lactone-containing natural products 
since they contain unique structural frameworks and exhibit interesting biological 
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activities. The utility TMAL and NCAL reactions, which are asymmetric β-lactone 
forming processes developed in our group have been demonstrated in various total 
syntheses of β-lactone-containing natural products such as FDA approved antiobesity 
(−)-orlistat,81h (−)-belactocin C,81i and the highly potent anticancer (−)-salinosporamide 
A.105  
To date, there is no reported evidence of synthetic studies toward spongiolactone. 
We envisioned applying the NCAL methodology as a key step to construct the β-lactone 
core structure of spongiolactone. Importantly, this strategy would allow us to investigate 
the possibility of double asymmetric synthesis in more complex NCAL substrates and 
expand the scope of reaction conditions.  
Previously, several synthetic strategies were studied for the preparation of 
aldehyde acid substrates for the NCAL process.107 In the first route, key steps involved 
an Hajos-Parrish Robinson annulation to achieve decalin 4.37. Either (−)-proline or (+)-
proline were then employed to prepare each enantiomer of spongiolactone since the 
absolute stereoconfiguration remains unknown. A subsequent Heck coupling with 
cyclohexene 4.39 to form the stereogenic quaternary carbon, followed by oxidative 
coupling to obtain aldehyde acid 4.41. The final step involved the NCAL reaction to 
afford spongiolactone (Scheme 4.9). Due to the difficulties with selective ketone 
protection, such as no reaction-taking place or substrate decomposition, this route was 
abandoned. 
Keeping the same synthetic strategy involving a Heck coupling and the NCAL 
process in the late stages of the synthesis, the aldehyde acid precursor was alternatively 
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prepared from a Micheal addition/enolate trapping strategy (Scheme 4.10). We decided 
to begin this synthetic route in racemic fashion to expedite exploration of the full 
synthesis and then complete an asymmetric synthesis later. 
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The enone (±)-4.42 was racemically prepared from a Diels-Alder reaction 
followed by a Baylis-Hillman alkylation to obtain α-substituted enone (±)-4.43. 
Subsequent, vinyl cuprate addition and electrophilic trapping of the resulting enolate 
yielded enol (±)-4.44, which was set up for the Heck coupling and ultimately preparation 
of the aldehyde acid as a substrate for NCAL process. This route appeared to be 
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problematic due to scale up problem found in the preparation of enone (±)-4.42 and 
decomposition that took place in Baylis-Hillman reaction. Extensive optimizations were 
tried, however, no satisfying improvements were observed. Therefore, we decided to 
peruse an alternative pathway.  
Attempts in preparing the aldehyde acid precursor were successful when Stork-
Danheiser protocol was employed (Scheme 4.11).108 The vinylogous ester 4.47 was 
prepared from a Michael addition between the commercially available 1,3 
cyclohexanedione (4.45) and t-butyl acrylate to afford diketone 4.46. Subsequent 
methylation by dimethyl sulfate yielded 4.47 in quantitative yield.  
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Then, a Stork-Danheiser alkylation of 4.47 with benzyloxy chloromethyl ether 
provided α-substituted enone (±)-4.48 followed by reduction and demethylation upon 
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acidic work up gave enone (±)-4.49. To prepare the substrate for Heck coupling, vinyl 
cuprate addition followed by electrophilic trapping of the enolate yielded enol (±)-4.50 
in low yield. Although enol (±)-4.50 was successfully prepared, the Heck coupling 
failed. Several attempts to optimize the Heck coupling were studied but no promising 
results were found. Due to the difficulties encountered in this strategy, we decided to 
consider an alternative route.  
 
4.1.4. Retrosynthetic Analysis Toward the Total Synthesis of Spongiolactone 
Many routes were tried during our synthetic pursuit of spongiolactone. However, 
copious amounts of problems were encountered due to the instability of intermediates 
and impractical scale up conditions. Therefore, the synthetic route was revised to 
construct the fused tricyclic β-lactone core by the NCAL process in the early stage. In 
this way, the resulting core structure of spongiolactone is set for substrate control in the 
late stage functional group manipulations to make this a more concise and feasible 
strategy. Due to the unsuccessful Heck coupling as was previously described, we 
envisioned that the installation of the cyclohexyl appendage baring a stereogenic 
quaternary carbon could be completed by nucleophilic addition, and the formation of 
stereogenic quaternary center will be induced by substrate and reagent control.  
 After careful consideration, we planed to begin the full synthetic route by 
utilizing racemic materials, since the absolute configuration of spongiolactone remains 
unknown and several diastereomers of spongiolactone will be essential for screening 
protein targets and their bioactivities in basic cell biological studies. The asymmetric 
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synthesis will be carried out later. We envisioned that the synthesis of spongiolactone 
could be accomplished after regioselective dehydration to obtain the tetrasubstituted 
olefin, and installation of the isovaleric ester of alcohol 4.53. The key step in the late 
stage synthesis involves diastereoselective allylic zinc addition, developed by 
Knochel,109 to install the pendent cyclohexane moiety and a stereogenic quaternary 
carbon by the SEʹ′ reaction of novel zincate 4.54 and the β-lactone core 4.52. The fused 
tricyclic β-lactone 4.52 that is utilized as the key intermediate can be derived from the 
NCAL reaction with a corresponding aldehyde acid (±)-4.51. The aldehyde acid (±)-4.51 
can be readily prepared from the cheap and commercially available 1,3 
cyclohexanedione (4.45) via Stork-Danheiser kinetic alkylation as explain in the 
previous synthetic route (Scheme 4.12).  
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4.2. Results and Discussion 
A concise, racemic synthesis toward spongiolactone is envisioned by using 
inexpensive and commercially available 1,3-cyclohexanedione as the primary substrate. 
The key steps involve an intramolecular nucleophile-catalyzed aldol-lactonization 
(NCAL) reaction and diastereoselective allylic zinc addition to construct the fused 
tricyclic β-lactone core (4.52). These steps deliver the diastereoselective setting of four 
contiguous stereogenic centers and formation of the cyclohexane appendage with a 
stereogenic quaternary carbon.  
 
4.2.1. Preparation of Aldehyde Acid as NCAL Substrates 
Based on previous studies, the aldehyde acid (±)-4.51 was prepared from 1,3 
cyclohexanedione (4.45) via the Stork-Danheiser kinetic alkylation protocol. Extensive 
optimizations and synthetic modifications to enable large-scale synthesis of aldehyde 
acid (±)-4.51 were studied. 
Treatment of 1,3 cyclohexanedione (4.45) with t-butyl acrylate followed by 
dimethyl sulfate in DMF successfully provided vinylogous ester 4.47 via the two-step, 
one-pot Michael addition and methylation in quantitative yield (Scheme 4.13). This 
process improved the synthetic efficiency by one step shortening the overall synthesis of 
spongiolactone. 
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Extensive optimizations of the Stork-Danheiser kinetic alkylation were studied 
due to the impractical yield and undesired regioselectivity that was observed when 
LDA/THF conditions were employed. Fortunately, deprotonation of vinylogous ester 
4.47 by LHMDS and use of excess benzyloxy chloromethyl ether in toluene delivered 
desired α-substituted enone (±)-4.48 in good yield without O-alkylation, alkylation at 
the t-butyl ester side chain or γ-alkylation (Scheme 4.14).  
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Chemoselective reduction of the α,β-unsaturated ketone via a Luche reduction, 
avoiding the reduction of t-butyl ester which observed when DIBAL-H was used, 
followed by demethylation upon acidic work up furnished γ-substituted enone (±)-4.49 
in good yield (Scheme 4.15).  
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Then, cuprate addition of the enone (±)-4.49 with 2-methyl-1-propenyl 
magnesium bromide (R=Me) gave the desired trimethyl silyl enol ether (±)-4.55 with 
good diastereoselectity (dr, 10:1), which was better than when vinyl magnesium bromide 
(R=H) was used (dr, 5:1). The trimethyl silyl enol ether (±)-4.55 was carried on to the 
next step without purification. Treatment (±)-4.55 with TsOH in CH3CN, leading to the 
one-pot desilylation and deprotection of the t-butyl ester yielded acid (±)-4.56 in 
excellent yield (Scheme 4.16).  
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Note that employing TFA/CH2Cl2 or TsOH/CH2Cl2 (Table 4.2) caused the 
formation of undesired product (±)-4.56b, which is derived from deprotection of the 
benzyl ether under strong acidic conditions to obtain primary alcohol (±)-4.56a, 
followed by nucleophilic addition (Scheme 4.17). The structure of the undesired product 
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was confirmed by COSY and HMQC. Finally, ozonolysis of alkene acid (±)-4.56 
afforded aldehyde acid (±)-4.51 as a substrate for the NCAL process (Scheme 4.18).  
 
Table 4.2. Optimization of one-pot desilylation and deprotection of t-butyl ester. 
Entry Condition (±)-4.56 (±)-4.56a 
1 TsOH (2 equiv), CH3CN, 23 oC, 6 h 93% 0% 
2 TsOH (2 equiv), CH3CN, 23 oC, 12 h 79% 10% 
3 TsOH (2 equiv), CH2Cl2, 23 oC, 12 h 0% 58% 
4 TFA (20 equiv), CH2Cl2, 23 oC, 12 h 82% 13% 
5 TFA (30 equiv), CH2Cl2, 23 oC, 12 h 0% 62% 
6 SnCl4 (2 equiv), CH2Cl2, 23 oC, 6 h 0% 52% 
            Yields refer to isolated yield. 
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Scheme 4.18 
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In summary, aldehyde acid (±)-4.51 was racemically synthesized from a 
commercially available substrate in six steps with 32% overall yield. Along the course of 
this study, alternative routes were tried for a more concise strategy starting from 
commercially available 3-ethoxycyclohex-2-enone (4.57) to achieve the desired 
aldehyde acid (±)-4.59 in 3 steps. However, the results were unsatisfying (Scheme 4.19).  
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4.2.2. Synthesis of Diastereomeric Tricyclic Cores of Spongiolactone: Double 
Diastereoselectivity and Kinetic Resolution via the NCAL Process with 
Chiral Lewis Bases 
The successful preparation of the aldehyde acid (±)-4.51 in racemic fashion 
allowed further studies of the synthesis of the fused tricyclic β-lactone core (4.52) 
employing NCAL process, which has been planned as one of the key step toward the 
synthesis of spongiolactone. Although the NCAL process had never been attempted in 
such a complex setting, the bis-cyclization process of aldehyde acid (±)-4.51 with 
Mukaiyama’s reagent and triethylamine underwent smoothly and only required minimal 
optimization to obtain the bicyclic β-lactone product, which obtained as white crystals. 
The fully characterization including X-ray crystallographic analysis revealed the relative 
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stereochemistry of the derived β-lactone (Scheme 4.20).  
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Unfortunately, the relative stereochemistry of β-lactone moiety of (±)-4.60 did 
not match with spongiolactone (4.1). The resulted β-lactone moiety was formed in the β-
face and showed anti-relationship with benzyl ether. Additionally, the single X-ray 
structure confirmed that no epimerization happened in this process.  
This result can be rationalized by substrate control and stereoelectronic effect. 
Since the NCAL reaction of aldehyde acid (±)-4.51 was performed at 23 oC, it is 
reasonable to assume that this process is under thermodynamic control leading to a 
reversible process to deliver the more stable product. Once E-acyl ammonium enolates 
were generated, ammonium enolates 4.52a and 4.60a were in equilibrium via bond-
rotation. Following an aldol-lactonization process yields β-lactones 4.52a and 4.60a 
(Scheme 4.21).  
4.60 
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As shown in the transition state arrangement, the formation of ammonium 
enolate 4.60a was favored due to less steric hindrance between β-lactone and benzyl 
ether moiety and lower dipole moment from carbonyl moiety, comparing to ammonium 
enolates 4.52a (Scheme 4.22). Even though the ammonium enolate 4.60a has larger A1,3 
strain (1,3-allylic strain), the steric effects play an important role, resulting 
predominantly in the generation of ammonium enolate 4.60a and β-lactone 4.60 was 
obtained a single diastereomer. 
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Realizing that the wrong diastereomer was obtained from the key NCAL 
reaction, governed by substrate control, we have thought about two synthetic ideas. First, 
we plan to optimize the NCAL reaction of aldehyde acid (±)-4.51 by employing reagent 
control to override substrate preference and accomplish the desired β-lactone core 4.52 
for the total synthesis of spongiolactone. Second, in consideration of the inconclusive 
stereoconfiguration of spongiolactone, the fused tricyclic β-lactone 4.60 is continuously 
employed in late stage of the synthesis to begin the synthetic study of the 
diastereoselective allylic zinc addition which is one of the key steps in this synthesis to 
construct a stereogenic quaternary carbon. The resulting products will enable to confirm 
the relative stereochemistry of spongiolactone.  
 To accomplish the desired tricyclic β-lactone 4.52, we envisioned the use of 
chiral Lewis bases (Figure 4.5) as a chiral reagent to influence stereochemical outcome 
by overcoming inherent substrate bias through the reagent control in the double 
diastereoselective NCAL process.  
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Figure 4.5. Chiral Lewis bases for double diastereoselective NCAL. 
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Based on our previous studies, various types of chiral nucleophiles such as 
cinchona alkaloids101,103 and tetramisole analogs104 were studied for double 
diastereodifferentiation of NCAL for both aldehyde acid and keto acid substrates to 
achieve good to excellent diastero- and enantioselectivity. In the case of complex 
aldehyde acid (±)-4.51, several chiral nucleophiles were studied (Scheme 4.23) and the 
differences of diastereoselectivities were observed (Table 4.3).  
Initial investigation of double diastereoselective NCAL reaction, employing 
racemic homobenzotetramisole (HBTM) developed by Birman109 and racemic 7-
benzyloxy-6,7-dihydro-5H-pyrrolo-[1,2-a]-imidazole (OBn-DPI) developed by Zhang110 
showed the improvement of diastereoselectivity favoring the desired β-lactone core 4.52. 
Fully characterization including 2D-NMR analysis revealed the relative stereochemistry 
of the derived β-lactone 4.52. The stereogenic outcome of tricyclic β-lactone 4.52 was 
confirmed by NOESY (Figure 4.6).  
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Table 4.3. Investigation of chiral nucleophiles for double diastereoselective NCAL 
process of aldehyde acid (±)-4.51. 
 
Entry Nucleophile Yielda drb 4.52:4.60 ee of 4.52c ee of 4.60c 
1 Et3Nd 71% 1:10 - - 
2 (±)-HBTM 65% 1:2 - - 
3 (±)-OBn-DPI 35% 1:5 - - 
4 O-TMS-Quinidine 5% 1:5 >99% 45% 
5 O-TMS-Quinine 10% 1:7 78% 39% 
6 (S)-HBTM 42% 1:1 98% (+)-4.52 52% 
7 (R)-HBTM 27% 1:2 96% (−)-4.52 38% 
8 (-)-Tetramisole 3% 1:6 37% 35% 
aReaction was run on 100 mg scale and values refer to isolated yield by Prep-TLC. bEnantiomeric excess 
was determined by Chiral HPLC (OD column, 10% IPA/Hexanes, 0.9 mL/min). cDiastereomeric ratio was 
determined by 1H-NMR (500MHz) of the crude reaction mixture. d5 equiv of Et3N was used as a base and 
nucleophile.  
 
OBn
O
H
O
O H
H
H
HaHb
Hb
Ha
(+)-4.52  
Figure 4.6. Relative stereochemistry and structure analysis by NOESY of (+)-4.52. 
 
Since the tricyclic β-lactone (+)-4.52 was obtained as colorless oil, the 
conversion of benzyl ether (+)-4.52 via hydrogenation and esterification with 
commercially available p-bromobenzoyl chloride (Scheme 4.24) was successful to 
achieve a solid p-bromobenzyl ester (+)-4.52b for the single X-ray crystallographic 
analysis. However, single X-ray crystallographic studies of ester (+)-4.52b failed since 
only twined crystals were obtained.  
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Further investigation of optically active chiral nucleophiles (Table 4.3, entries 4-
8) provided the interesting results. (S)-HBTM (Table 4.3, entry 6) appeared to be the 
best nucleophile giving the best yield of bicyclic β-lactone (+)-4.52 with the highest 
degree of diastereoselectivity (dr, 1:1 of 4.52:4.60) compared to Et3N (dr, 1:10). On the 
other hand, (R)-HBTM did not increase the level of diastereoselectivity and did not 
reverse the diastereoselectivity toward the formation of β-lactone (−)-4.52. These results 
showed that (S)-HBTM is a matched catalyst. Surprisingly, the desired β-lactone core 
4.52, derived from the enantiopure chiral nucleophiles such as O-TMS-Quinidine, (S)-
HBTM, and (R)-HBTM, was obtained in excellent enantioselectivity (Table 4.3, entries 
4, 6 and 7). To the best of our knowledge, these results represent the first example of 
kinetic resolution via a double diastereoselective NCAL process. Note that in all cases, 1 
equivalent of chiral nucleophile was used to maximize the conversion to the resulting 
bicyclic β-lactone adduct; although, it was needed at catalytic amounts. 
As the purpose to improve diastereoselectivity, extensive optimizations of kinetic 
resolution and double diastereoselective NCAL process of aldehyde acid (±)-4.51 were 
studied using (±)-HBTM as a nucleophile. Note that 3 equivalents of Mukaiyama’s 
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reagent, 1 equivalent of (±)-HBTM and 4 equivalents of Hünig’s base were used as a 
general condition. Optimizations of reaction conditions were studied by varying the 
activating agents, solvents, concentrations, additives, and addition methods were studied 
(Table 4.4).  
In summary, the NCAL reaction of aldehyde acid (±)-4.51 using (±)-HBTM was 
optimal at a concentration of 0.03 M (entry 3) to obtain the highest level of 
diastereoselectivity toward the formation of the desired β-lactone 4.52 and Mukaiyama’s 
reagent was the best activation agent for this aldehyde acid. TsCl provided low yield 
(entry 5) and no reaction was observed when using MsCl (entry 6). Polar solvents such 
as CH3CN, THF and Et2O (entries 7-9) did not help increasing the formation of the 
desired β-lactone core 4.52 and non-polar solvents such as toluene and hexanes (entries 
10-12) caused no reaction due to solubility issues. The most interesting results were 
observed when the additives were added into the reactions. Slow addition of Hünig’s 
base (thermodynamically formed an ammonium enolate) increased the formation of 
undesired β-lactone 4.60 (Table 4.4, entry 13). Addition of K2CO3 to accelerate the 
reaction tremendously increased the formation of 4.60 (Table 4.4, entry 14). Adding 
hexamethylphosphoramide (HMPA) as a co-solvent to stabilize the high dipole moment 
of the transition state arrangement of 4.52 (Table 4.4, entry 15) did not significantly 
improve the NCAL outcome. Finally, addition of excess amount of Hünig’s base (Table 
4.4, entry 16) and heating at 50 oC (Table 4.4, entry 17) significantly assisted the 
formation of the undesired β-lactone 4.60.  
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Table 4.4. Optimizations of kinetic resolution and double diastereoselective NCAL 
process of aldehyde acid (±)-4.51 using (±)-HBTM as a nucleophile.  
 
Entry 
Activating Agent 
(3 equiv) 
Solvent Conc. Yielda 
dr 
4.52:4.60b 
1 Mukaiyama’s reagent CH2Cl2 0.10 51% 1:2.1 
2 Mukaiyama’s reagent CH2Cl2 0.06 55% 1:2.0 
3 Mukaiyama’s reagent CH2Cl2 0.03 42% 1:1.7 
4 Mukaiyama’s reagent CH2Cl2 0.01 10% 1:1.6 
5 TsCl CH2Cl2 0.03 25% 1:1.3 
6 MsCl CH2Cl2 0.03 NRc -- 
7 Mukaiyama’s reagent CH3CN 0.03 1% 1:3.1 
8 Mukaiyama’s reagent THF 0.03 7% 1:4.4 
9 Mukaiyama’s reagent Et2O 0.03 NR -- 
10 Mukaiyama’s reagent Toluene 0.03 NR -- 
11 Mukaiyama’s reagent Benzene 0.03 NR -- 
12 Mukaiyama’s reagent Hexanes 0.03 NR -- 
13 Mukaiyama’s reagent Slow addition of base CH2Cl2 0.03 79% 1:3.8 
14 Mukaiyama’s reagent 3 equiv K2CO3 
CH2Cl2 0.03 68% 1:30 
15 Mukaiyama’s reagent 10 equiv HMPA CH2Cl2 0.03 22% 1:2.5 
16 Mukaiyama’s reagent 50 equiv i-Pr2NEt 
CH2Cl2 0.03 72% 1:6.5 
17 Mukaiyama’s reagent Heat at 50 oC CH2Cl2 0.03 53% 1:7.3 
aValues refers to estimated yield, which calculated from HPLC calibration curve. bDiastereomeric 
ratio determined by 1H-NMR (500 MHz) of the crude reaction mixtures. cNR means no reaction.  
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 These results suggested that the undesired β-lactone 4.60 is both the 
thermodynamic and kinetic product. Therefore, the condition shown in entry 3 (Table 
4.4), using (S)-HBTM, was the best procedure giving the highest diastereoselectivity (dr, 
1:1) for the preparation of the desired β-lactone core (+)-4.52. 
 
4.2.3. Cyclohexenyl Zinc Additions: Total Synthesis of 6, 15-Bis-epi-spongiolactone  
Knochel and coworkers109 developed a strategy to construct the quaternary 
carbon in an asymmetric fashion. Addition of allyl zinc to ketones offers a 
straightforward synthesis of homoallylic alcohols bearing quaternary centers. The 
advantage of this approach is the use of the allylic zinc reagents, which are stable and 
easy to prepare. Moreover, this reaction precedes diastereoselectively and 
regioselectively under mild conditions. Recently, Knochel reported a method for 
preparation of di- and trisubstituted allylic zinc reagents by using LiCl-mediated 
insertion of zinc dust into alkyl, aryl, and heteroaryl iodides leading to organozinc 
reagents in good yields (Scheme 4.25). 
 
Scheme 4.25 
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To explore the late stage synthesis and confirm the relative stereochemistry of 
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spongiolactone, the fused tricyclic β-lactone 4.60 was employed as a substrate for the 
diastereoselective allylic zinc addition, which is the key step to construct the stereogenic 
quaternary carbon. The new allylic zinc reagent required for spongiolactone was 
prepared from an inexpensive commercially available isophorol (3,5,5-
trimethylcyclohexn-1-ol) (4.68) via chlorination and zinc insertion (Scheme 4.26). The 
chlorination was achieved via nucleophilic substitution by treating 3,5,5-
trimethylcyclohexn-1-ol (4.68) with N-chlorosuccinimide in the presence of dimethyl 
sulfide.111 The derived allyl chloride 4.69 was employed as the substrate for LiCl-
mediated zinc insertion developed by Knochel and co-workers112 to deliver zincate 4.70. 
Concentration of cyclohexnyl zinc reagent 4.70 was determined by iodine titration. 
Zincate 4.70 was obtained in low yield due to Wurtz coupling, which was the undesired 
homo-coupling reaction between 4.69 and 4.70 that is usually observed as a by-product 
in this process. We tried to optimize the zinc insertion to increase the yield of the 
formation of the desired zincate 4.70; however, the condition shown in Scheme 4.26 was 
the best. The zincate 4.70 was stable at 0 oC and slowly decomposed at higher 
temperatures. 
 
Scheme 4.26 
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The successful preparation of new zincate 4.70 allowed the further study of the 
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diastereoselective allylic zinc addition of the fused tricyclic β-lactone 4.60. To our 
delight, the diastereoselective allylic zinc addition of new zincate 4.70 to the ketone of 
fused tricyclic β-lactone (±)-4.60 in the presence of β-lactone underwent smoothly to 
achieve homoallylic alcohol (±)-4.71 as a major diastereomer in quantitative yield (95%) 
and excellent diastereoselectivity (Scheme 4.27). No trace of β-lactone ring opening was 
observed.  
The derived alcohol (±)-4.71 was fully characterized and the relative 
stereochemistry was confirmed by single X-ray crystallographic analysis, disclosing the 
stereogenic outcome of the all-carbon quaternary center. The X-ray structure showed an 
anti-relationship between methyl group on an all-carbon quaternary center and the 
adjacent tertiary alcohol. 
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We proposed a transition state arrangement of the diastereoselective allylic zinc 
addition of zincate 4.70 to the fused tricyclic β-lactone (±)-4.60 based on Knochel’s 
evidence.109 The diastereoselectivity was controlled by the cyclic chair-like transition 
state arrangement (Figure 4.7). The zincate 4.70 generally approached the ketone of (±)-
4.60 on the β-face due to steric hindrance of substrate. The SE2' mechanism resulted in 
the formation of two new quaternary centers with an anti-relationship yielding methyl 
group on the β-face and tertiary alcohol on α-face. 
 
O
ClZn
O
O
OBn
H
H
H
4.72  
Figure 4.7. Chair-like transition state of allyl zinc addition of ketone (±)-4.60. 
 
Comparing to spongiolactone (Scheme 4.27), the relative stereochemistry of all 
stereogenic centers of (±)-4.71 was matched with reported structure of natural product, 
except for the stereochemistry of the β-lactone moiety. Therefore, the synthesis was 
continued to prove and confirm relative stereochemistry of target molecule 4.1. 
To complete the synthesis, homoallylic alcohol (±)-4.71 was reduced by 
employing Pearlman catalyst (Pd(OH)2/C)113 under hydrogen atmosphere in ethanol to 
simultaneous hydrogenation of olefin and hydrogenolysis of benzyl group in the same 
operation to yield saturated alcohol (±)-4.73. Finally, selective esterification of primary 
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alcohol (±)-4.73 with isovaleric acid (4.74) followed by dehydration yielded 
spongiolactone derivatives (±)-4.76 and (±)-4.77 (Scheme 4.28).  
Scheme 4.28 
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The comparison of 1H-NMR (Figure 4.8) and 13C-NMR (Table 4.5) of (±)-4.76 
and other spongiolactone derivatives ((±)-4.77 and (±)-4.77a) to spongiolactone (4.1) 
and 3ʹ′-norspongiolactone (4.4) showed different chemical shift patterns, especially at β-
lactone moiety. These results suggested that the derived spongian diterpenes (±)-4.76 
was the (±)-6,15- bis-epimer of spongiolactone. Additionally, this synthetic study used the 
benzyl group as the only protecting group. It was incorporated through a commercially 
available reagent, benzyloxy chloromethyl ether, and removed in the same step with 
olefin reduction. Therefore, the overall strategy was significantly concise and efficient due 
to no protection and deprotection step involved in the synthesis. The overall synthetic study 
toward 6,15-bis-epi-spongiolactone ((±)-4.76) was completed with a longest linear 
sequence of 11 steps from commercially available staring material with 4% overall yield.  
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1H-NMR of 3ʹ′-norspongiolactone (4.4) was reported by Jaspar.95 
 
Figure 4.8. Comparison of 1H-NMR of 3ʹ′-norspongiolactone (4.4) and 6,15-bis-epi-
spongiolactone ((±)-4.76) and synthetic spongiolactone derivatives ((±)-4.77 and (±)-
4.77a). 
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Table 4.5 Comparison of 13C-NMR of spongiolactone (4.1), 3ʹ′-norspongiolactone (4.4) 
and 6,15-bis-epi-spongiolactone ((±)-4.76). 
 
Position 4.1 4.4 Δ (4.1-4.76) 4.76 Δ (4.1-4.76) 
1 38.3 38.3 0.0 38.166 0.13 
2 20.9 20.9 0.0 20.919 0.02 
3 39.7 39.6 0.1 39.619 0.08 
4 31.4 31.4 0.0 31.346 0.05 
5 49.9 49.9 0.0 47.680 2.22 
6 54.3 54.1 0.2 53.650 0.65 
7 30.5 30.4 0.1 31.189 0.67 
8 133.7 133.5 0.2 126.820 6.88 
9 139.4 139.0 0.4 142.372 2.97 
10 39.4 39.2 0.2 39.415 0.02 
11 26.3 26.6 0.3 26.787 0.49 
12 26.8 26.2 0.6 26.792 0.01 
13 36.8 36.6 0.2 33.186 3.61 
14 50.2 50.2 0.0 50.059 0.14 
15 79.9 80.1 0.2 75.737 4.16 
16 67.6 67.8 0.2 67.404 0.20 
17 26.5 26.0 0.5 25.903 0.60 
18 32.7 32.9 0.2 33.131 0.43 
19 30.3 30.4 0.1 29.727 0.57 
20 171.8 172.2 0.4 171.194 1.50 
1’ 172.9 173.7 0.8 173.242 0.61 
2’ 43.3 36.1 7.2 43.477 0.18 
3’ 25.6 18.4 7.2 25.669 0.07 
4’ 22.4 13.7 8.7 22.474 0.07 
5’ 22.4 - - 22.474 0.07 
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4.2.4. Cyclohexenyl Zinc Additions: Synthetic Study Toward the Total Synthesis of 
Spongiolactone 
The successful preparation of zincate 4.70 and the excellent diastereoselectivity 
achieved in the allyl zinc addition step in the presence of β-lactone provided the 
promising synthetic route to spongiolactone. Therefore, we decided to employ the 
identical late stage strategy to accomplish the total synthesis of spongiolactone. The 
desired fused tricyclic β-lactone core (+)-4.52 was functionalized with zincate 4.70 via 
the diastereoselective allyl zinc addition under the same condition described previously 
(Scheme 4.29).  
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Unfortunately, the desired homoallylic alcohol 4.79 was not formed under this 
condition. Only α-addition of zincate 4.70 to the ketone yielding 4.80 and β-lactone ring 
opening (4.78) were observed. Several attempts to improve the overall results of the 
diastereoselective allyl zinc addition of the desired β-lactone core (+)-4.52 were tried 
(Table 4.6). However, this reaction was remained unsuccessful. The results showed that 
raising the temperature, use of non-polar solvents and addition of mild Lewis acid only 
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led to β-lactone ring opening adduct (4.78). These results suggested that the β-lactone 
moiety of (+)-4.52 was more reactive than the ketone in this case due to substrate 
constraints. Furthermore, there was probably no chelation between zincate 4.70 and 
ketone or β-lactone, since only α-addition adducts were observed.  
 
Table 4.6. Optimizations of diastereoselective allyl zinc addition of the desired β-
lactone core (+)-4.52 with zincate 4.70. 
 
Entry Conditiona 
Yield of  
4.78b 
Yield of 
4.80b 
Recovery 
of (+)-
4.52 
1 THF, −78 oC 16%, dr 1:1 37%, dr 3:1 8% 
2 THF, 0 oCc 75%, dr 1:1 0% 8% 
3 Et2O, −78 oC 26%, dr 2:1 0% 59% 
4 Toluene, −78 oC 46%, dr 1:1 17%, dr 1:1 28% 
5 THF/HMPA (3:1), −78 oC NRd NR 91% 
6 In(OTf)3, THF, −78 oC 73%, dr 3:1 0% 0% 
7 Sc(OTf)3, THF, −78 oC 70%, dr 2:1 0% 0% 
a10 equiv of zincate was added. They were no reaction when using 5 equiv of zincate. bValues 
refers to isolated yield and the diastereomeric ratios were determined by 1H-NMR (500 MHz) of 
the crude reaction mixtures. dNR means no reaction.  
 
 
We thus sought an alternative reaction that could override substrate constraint.  
Several methodologies for diastereoselective production of homoallylic alcohols bearing 
quaternary centers were reported involving In-mediated allylic addition,114 titanium- 
catalyzed formation of organozinc115 and zinc-mediated aqueous Barbier type 
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reaction.116 Various conditions were studied (Scheme 4.30) aiming for allylic addition to 
the ketone of the fused tricyclic β-lactone (+)-4.52. However, all attempts failed to 
provide the desired homoallylic alcohol 4.79. In all cases, no reaction was observed. 
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                 4) 4.69, Zn, THF, aq. NH4Cl (sat.), -20 oC to 23 oC
                 5) 4.70, ZnOTf, THF, -78 oC to 23 oC
 
 
Structural modification of β-lactone (+)-4.52 by appending the isovaleric ester 
side chain to increase electrophilicity of the ketone via inductive effect was considered 
to be an alternative route to solve the problem. The β-lactone (+)-4.52c was prepared 
and subjected to the standard diastereoselective allyl zinc addition. However, only the β-
lactone ring opening adduct 4.81 was observed as the major product (Scheme 4.31). This 
reaction was done in small-scale and monitored by LC/MS. We found molecular mass 
corresponding to 4.81 but no β-lactone absorption on IR spectrum.   
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4.2.5. Alternative Strategies Toward the Total Synthesis of Spongiolactone 
The successful preparation of 6,15-bis-epi-spongiolactone (4.76a) generally 
highlighted the synthetic application of the derived homoallylic alcohol (±)-4.71 as the 
intermediate to achieve spongiolactone (4.1) via β-lactone ring opening and β-lactone 
reformation. The successful one-pot β-lactone ring opening and epimerization of (±)-
4.71 to obtain hydroxyl acid (±)-4.83 (Scheme 4.32) allowed the further studies of β-
lactone reformation through a Mitsunobu cyclization to correct the stereochemistry of β-
lactone.  
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The resulting hydroxyl acid (±)-4.83 was treated under Mitsunobu condition for 
the formation of β-lactone (±)-4.85, which has the correct β-lactone stereochemistry. 
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Several conditions were tried (Scheme 4.33) including heating up to 70 oC. However, β-
lactone (±)-4.85 was not formed. Only recovery of starting hydroxyl acid (±)-4.83 was 
observed without β-elimination of the secondary alcohol. 
 
Scheme 4.33 
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                 4) PPh3, DIAD, Et2O, Et3N, 23 oC to reflux  
   
Further optimization by activation of secondary alcohol to a good leaving group 
via tosylation yielded no β-lactone (Scheme 4.34). Only β-elimination product ((+)-4.86) 
was observed along with the remaining starting material ((+)-4.83). 
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Since diastereoselective allylic zinc addition of β-lactone (+)-4.52 was 
problematic, we also considered modifying the synthetic route by installation of 
cyclohexane appendage and the all-carbon quaternary center in the early stage. Thus, 
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ketone (±)-4.87 was treated with a set of alternative methods for allylic addition for the 
preparation of homoallylic alcohol (±)-4.88. Unfortunately, no additional adduct was 
observed (Scheme 4.35). Further experiments will be studied. 
 
Scheme 4.35 
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                  5) 4.69, Zn, THF, Cp2TiCl2, -20 oC to 23 oC
                  6) 4.69, Zn, THF, aq. NH4Cl (sat.), -20 oC to 23 oC
                  7) 4.70, ZnOTf, THF, -78 oC to 23 oC  
 
4.3. Conclusion 
 Several synthetic strategies toward the total synthesis of spongiolactone have 
been studied by employing the intramolecular nucleophile-catalyzed aldol-lactonization 
(NCAL) reaction as the key step to construct the fused tricyclic β-lactone core. In this 
study, we reported the first result of kinetic resolution and double diastereoselective 
NCAL process catalyzed by (S)-HBTM. Furthermore, a highly diastereoselective allyl 
zinc addition to install an all-carbon quaternary center and pendent cyclohexane was 
developed. These successful methodologies allowed further functional group 
manipulations to accomplish the total synthesis of (±)-6,15-bis-epi-spongiolactone (4.76) 
in a longest linear sequence of 11 steps from a commercially available staring material with 
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no protection and deprotection steps. The spongiolactone derivatives ((±)-4.76, (±)-4.77 
and (±)-4.77a) will enable SAR studies to identify the molecular protein target.  
Although we could access the desired core β-lactone core of this natural product, 
the diastereoselective allyl zinc addition to install an all-carbon quaternary center and 
pendent cyclohexane was unsuccessful. As the results, the total synthesis of 
spongiolactone is remaining underway and continues to be further developed. 
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CHAPTER V 
 
CONCLUSIONS 
 
As an interdisciplinary program in nature that entails organic synthesis and 
chemical biology, we had developed a set of second generation diazo reagents with the 
smaller steric footprint, namely the α-trifluoroethyl (HTFB), α-cyano and p-azidophenyl 
diazo reagents for simultaneous arming and SAR studies of bioactive natural products 
via O−H insertion protocol for derivatization of the alcohol-containing natural products. 
Useful reactivity and both chemo- and site (chemosite) selectivities were observed when 
the α-trifluoroethyl diazo reagent was employed. This diazo reagent (HTFB) provided 
similar reactivity comparing to the first generation diazo reagent bearing p-bromophenyl 
substituent (HBPA) with the advantage of enabling the use of 19F-NMR to facilitate 
small-scale, crude derivatization reaction analysis. Modulating natural product-cellular 
receptor interactions highlighted the profound application of new α-trifluoroethyl diazo 
reagent (HTFB) as it showed selective protein binding in IL-2 reporter assay of FK506 
derivatives and provided the better retention of biological activity in hMetAP2 
proliferation assay of fumagillol derivatives comparing to p-bromophenyl diazo reagent 
(HBPA). The synthetic useful of new α-trifluoroethyl diazo reagent (HTFB) and the 
development of mild and mono-functionalization O−H insertion for derivatization of 
alcohol-containing natural products have provided a great synthetic tool for basic 
cellular studies for investigating the information-rich content of complex natural 
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products leading to the identification of medically relevant protein targets and the 
discovery of potential therapeutic agents for human diseases. 
As the course of synthetic program involving β-lactone chemistry and synthesis 
of β-lactone containing natural products, the SnCl4-promoted tandem Mukaiyama aldol-
lactonization (TMAL) and intramolecular nucleophile-catalyzed aldol-lactonization 
(NCAL) reaction, which are the synthetic methodologies developed in the Romo group 
were studied for the synthesis of β-lactam congeners of orlistat and synthetic studies 
toward the total synthesis of spongiolactone, respectively. 
A set of β-lactam derivatives of orlistat was synthesized for structure-activity 
relationship studies (SAR) to evaluate their fatty acid synthase inhibitory activities in 
comparison with orlistat. The SnCl4-promoted tandem Mukaiyama aldol-lactonization 
(TMAL) reaction yielded the cis-β-lactone in moderate to excellent diastereoselectivity, 
followed by conversion of cis-β-lactone to the trans-β-lactam via a one-pot β-lactone 
ring opening and intramolecular Mitsunobu cyclization furnishing β-lactam analogs. The 
inhibitory activities of the derived β-lactam derivatives were determined in a 
biochemical fluorogenic assay using recombinant FAS-TE and the micro-molar range 
FAS-TE inhibitory activities were observed. Although, these series of β-lactam 
derivatives showed lower potency compared to the related β-lactone, the enhanced 
stability of these derivatives suggests that this class of compounds should be further 
investigated as potential fatty acid synthase inhibitors. 
In the synthetic studies toward the total synthesis of spongiolactone, an 
intramolecular nucleophile-catalyzed aldol-lactonization (NCAL) reaction was 
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employed as the key step to construct the fused tricyclic-β-lactone core. This synthetic 
strategy highlighted the useful application of NCAL reaction toward the formation of 
bicyclic-β-lactones from the complex aldehyde acid. Importantly, we have developed a 
double diastereoselection and, for the first time, kinetic resolution via the NCAL process 
by using (S)-HBTM as a nucleophile, which enabled an enantioselective strategy to 
access the fused tricyclic β -lactone and set the four contiguous stereogenic centers of 
spongiolactone core. The quaternary carbon on the pendant cyclohexyl moiety was 
achieved by a diastereoselective allylic zinc addition that proceeded with high 
diastereoselectivity and excellent yield. Even though the total synthesis of 
spongiolactone has not yet been completed, we accomplished the total synthesis of (±)-
6,15-bis-epi-spongiolactone via an 11-step longest linear sequence from commercially 
available staring materials without protection and deprotection steps emphasizing 
concise and feasibility of our strategy. The derived spongiolactone derivatives will be 
further SAR studies to identify the molecular protein targets and mode of action toward 
cancer cell lines. 
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General Methods 
Reactions were carried out in flame-dried glassware and magnetically stirred 
under a nitrogen atmosphere, unless otherwise noted. Commercial solvents and reagents 
were used as received, unless otherwise stated. Anhydrous solvents were dried over 
neutral alumina and 4Å molecular sieves. Tetrahydrofuran (THF) was distilled 
immediately prior to use from sodium metal/benzophenone ketyl. Methanol (MeOH) 
was distilled from magnesium methoxide. Triethylamine (Et3N), diisopropylamine 
(Hunig’s base) were distilled from calcium hydride immediately prior to use. Zinc dust 
and Lithium chloride (LiCl) were dried by heating at 130 oC for 15 min under high 
vacuum prior to use. Brine refers to a saturated aqueous solution of sodium chloride. All 
reactions were monitored by thin layer chromatography (TLC) performed using glass-
backed silica gel 60F254 (Merck, 250 µm thickness) and liquid chromatography-mass 
spectrometry (LC-MS) on a 3µ C18 column, 150 x 2.0 mm. Acetonitrile and water were 
used as mobile phase and no acid was added to the mobile phase, unless otherwise noted. 
Yields refer to chromatographically and spectroscopically pure compounds unless 
otherwise stated. Flash column chromatography was performed using 60Å silica gel 
(230-400 mesh) as a stationary phase as described by Still.1 Preparative TLC was 
performed using glass-backed silica gel plate (60 Å, 20 x 20 cm, 250 µm, F254) and 
developed with indicated HPLC-grade solvents. Bands were identified by UV activity. 
Silica gel was scraped off the plate, and placed into a 15 mL test tube. The organic 
                                                
1 Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923. 
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residue was extracted by suspending the silica gel in 5% methanol in ethyl acetate, 
filtering, and repeating three times. The combined organic solvents were filtered through 
a cotton plug in a pipette and a 0.45 µm nylon disc was used to remove fine particles of 
silica gel. Preparative HPLC was performed using a 3µ C18 column, 150 x 4.6 mm. 
Acetonitrile and water were used as mobile phase and no acid was added to the mobile 
phase, unless otherwise noted. All optical rotation measurements were made at 20 °C in 
a 10 millimeter cell (length); concentration (c) is reported in g/100mL. Infrared spectra 
were recorded with a Nicolet Impact 410 FTIR and a Bruker VERTEX 27 FTIR 
spectrometer. 1H-NMR and 13C-NMR spectra were recorded on a Unity Inova 500 and 
Inova 300 spectrometer. 1H-NMR chemical shifts are reported as δ values in ppm 
relative to tetramethylsilane (TMS, 0.00 ppm) or residual CHCl3 (7.27 ppm). 1H-NMR 
coupling constants (J) are reported in Hertz (Hz), and multiplicities are indicated as 
follows: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), dd 
(doublet of doublets), ddd (doublet of doublet of doublets), dt (doublet of triplets), bs 
(broad singlet), apparent (app). Unless indicated otherwise, deuterochloroform (CDCl3) 
served as an internal standard (77.3 ppm) for all 13C spectra. Mass spectra were obtained 
on a VG analytical 70S high resolution, double focusing, sectored (EB) mass 
spectrometer at the center for Chemical Characterization and Analysis (Texas A&M). 
Enantiomeric excess (ee) was determined by normal phase chiral HPLC (Agilent 
chromatography) analysis using OD and IA columns (Chiralpak, Daicel Chemical 
Industries, LTD.) and HPLC grade hexanes and isopropanol were used as mobile phase 
and no acid/base was added to the mobile phase, unless otherwise noted. For tabulated 
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1H and 13C-NMR data of natural product derivatives, coupling constants (J) are shown 
after the multiplicity in parentheses. The natural product chemical shifts are highlighted 
in blue while the diazoacetate is highlighted in red. The numbering of carbons in natural 
products and derivatives was adopted from initial isolation papers. The following 
abbreviations are used in the experimental section: p-ABSA, 4-
acetamidobenzenesulfonyl azide; DBU, 8-Diazabicyclo[5.4.0]undec-7-ene; DCC, 
dicyclohexylcarbodiimide; DMAP, N,N-4-dimethylaminopyridine; EDCI, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide; HTFB, hex-5-ynyl 2-diazo-4,4,4-trifluoro 
butanoate; HBPA, hexynyl-α-p-bromophenyl diazoacetate; DIAD, diisopropyl 
azodicarboxylate; HMPA, hexamethylphosphoramade. 
 
Chapter II - Modulating Natural Product-Cellular Receptor Interactions: New 
Diazo Reagents with Small Steric Footprints for Simultaneous Arming and 
Structure-Activity Studies of Alcohol-Containing Natural Products 
 
2A. Safety Hazards and Precautions for the Use of Diazoesters and Azides2 
Diazoesters: Diazo compounds are known to be toxic and unstable towards 
strong protic and Lewis acids and can decompose by prolonged exposure to light and/or 
contact with metal salts. Even though diazoacetates are known to be more stable than 
their alkyl counterparts, throughout this study, all diazoesters were stored in the dark at   
                                                
2 Peddibhotla, S.; Dang, Y.; Liu, J. O.; Romo, D. J. Am. Chem. Soc. 2007, 129, 11222. 
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-10 °C in glass vials. Although during this work we did not experience any 
uncontrollable reactions with the diazo reagents prepared, we suggest that all reactions 
be carried out in a well-ventilated fume hood and behind a safety shield.  
Azides: Due to the heat sensitive nature of azides, distillation or sublimation as 
purification techniques are not recommended. Column chromatography may contribute 
to decomposition, especially when using halogenated solvents. During our studies, 
reactions were conducted on medium scale (1-5 g) and no incidents were encountered 
with the compounds used. Extra caution must be taken to make certain that waste-
containing azides should not come in contact with acid, which may cause the formation 
of highly toxic hydrogen azide (toxicity similar to that of hydrogen cyanide). 
 
B) Synthesis of Diazo Reagents: 3a-3d 
Synthesis of hex-5-ynyl 2-diazo-4,4,4-trifluorobutanoate (2.7a, HTFB) 
 
O
O
F3COH
O
F3C
2.7a-1 2.7a-2  
Hex-5-ynyl 4,4,4-trifluorobutanoate (2.7a-2). 4,4,4-trifluorobutanoic acid 
(2.7a-1) (3.40 g, 23.93 mmol) was dissolved in dry dichloromethane (100 mL) in a 
flame-dried flask under a nitrogen atmosphere. EDCI.HCl (6.88 g, 35.89 mmol) and 
DMAP (3.48 g, 28.72 mmol) were added and the mixture was stirred at ambient 
temperature (23 °C) for 10 min. 5-Hexyn-1-ol (3.63 mL, 30.50 mmol) was then slowly 
added dropwise. The mixture was stirred at ambient temperature for 2 h, and then 
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quenched with 1% HCl (50 mL). The organic layer was separated and the aqueous layer 
was extracted with dichloromethane (3 x 50 mL). The combined organic layers were 
washed with saturated NaHCO3 (50 mL) and brine (50 mL), dried over anhydrous 
magnesium sulfate and concentrated under reduced pressure (rotary evaporator) to 
obtain a light yellow oil. The crude ester was purified by flash chromatography on SiO2 
(95:5 of hexanes:EtOAc) to afford hex-5-ynyl 4,4,4-trifluorobutanoate (2.7a-2) as a 
colorless oil (4.9 g, 92%); TLC (80:20, hexanes:EtOAc): Rf = 0.65; IR (thin film) cm-1: 
3307, 2113, 1741, 1137; 1H-NMR (500 MHz, CDCl3), δ 4.13 (t, J = 6.3 Hz, 2H), 2.57 (t, 
J = 8.3 Hz, 2H), 2.50-2.42 (m, 2H), 2.23 (dt, J = 7.1, 2.4 Hz, 2H), 1.96 (t, J = 2.4 Hz, 
1H), 1.80-1.72 (m, 2H), 1.62-1.58 (m, 2H); 13C-NMR (125 MHz, CDCl3) δ 170.8, 126.5 
(q, J = 273.8 Hz, CF3), 83.6, 68.8, 64.6, 29.0 (q, J = 30 Hz, CH2CF3), 27.4, 26.9 (q, J = 
2.5 Hz, CH2CH2), 24.8, 18.0; HRMS (ESI+) Calcd for C10H13F3O2Li[M+Li]: 229.1028, 
Found: 229.1030.  
 
O
O
F3C
OPh
2.7a-3
O
O
F3C
2.7a-2  
Hex-5-ynyl 2-benzoyl-4,4,4-trifluorobutanoate (2.7a-3). hex-5-ynyl 4,4,4-
trifluoro butanoate (2.7a-2) (6.0 g, 27.00 mmol) was dissolved in dry acetonitrile (100 
mL) in a flame-dried flask under a nitrogen atmosphere. Benzoyl chloride (9.5 mL, 
81.81 mmol) and triethylamine (22.50 mL, 161.57 mmol) were added at ambient 
temperature (23 °C). The mixture was then cooled to 0 °C and stirred for 10 min. 
Titanium tetrachloride (≥98.0%, Fluka; 5 mL, 45.60 mmol) was slowly added over 30 
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min via a syringe pump. The brown reaction mixture was warmed to ambient 
temperature for 15 min, and then heated to reflux at 90 °C for 30 min. Then, the mixture 
was cooled to ambient temperature, quenched with water and extracted with EtOAc (3 x 
50 mL). The combined organic extracts were washed with brine (2 x 50 mL), dried over 
anhydrous magnesium sulfate and concentrated under reduced pressure (rotary 
evaporator) to afford a light brown oil. The crude keto-ester was purified by flash 
chromatography on SiO2 (95:5 of hexanes:EtOAc) to afford hex-5-ynyl 2-benzoyl-4,4,4-
trifluorobutanoate (2.7a-3) as a yellow oil (7.9 g, 90%) that exists as a mixture of 
keto/enol forms; TLC (80:20, hexanes:EtOAc): Rf = 0.60; IR (thin film) cm-1: 3304, 
3064, 1791, 1744; 1H-NMR (500 MHz, CDCl3) δ 8.17-8.15 (m, 1H), 8.03-8.01 (m, 1H), 
7.67-7.61 (m, 1H), 7.54-7.49 (m, 2H), 4.67 (t, J = 6.7 Hz, 1H), 4.12 (t, J = 6.7 Hz, 2H), 
2.97-2.89 (m, 2H), 2.10 (dt, J = 2.4, 6.8 Hz, 2H,), 1.92 (t, J = 2.7 Hz, 1H), 1.68-1.62 (m, 
2H), 1.43-1.37 (m, 2H); 13C-NMR (125 MHz, CDCl3) δ 192.2, 167.5(enol), 162.2(keto), 
153.1, 134.4, 134.0, 130.4, 127.5 (q, J = 210 Hz, CF3), 128.8, 128.2, 83.4, 68.8, 65.6, 
47.7, 32.7 (q, J = 31.3 Hz, CH2CF3), 27.1, 24.4, 17.7; HRMS (ESI+) Calcd for 
C17H17F3O3Li [M+Li]: 333.1290, Found: 333.1292. 
 
N2
O
O
2.7a (HTFB)
F3CO
O
F3C
OPh
2.7a-3  
Hex-5-ynyl 2-diazo-4,4,4-trifluorobutanoate (2.7a, HTFB). Hex-5-ynyl 2-
benzoyl-4,4,4-trifluorobutanoate (2.7a-3) (1.65 g, 5.06 mmol) was weighed into a flame-
dried flask and dissolved in dry acetonitrile (50 mL). The reaction mixture was cooled at 
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0 °C under a nitrogen atmosphere. p-ABSA (3.65 g, 15.18 mmol) was added into the 
reaction mixture followed by DBU (2.27 mL, 15.18 mmol). The mixture was slowly 
warmed up to ambient temperature (23 °C). The reaction flask was covered by 
aluminum foil and stirred at ambient temperature for 4 h. After all the starting material 
was consumed as observed by TLC, all the volatiles were evaporated under reduced 
pressure (rotary evaporator). The residue was purified by flash chromatography (95:5 of 
hexanes:EtOAc) and the hex-5-ynyl 2-diazo-4,4,4-trifluorobutanoate (2.7a, HTFB) was 
obtained as a yellow oil (0.73 g, 58%); TLC (80:20, hexanes:EtOAc): Rf = 0.53; IR (thin 
film) cm-1: 3313, 2096, 1699, 1137; 1H-NMR (500 MHz, CDCl3), δ 4.23 (t, J = 6.8 Hz, 
2H), 3.13 (q, J = 16.0 Hz, 2H), 2.26-2.20 (dt, J = 2.5, 6.7 Hz, 2H), 1.96 (t, J = 2.8 Hz, 
1H), 1.84-1.74 (m, 2H), 1.64-1.54 (m, 2H);  13C-NMR (125 MHz, CDCl3) δ 165.9, 125.1 
(q, J = 271.3 Hz, CF3), 83.9, 69.1, 65.3, 29.3 (q, J = 58.6 Hz, CH2CF3), 28.0, 25.1, 18.3 
(C=N2 signal not observed); 19F NMR (300 MHz, CDCl3), δ 67.31 (3F, broad s); HRMS 
(ESI+) Calcd for C10H11F3O2N2Li [M+Li]: 255.0933, Found: 255.0919. 
 
Synthesis of hex-5-ynyl 2-diazo-3,3,3-trifluoropropanoate (2.7b) 
 
F3C
OH
O
F3C
O
O
2.7b-1 2.7b-2  
Hex-5-ynyl 3,3,3-trifluoropropanoate (2.7b-2). 3,3,3-trifluoropropanoic acid 
(2.7b-1) (0.50 g, 3.92 mmol) was dissolved in dry dichloromethane (25 mL) in a flame-
dried flask under a nitrogen atmosphere. EDCI.HCl (1.13 g, 5.88 mmol) and DMAP 
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(0.57 g, 4.71 mmol) were added and the mixture was stirred at ambient temperature (23 
°C) for 10 min. 5-Hexyn-1-ol (0.6 mL, 5.49 mmol) was then slowly added dropwise. 
The mixture was stirred at ambient temperature for 4 h, and then quenched with 1% HCl 
(20 mL). The organic layer was separated and the aqueous layer was extracted with 
dichloromethane (3 x 50 mL). The combined organic layers were washed with saturated 
NaHCO3 (20 mL) and brine (20 mL), dried over anhydrous magnesium sulfate and 
concentrated under reduced pressure (rotary evaporator) to give a light yellow oil. The 
crude ester was purified by flash chromatography on SiO2 (95:5 of hexanes:EtOAc) to 
afford hex-5-ynyl 3,3,3-trifluoropropanoate (2.7b-2) as a colorless oil (0.67 g, 83%); 
TLC (80:20, hexanes:EtOAc): Rf = 0.53; IR (thin film) cm-1: 3313, 2117, 1752, 1217; 
1H-NMR (500 MHz, CDCl3), δ 4.20 (t, J = 6.7 Hz, 2H), 3.17 (q, J = 10.0 Hz, 2H), 2.24 
(dt, J = 2.7, 7.0 Hz, 2H), 1.95 (t, J = 2.7 Hz, 1H), 1.84-1.74 (m, 2H), 1.64-1.54 (m, 2H); 
13C-NMR (125 MHz, CDCl3) δ 165.8, 129.4 (q, J = 176.3 Hz, CF3), 83.8, 68.9, 64.5, 
29.1 (q, J = 61.3 Hz, CH2CF3), 27.8, 24.9, 18.1; HRMS (ESI+) Calcd for C9H11F3O2Li 
[M+Li]: 215.0871, Found: 215.0867. 
 
F3C
N2
O
O
2.7b
Unstable
F3C
O
O
2.7b-2  
Hex-5-ynyl 2-diazo-3,3,3-trifluoropropanoate (2.7b). Hex-5-ynyl 3,3,3-
trifluoro propanoate (2.7b-3) (0.67 g, 3.23 mmol) was weighed into a flame-dried flask 
and dissolved in dry acetonitrile (30 mL). The reaction mixture was cooled at 0 °C under 
nitrogen atmosphere. p-ABSA (3.65 g, 15.18 mmol) and DBU (2.27 mL, 15.18 mmol) 
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were added. The reaction flask was covered by aluminum foil and gradually warmed up 
to ambient temperature (23 °C) for 2 h. After all the starting material was consumed as 
observed by TLC, all the volatiles were evaporated under reduced pressure (rotary 
evaporator) and the crude product was determined by 1H-NMR. However, the desired 
diazo reagent decomposed during attempted purification by flash chromatography on 
SiO2. 
 
Synthesis of hex-5-ynyl 2-cyano-2-diazoacetate (2.7c) 
 
NC
OH
O
NC
O
O
 2.7c-1 2.7c-2  
Hex-5-yn-1-yl 2-cyanoacetate (2.7c-2). 2-cyanoacetic acid (2.7c-1) (1.30 g, 
15.52 mmol) was dissolved in dry dichloromethane (100 mL) in a flame-dried flask 
under a nitrogen atmosphere. DCC (3.20 g, 15.52 mmol) was added as a solid and the 
mixture was stirred at ambient temperature (23 °C) for 10 min. 5-Hexyn-1-ol (0.6 mL, 
5.49 mmol) was slowly added dropwise and the mixture was stirred at ambient 
temperature for 1 h. The reaction was then quenched with 1% HCl (20 mL) and filtered 
to remove solids. The organic layer was separated and the aqueous layer was extracted 
with dichloromethane (3 x 50 mL). The combined organic layers were washed with 
saturated NaHCO3 (50 mL) and brine (50 mL), dried over anhydrous magnesium sulfate 
and concentrated under reduced pressure (rotary evaporator) to give a red oil. The crude 
ester was purified by flash chromatography on SiO2 (90:10 of hexanes:EtOAc) to afford 
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hex-5-yn-1-yl 2-cyanoacetate (2.7c-2) as an orange oil (2.31 g, 90%); TLC (80:20, 
hexanes:EtOAc): Rf = 0.33; IR (thin film) cm-1: 3305, 2226, 1750, 1154; 1H-NMR (500 
MHz, CDCl3), δ 4.23 (t, J = 6.7, 2H), 3.46 (s, 2H), 2.24 (dt, J = 2.7, 7.1 Hz, 2H), 1.96 (t, 
J = 2.7 Hz, 1H), 1.84-1.79 (m, 2H), 1.75-1.63 (m, 2H); 13C-NMR (125 MHz, CDCl3) δ 
162.9, 113.0, 83.4, 68.9, 66.2, 27.1, 24.6, 24.4, 17.8; HRMS (ESI+) Calcd for 
C9H11NO2Li [M+Li]: 172.0905, Found: 172.0921. 
 
NC
N2
O
O
2.7c
NC
O
O
2.7c-2  
Hex-5-ynyl 2-cyano-2-diazoacetate (2.7c). Hex-5-yn-1-yl 2-cyanoacetate (2.7c-
2) (1.42 g, 8.60 mmol) was weighed into a flame-dried flask and dissolved in dry 
acetonitrile (50 mL). Imidazole-1-sulfonyl azide hydrochloride that was freshly prepared 
by Goddard-Borger’s protocol3 (2.16 g, 10.32 mmol) was added into the reaction 
mixture at ambient temperature (23 °C) under a nitrogen atmosphere. Pyridine (3.5 mL, 
43.0 mmol) was then slowly added and the reaction mixture was stirred at 40 °C for 24 
h. After all the starting material was consumed as observed by TLC, the mixture was 
diluted with EtOAc (50 mL), washed with 1N HCl (50 mL) and brine (50 mL), dried 
over anhydrous magnesium sulfate and concentrated under reduced pressure (rotary 
evaporator) to give a yellow residue. The crude product was purified by flash 
chromatography on SiO2 (80:20 of hexanes:EtOAc) and the diazoacetate 2.7c was 
obtained as a yellow oil (0.79 g, 48 %); TLC (80:20, hexanes:EtOAc): Rf = 0.47; IR (thin 
                                                
3 Goddard-Borger, E. D.; Stick, R. V. Org. Lett., 2007, 9, 3797. 
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film) cm-1: 3292, 2226, 2125, 1720; 1H-NMR (500 MHz, CDCl3), δ 4.26 (t, J = 6.5, 2H), 
2.20 (dt, J = 2.4, 7.1 Hz, 2H), 1.94 (t, J = 2.7 Hz, 1H), 1.82-1.76 (m, 2H), 1.59-1.53 (m, 
2H); 13C-NMR (125 MHz, CDCl3) δ 161.3, 107.2, 83.3, 68.9, 66.6, 27.3, 24.6, 17.8 
(C=N2 signal not observed); HRMS (ESI+) Calcd for C9H9N3O2Li [M+Li]: 198.0855, 
Found: 198.0867. 
 
Synthesis of hex-5-ynyl 2-(4-azidophenyl)-2-diazoacetate (2.7d) 
 
H2N
O
OH
N3
O
OH
2.7d-1 2.7d-2  
2-(4-azidophenyl)acetic acid (2.7d-2). 2-(4-azidophenyl)acetic acid (2.7d-2) 
was prepared by the procedure reported by Knaus.4 2-(4-aminophenyl)acetic acid (2.7d-
1) (2.0 g, 13.23 mmol) was dissolved in a concentrated hydrochloric acid (20.0 mL) at 0 
°C. An aqueous solution of NaNO2 (0.92 g, 13.34 mmol; in water 70 mL) was slowly 
added over 15 min by an addition funnel. The reaction mixture was stirred at 0 °C for 20 
min. An aqueous solution of NaN3 (8.6 g, 132.28 mmol; in water 200 mL) was then 
slowly added over a period of 15 min by an addition funnel. The reaction mixture was 
then slowly warm to ambient temperature (23 °C). After 30 min, the mixture was 
partitioned with EtOAc. The organic layer was separated and the aqueous layer was 
extracted with EtOAc (3 x 20 mL). The combined organic layers were dried over 
anhydrous magnesium sulfate and concentrated by rotary evaporator to obtain 2-(4-
                                                
4 Rao, P.; Uddin, J.; Knaus, E. E. J. Med. Chem. 2004, 47, 3972. 
 145 
azidophenyl)acetic acid (2.7d-2) as a light yellow-brown crystal (2.30 g, 99%). The 
material was of sufficient purity to be carried directly to the next step. TLC (50:50, 
hexanes:EtOAc): Rf = 0.45; IR (thin film) cm-1: 2123, 1696, 1507, 1320; 1H-NMR (500 
MHz, CDCl3), δ 7.28-7.24 (d, J = 8.7 Hz, 2H), 7.00-6.93 (d, J = 8.7 Hz, 2H), 3.63 (s, 
2H); 13C-NMR (125 MHz, CDCl3) δ 177.6, 139.3, 130.8 (2), 129.8, 119.2 (2), 40.2; 
HRMS (ESI–) Calcd for C8H6N3O2[M-H]: 176.0460, Found: 176.0468. 
 
N3
O
O
2.7d-3
N3
O
OH
2.7d-2  
Hex-5-yn-1-yl 2-(4-azidophenyl)acetate (2.7d-3). 2-(4-azidophenyl)acetic acid 
(2.7d-2) (2.30 g, 12.95 mmol) was dissolved in dry dichloromethane (100 mL) in a 
flame-dried flask and stirred at ambient temperature (23 °C) under a nitrogen 
atmosphere. Oxalyl chloride (1.70 mL, 19.42 mmol) was slowly added, followed by 
DMF (0.2 mL, 2.59 mmol). The reaction mixture was stirred at ambient temperature for 
4 h. All volatiles were evaporated under reduced pressure (rotary evaporator). The crude 
acid chloride was dissolved again in dichloromethane (100 mL) and stirred at ambient 
temperature. 5-Hexyn-1-ol was added into the reaction followed by Et3N (2.15 mL, 
15.54 mmol) and DMAP (0.32 g, 2.59 mmol). The reaction mixture was stirred at 
ambient temperature for 12 h. The mixture was then quenched with saturated NH4Cl (50 
mL) and extracted with dichloromethane (3 x 50 mL). The combined organic layers 
were washed with water, dried over anhydrous sodium sulfate and concentrated under 
reduced pressure (rotary evaporator). The crude ester was purified by flash 
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chromatography on SiO2 (95:5 of hexanes:EtOAc) to afford hex-5-yn-1-yl 2-(4-
azidophenyl)acetate (2.7d-3) as a light yellow oil (2.48 g, 74%); TLC (90:10, 
hexanes:EtOAc): Rf = 0.40; IR (thin film) cm-1: 3298, 2117, 1735, 1607; 1H-NMR (500 
MHz, CDCl3), δ 7.27-7.25 (d, J = 4 Hz, 2H), 6.99-6.97 (d, J = 8.3 Hz, 2H), 4.11 (t, J = 
6.7, 2H), 3.60 (s, 2H), 2.22-2.19 (dt, J = 2.4, 7.0 Hz, 2H), 1.96 (t, J = 2.7 Hz, 1H), 1.77-
1.72 (m, 2H) 1.58-1.52 (m, 2H); 13C-NMR (125 MHz, CDCl3) δ 171.4, 138.9, 130.7 (2), 
130.6, 119.1 (2), 83.8, 68.7, 64.4, 40.7, 27.5, 24.8, 17.9; HRMS (ESI+) Calcd for 
C14H16N3O2 [M+H]: 258.1243, Found: 258.1251. 
 
N3
O
O
N2
2.7d
N3
O
O
2.7d-3  
Hex-5-ynyl 2-(4-azidophenyl)-2-diazoacetate (2.7d). Hex-5-yn-1-yl 2-(4-azido 
phenyl)acetate (2.7d-3) (0.44 g, 1.71 mmol) was weighed into a flame-dried flask and 
dissolved in dry acetonitrile (15 mL). The reaction mixture was stirred at ambient 
temperature (23 °C) under a nitrogen atmosphere. p-ABSA (1.23 g, 5.13 mmol) was then 
added followed by slow addition of DBU (1.53 mL, 10.26 mmol). The reaction flask 
was covered by aluminum foil and stirred at ambient temperature for 30 min. After all 
the starting material was consumed as observed by TLC, all volatiles were evaporated 
under reduced pressure (rotary evaporator). The residue was purified by flash 
chromatography on SiO2 (99:1of hexanes:EtOAc) and the diazoacetate 2.7d was 
obtained as a yellow oil (0.33 g, 68%): TLC (90:10, hexanes:EtOAc): Rf = 0.63; IR (thin 
film) cm-1: 3307, 2125, 2075, 1702; 1H-NMR (500 MHz, CDCl3), δ 7.45-7.43 (d, J = 8.8 
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Hz, 2H), 7.03-7.02 (d, J = 8.8 Hz, 2H), 4.28 (t, J = 6.7, 2H), 2.26-2.22 (dt, J = 2.4, 6.7 
Hz, 2H), 1.96 (t, J = 2.7 Hz, 1H), 1.85-1.79 (m, 2H) 1.64-1.59 (m, 2H); 13C-NMR (125 
MHz, CDCl3) δ 165.0, 137.5, 125.2 (2), 121.9, 119.6 (2), 83.7, 68.8, 64.5, 27.7, 24.7, 
18.0 (C=N2 signal not observed). HRMS (ESI+) Calcd for C14H13N5O2Li [M+Li]: 
290.1229, Found: 290.1252. 
 
(C) General Procedure for O-H Insertion with Gibberellic Acid Methyl Ester (2.3) 
Gibberellic acid methyl ester5 (20 mg, 0.055 mmol) and rhodium catalyst (0.0028 
mmol, 0.05 equiv) were weighed into a flame-dried, round-bottomed flask. The solids 
were suspended in dry dichloromethane (3 mL) and stirred at ambient temperature (23 
°C) under a nitrogen atmosphere (Note: some rhodium catalyst did not dissolve). A 
solution of HTFB diazo reagent 2.7a (0.165 mmol, 3 equiv,) in dry dichloromethane (1 
mL) was prepared and slowly added via a syringe pump over a 1 h period. The reaction 
mixture was stirred at ambient temperature for 1 h. The solvent was then evaporated 
under reduced pressure (rotary evaporator), and the residue was purified by preparative 
TLC (60:40 of hexanes:EtOAc) to afford ethers 2.8a-d, 2.9a-d and recovered gibberellic 
acid methyl ester.  
                                                
5 Gibberellic acid methyl ester was prepared by a similar procedure as previously 
described (ref. 1). 
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TLC (60:40, hexanes: EtOAc): Rf = 0.40 (2.8a) and 0.33 (2.9a); HRMS (ESI+) 
Calcd for C30H35F3O8Li [M+Li]: 587.2444, Found: 587.2456. 
 
Table A-1. 1H-NMR (500 MHz, CDCl3) of 2.8a and 2.9a.  
Carbon 
Number 
Gibberellic acid 
methyl ester (2.3)6 2.8a 2.9a 
1 6.35 (d, 9) 6.40 & 6.39 (d, 9.3) 6.31 & 6.29 (d, 9.3) 
2 5.91 (dd, 9, 3.5) 6.00, 5.98 (dd, 3.4, 
9.3) 
5.91, 5.87 (dd, 3.3, 9.3) 
3 4.16 (d, 3) 4.02 & 4.01(d, 3.4) - 
5 2.80 (d, 10.5) 3.32 & 3.30 (d, 10.7) 3.20 & 3.18 (d, 10.7) 
6 3.21 (d, 10.5) 2.76 & 2.74 (d, 10.7) 2.78 & 2.76 (d, 10.3) 
17 5.28 & 4.97 (broad s) 5.26 & 4.95 (broad s) 5.21 & 5.03 (broad s) 
18 1.25 (s) 1.25, 1.24 (s) 1.24 (s) 
20 3.74 (s) 3.72 (s) 3.74 (s) 
----------- HTFB (2.7a) ------------- ------------- 
a - - - 
b 3.13 (q, 16.0) 2.63-2.57 (m) 2.57-2.49 (m) 
c - 4.16-4.12 (m) 4.15-4.11 (m) 
d - - - 
e 4.23 (t, 6.8) 4.20 (t, 6.9) 4.20 (t, 6.9) 
                                                
6 Preiss, Adam, G.; Samon, D.; Budesinky, M. Magn. Reson. Chem. 1987, 25, 239. 
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Table A-1. 1H-NMR (500 MHz, CDCl3) of 2.8a and 2.9a (continued).  
Carbon 
Number 
Gibberellic acid 
methyl ester (2.3) 2.8a 2.9a 
f 1.84-1.74 (m) - - 
g 1.64-1.54 (m) - - 
h 2.26-2.20 (dt, 2.5, 6.7) 2.69-2.54 (m) 2.58-2.49 (m) 
i - - - 
j 1.96 (t, 2.8) 1.95 (t, 3.0) 1.97 (t, 3.0) 
 
 
Table A-2.13C-NMR (125 MHz, CDCl3) of 2.8a and 2.9a. 
Carbon 
Number 
Gibberellic acid 
methyl ester (2.3) 2.8a 2.9a 
1 132.4 127.6 132.4 
2 133.3 134.4 132.7 
3 70.0 70.6 67.5 
4 53.4 53.4 & 53.0 53.3 
5 53.7 53.8 52.7 
6 51.3 53.3 50.4 
7 172.3 172.19 172.3 
8 50.7 50.2 43.4 
9 50.9 50.7 50.5 
10 90.7 90.5 & 90.3 90.3 & 90.2 
11 17.3 17.0 17.0 
12 38.5 38.0 29.6 
13 78.2 78.2 84.9 & 85.1 
14 45.0 44.9 39.0 
15 43.3 43.1 36.7 
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Table A-2.13C-NMR (125 MHz, CDCl3) of 2.8a and 2.9a (continued). 
Carbon 
Number HTFB (2.7a) 2.8a 2.9a 
16 157.1 156.9 152.1 & 151.6 
17 108.0 107.5 110.2 & 109.7 
18 14.0 14.5 14.3 & 14.0 
19 178.3 177.8 178.2 
20 52.4 52.1 52.2 
-------------
------------- 
HTFB (2.7a) -----------------
--------- 
-------------------
------- a 125.1 (q, 271.3) 125.1 (q, 
271.3) 
127.2 (q, 298.8) 
b 29.3 (q, 58.6) 29.3 (q, 58.6) 38.2 (q, 13.8) 
c - 74.7 69.2 
d 165.9 169.60 171.2 
e 65.3 65.5 65.0 
f 28.0 27.4 27.3 
g 25.1 24.7 24.5 
h 18.3 18.0 17.9 
i 83.9 83.4 83.5 
j 68.8 69.1 68.9 
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TLC (60:40, hexanes:EtOAc): Rf = 0.31 (2.8d) and 0.25 (2.9d); HRMS (ESI–) 
Calcd for C34H36N3O8 [M-H]: 614.2502, Found: 614.2530. 
 
Table A-3. 1H-NMR (500 MHz, CDCl3) of 2.8d and 2.9d. 
Carbon 
Number 
Gibberellic acid 
methyl ester (2.3) 2.8d 2.9d 
1 6.35 (d, 9) 6.35 & 6.33 (d, 9.8) 
6.28 & 6.27 (d, 9.8) 
6.33 & 6.31 (d, 10.9) 
 2 5.91 (dd, 9, 3.5) 5.92, 5.90 (dd, 3.6, 
9.3) 
7.78, 5.77 (dd, 3.4, 
9.3) 
6.15, 6.13 (dd, 3.7, 9.7) 
3 4.16 (d, 3) 3.74 & 3.73 (d, 3.9) 3.95 & 3.91 (d, 3.4) 
5 2.8 (d, 10.5) 3.41 & 3.38 (d, 10.9) 3.40 & 3.38 (d, 10.9) 
    
6 3.21 (d, 10.5) 3.23 & 2.21 (d, 10.7) 3.23 & 2.21 (d, 10.7) 
17 5.28 & 4.97 (broad s) 5.27 & 4.96 (broad s) 5.00 & 4.98 (broad s) 
18 1.25 (s) 1.24 (s) 1.27 (s) 
20 3.74 (s) 3.68 (s) 3.68 (s) 
----------- 2.7d -------------------------- -------------------------- 
a 7.45-7.43 (d, 8.8) 7.43-7.41 (d, 8.8) 7.43-7.41 (d, 8.8) 
b 7.03-7.02 (d, 8.8) 7.04-7.02 (d, 7.8) 7.04-7.02 (d, 7.8) 
c - 5.01 (s) 5.01 (s) 
e 4.28 (t, 6.7) 4.13 (t, 6.8) 4.13 (t, 6.8) 
f 2.26-2.22 
(dt, 2.4, 6.7) 
- - 
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Table A-3. 1H-NMR (500 MHz, CDCl3) of 2.8d and 2.9d (continued). 
Carbon 
Number 
Gibberellic acid 
methyl ester (2.3) 2.8d 2.9d 
    
g 1.64-1.59 (m) - - 
h 1.85-1.79 (m) 2.80-2.72 (m) 2.80-2.72 (m) 
j 1.96 (t, 2.7) 1.95 (t, J = 2.9) 1.95 (t, J = 2.9) 
This reaction provided a mixture of chemosite isomers and diastereomers. 
 
D) Synthesis of Natural Product/HTFB Ethers; 2.4b-2.15b and Tabulated 1H and 
13C-NMR Data 
 Brefeldin A 13-HTFB ether, 2.4b/2.4ʹ′. Brefeldin A 
(2.4a) (4.8 mg, 0.017 mmol) and rhodium acetate dimer (0.38 
mg, 5 mol%) were weighed into a flame-dried, round-bottomed 
flask under a nitrogen atmosphere and the solids were 
dissolved in CH2Cl2 (1 mL). Then, a solution of hex-5-ynyl 4,4,4-trifluorobutanoate 
(HTFB, 2.7a) (12.8 mg, 0. 051 mmol) in 1 mL of CH2Cl2 was slowly added via a syringe 
pump over a 1 h period. After that, the mixture was allowed to stir at ambient 
temperature (23 °C) for an additional 1 h. The solvent was evaporated and the residue 
was purified by preparative TLC on SiO2 (50:50 of hexanes:EtOAc) to afford 4.9 mg of 
diastereomers 2.4b, 2.4b' (57% yield) and 1.1 mg of recovered brefeldin A (23% yield). 
The 1:1 mixture of diasteromers was further separated by preparative TLC on SiO2 
(60:40 of hexanes:EtOAc) to obtain 2.8 mg of 2.4b and 2.1 mg of 2.4b'; TLC (60:40 of 
2.4b and 2.4b'
O
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hexanes:EtOAc): Rf = 0.41 (2.4b) and 0.49 (2.4b'); HRMS (ESI+) Calcd for 
C26H35O6F3Li [M+Li]: 507.2546, Found: 507.2557. 
 
Table A-4. 1H-NMR (500 MHz, CDCl3) of 2.4b and 2.4b'. 
Carbon 
Number Brefeldin A (2.4a)
7 2.4b 2.4b' 
1 4.10 (d, 10) 4.06 (d, 10) 4.08 (d, 10) 
2 7.34 (dd, 15.5, 3) 7.34 (dd, 2, 16) 7.35 (dd, 3, 15.5) 
3 5.84 (dd, 15.5, 2) 5.91, 5.88 (dd, 2.5, 16) 5.92, 5.89 (dd, 2.0, 16) 
6 4.74-4.83 (m) 4.87-4.81 (m) 4.88-4.82 (m) 
10 5.60-5.70 (m) 5.72-5.66 (m) 5.73-5.67 (m) 
11 5.24 (dd, 15, 10) 5.25-5.22 (dd, 10, 15) 5.28-5.25 (dd, 10, 14.5) 
13 4.23 (m) 4.00 (m) 4.03 (m) 
15 1.22 (d, 6.5) - - 
---------- HTFB (2.7a) --------------------------- --------------------------- 
a - - - 
b 3.13 (q, 16.0) 2.60-2.46 (m) 2.64-2.48 (m) 
    
c - 4.36 (q, 5.0) 4.37 (q, 5.0) 
e 4.23 (t, 6.8) 4.22-4.18 (m) 4.22-4.18 (m) 
f 1.84-1.74 (m) 1.83-1.79 (m) 1.86-1.79 (m) 
g 1.64-1.54 (m) 1.65-1.61 (m) 1.66-1.60 (m) 
h 2.26-2.20 (dt, 2.5, 6.7) 
2.26-2.22 
(dt, 2.4, 6.8) 
2.26-2.23 
(dt, 3.0, 7.0) 
j 1.96 (t, 2.8) 1.97 (t, 2.4) 1.97 (t, 2.2) 
 
                                                
7 (a) Glaser, R.; Shiftan D.; Froimowitz, M. Magn. Reson. Chem. 2000, 38, 274. (b) 
Wang, Y.; Romo, D. Org. Lett. 2002, 4, 3231. (c) Argade, A. B.; Devraj, R.; Vroman, J. 
A.; Haugwitz, R. D.; Hollingshead, M.; Cushman, M. J. Med. Chem. 1998, 41, 3337. 
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Table A-5. 13C-NMR (125 MHz, CDCl3) of 2.4b and 2.4b'. 
Carbon 
Number 
Brefeldin A 
(2.4a) 2.4b 2.4b' 
1 76.0 Overlap with solvent peak Overlap with solvent peak 
2 151.5 151.5 151.3 
3 117.6 117.8 117.6 
4 166.5 166.2 165.9 
6 71.8 71.7 71.8 
7 34.1 34.2 34.0 
8 26.7 27.7, 26.9 27.5, 26.7 
9 31.8 32.0 31.8 
10 130.5 131.1 & 130.8 130.6 
11 136.5 136.2 136.1 
11a 44.3 39.5 40.5 
12 43.2 38.8 37.1 
13 72.6 76.1 75.9 
14 41.3 44.1 43.9 
14a 52.0 51.9 51.8 
15 20.9 20.9 20.9 
---------- HTFB (2.7a) -------------------------- -------------------------- 
a 125.1  (q, 271.3) Low intensity Low intensity 
b 29.3 (q, 58.6) 37.5 (q, 28.8) 37.1 (q, 31.3) 
c - 80.62 80.3 
d 165.9 171.1 171.19 
e 65.3 65.3 65.1 
f 28.0 29.9 29.7 
g 25.1 25.0 24.8 
h 18.3 18.2 18.0 
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Table A-5. 13C-NMR (125 MHz, CDCl3) of 2.4b and 2.4b' (continued). 
Carbon 
Number 
Brefeldin A 
(2.4a) 2.4b 2.4b' 
i 83.9 84.9 84.7 
j 68.8 69.1 68.9 
 
 
Paclitaxel 2ʹ′-HTFB ether, 2.11b/2.11bʹ′. Paclitaxel (2.11a) (5.7 mg, 0.0067 mmol) 
and rhodium acetate dimer (0.15 mg, 5 mol%) 
were weighed into a flame-dried, round-bottomed 
flask under a nitrogen atmosphere and the solids 
were dissolved in CH2Cl2 (1 mL). Then, a solution 
of hex-5-ynyl 4,4,4-trifluorobutanoate (HTFB, 2.7a) (6.7 mg, 0.040 mmol) in 1 mL of 
CH2Cl2 was slowly added via a syringe pump over a 2 h period. The mixture was then 
allowed to stir at ambient temperature (23 °C) for an additional 1 h. The solvent was 
evaporated and the residue was purified by preparative TLC on SiO2 (50:50 of 
hexanes:EtOAc) to afford 5.3 mg of a 5:1 mixture of diastereomers 2.11b/2.11bʹ′  (49% 
yield) and 1.1 mg of paclitaxel (20% yield) was recovered. TLC (90:10, 
CH2Cl2:acetone): Rf = 0.31; HRMS (MALDI) Calcd for C26H35O6F3K [M+K]: 
1112.3652, Found: 1112.3616. 
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Table A-6. 1H-NMR (500 MHz, CDCl3) and 13C-NMR (125 MHz, CDCl3) of 2.11b. 
Carbon 
Number 
1H-NMR data 
Palitaxol 
(2.11a) 
1H-NMR data 
2.11b (mixture of 
diastereomers) 
13C-NMR 
data 
Palitaxol 
(2.11a) 
13C-NMR data 
2.11b (mixture of 
diastereomers) 
NH 6.99 (d, 9) 7.15 (d, 10) - - 
NHBz - - 167.0 167.0 
1 - - 79.0 79.2 
     
2 5.67 (d, 7) 5.67 (d, 7) 74.9 75.0 
3 3.80 (d, 7) 3.79 (d, 7.5) 45.6 45.5 
4 - - 81.1 81.0 
4-OAc - - 170.3 169.1 
4-OAc - - 22.6 22.8 
5 4.94 (dd, 2, 9.5) 
4.96 
(dd, 1.5, 10.0) 84.4 84.4 
6 - - 35.6 35.5 
7 4.40 (ddd, 4, 7, 11) 4.43 (broad t, 9) 72.2 71.7 
8 - - 58.6 58.5 
9   203.6 203.7 
10 6.27 (s) 6.28 (s) 75.5 76.5 
10-OAc - - 171.3 170.1 
10-OAc - - 20.8 20.8 
11 - - 133.1 133.7 
12 - - 142.0 142.5 
13 6.23 (dt, 1, 9) 6.26 (broad t, 10) 72.3 72.1 
14 - - 35.7 35.7 
15 - - 43.2 43.2 
16 - - 26.9 26.8 
17 - - 21.8 22.3 
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Table A-6. 1H-NMR (500 MHz, CDCl3) and 13C-NMR (125 MHz, CDCl3) of 2.11b 
(continued). 
 
Carbon 
Number 
1H-NMR data 
Palitaxol 
(2.11a) 
1H-NMR data 
2.11b (mixture of 
diastereomers) 
13C-NMR 
data 
Palitaxol 
(2.11a) 
13C-NMR data 
2.11b (mixture of 
diastereomers) 
18 - - 14.8 14.86 & 14.13 
19 - - 9.5 9.6 
20 - - 76.5 76.7 
20a 4.30 (d, 8.5) 4.30 (d, 8.5) - - 
20b 4.19 (d, 8.5) 4.20 (d, 8.5) - - 
1’ - - 172.7 171.3 
2’ 4.79  (dd, 5.5, 3) 4.71 (d, 3) 73.2 74.0 
2’ OH 3.55 (d, 5.5) - - - 
3’ 5.79  (dd, 9, 2.5) 5.80 (dd, 1.0, 8) 55.0 54.5 
---------- HTFB (2.7a) ------------------ HTFB (2.7a) ------------------- 
a - - 125.1  
(q, 271.3) 
Low intensity 
b 3.13 (q, 16.0) 2.58-2.51 (m) 29.3 (q, 
58.6) 
29.5 (q, 42.5) 
c - 4.04-4.01 (m) - 81.4 
d - - 165.9 169.1 
e 4.23 (t, 6.8) 4.16 (t, 6.5) 65.3 65.7 
f 1.84-1.74 (m) Overlap  28.0 27.3 
g 1.64-1.54 (m) Overlap  25.1 24.6 
h 2.26-2.20 
(dt, 2.5, 6.7) 
Overlap  18.3 17.9 
i - Overlap  83.9 83.5 
j 1.96 (t, 2.8) Overlap  68.8 69.0 
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Ephedrine 2-HTFB ether, 2.12b/2.12bʹ′ . To a 
solution of hex-5-ynyl 4,4,4-trifluorobutanoate (HTFB, 2.7a) 
(135.1 mg, 0.54 mmol) in CH2Cl2 (1 mL) was added (−)-
Ephedrine 2.12a (30 mg, 0.182 mmol) and stirred at ambient 
temperature (23 °C) under a nitrogen atmosphere. Then, rhodium acetate (40.0 mg, 50 
mol%) was immediately added. The mixture was allowed to stir at ambient temperature 
for 1 h. The solvent was evaporated and the residue was purified by preparative TLC on 
SiO2 (60:40 of hexanes: EtOAc) to afford 34.2 mg (49% yield) of N−H insertion 
(2.12b/2.12bʹ′) as a 1:1 diastereomeric mixture and 7.5 mg of (−)-Ephedrine (25% yield) 
was recovered. Bis-derivatization derived from both N−H and O−H insertion was 
observed by LC-MS (~15%). TLC (50:50, hexanes:EtOAc): Rf = 0.56; HRMS (ESI+) 
Calcd for C20H27F3NO3 [M+H]: 386.1943, Found:  386.1940. 
 
Table A-7. 1H-NMR 500 MHz, CDCl3) and 13C-NMR (125 MHz, CDCl3) of 2.12b. 
Carbon 
Number 
1H-NMR data 
Ephedrine 
(2.12a) 
1H-NMR data 
2.12b (mixture 
of 
diastereomers) 
13C-NMR data 
Ephedrine (2.12) 
13C-NMR data 
2.12b (mixture of 
diastereomers) 
1 4.66-4.7 (m) 4.47-4.45 (dd, 3,7) 73.1 74.9 & 74.5 
1-OH - 4.81 (broad s) - - 
2 2.66-2.77 (m) 4.27-4.25 (t, 6) 60.4 61.5 & 61.0 
3 0.79 (d, 7) 0.84 (d, 6) 14.1 11.5 & 11.4 
4 2.39 (broad s) 2.52 (broad s) 33.9 34.5 & 34.0 
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Table A-7. 1H-NMR 500 MHz, CDCl3) and 13C-NMR (125 MHz, CDCl3) of 2.12b 
(continued). 
 
Carbon 
Number 
1H-NMR data 
Ephedrine 
(2.12a) 
1H-NMR data 
2.12b (mixture 
of 
diastereomers) 
13C-NMR data 
Ephedrine (2.12) 
13C-NMR data 
2.12b (mixture of 
diastereomers) 
1-phenyl 7.23-7.30 (4H, m) 
7.33-7.33 
(4H, m) 
141.7, 127.0, 
128.0, 126.1 
141.8 &141.6, 
127.0 & 126.9 
128.0 (2), 126.1 
(2) 
--------- HTFB (2.7a) ------------------ HTFB (2.7a) ------------------- 
a - - 125.1 (q, 271.3) 129.2 (q, 455.0) 
b 3.13 (q, 16.0) 3.12 (q, 10) 29.3 (q, 58.6) 29.6 (q, 33.1) 
c - 2.85 (m) - 60.3 (2) 
d - - 165.9 172.3 
e 4.23 (t, 6.8) 4.24-4.21 (t, 7) 65.3 64.7 & 64.5 
f 1.84-1.74 (m) 1.85-1.76 (m) 28.0 27.8 (2) 
g 1.64-1.54 (m) 1.64-1.56 (m) 25.1 24.9 & 24.7 
h 2.26-2.20 (dt, 2.5, 6.7) 
2.25-2.21 
(dt, 3, 5) 18.3 18.0 & 17.8 
i - - 83.9 83.5 
j 1.96 (t, 2.8) 1.96 (t, 3) 68.8 68.5 
 
 
FK506 32-HTFB Ether, 2.13b/2.13ʹ′ . FK506 (2.13a) (5 mg, 0.0062 mmol) and 
rhodium acetate (0.15 mg, 5 mol%) were weighed into a flame-dried, round-bottomed 
flask under a nitrogen atmosphere and the solids were dissolved in CH2Cl2 (1 mL). A 
solution of hex-5-ynyl 4,4,4-trifluorobutanoate (HTFB, 2.7a) (9.3 mg, 0.037 mmol) in 1 
mL of CH2Cl2 was slowly added via a syringe pump over a 2 h period. The mixture was 
allowed to stir at ambient temperature (23 °C) for 1 h. The solvent was evaporated and 
 160 
24
OMe
O
O
OH
OMe
O
HO
O
O
N
O
OMe
32
CH2CF3
O
O
O
ab
c
d
e
f
gh
ij
33
35
30
1
12
3
18
11
13
26
6
9
4
38
36
22
16
20
8
10
14
28
29
37
40
43
44
35
42
41
2.13b/2.13b'
the residue was purified by 
preparative TLC on SiO2 (50:50, 
hexanes:EtOAc) to afford 4.4 mg 
of a 7:1 mixture of diastereomers 
2.13b (major diastereomer) and 
2.13bʹ′(minor diastereomer) (64% 
yield) and 0.85 mg of recovered FK506 (17% yield). The 7:1 mixture of diasteromers 
were further separated by preparative TLC (60:40 %v/v of hexanes:EtOAc) to obtain a 
single diastereomer: Rf = 0.43 (2.13b) and 0.53 (2.13bʹ′); HRMS (MALDI) Calcd for 
C54H81F3NO14 [M+H]: 1024.5609, Found: 1024.5616.  
 
 
Table A-8. 1H-NMR (500 MHz, CDCl3) and 13C-NMR (125 MHz, CDCl3) of 2.13b. 
Carbon 
Number 
1H-NMR data 
FK5068 (2.13a) 
(mixture of 
rotamers) 
1H-NMR data 
2.13b (mixture 
rotamers) 
13C-NMR data 
FK506 (2.13a) 
(mixture of 
rotamers) 
13C-NMR data 
2.13b (mixture 
of rotamers) 
1 - - 169.0 & 168.7 169.0 & 168.7 
2 4.62 & 5.0 (d, 
5) 
4.61 & 5.0 (d, 
5) 
56.5 & 52.7 56.3 & 52.7 
3 - - 27.6 & 26.2 27.5 & 26.2 
4 1.28 & 1.69 (m) Overlap  21.1 & 20.8 21.1 & 22.7 
5 - - 24.5 24.6 & 24.5 
                                                
8 Tanaka, H.; Kuroda, A.; Marusawa, H.; Hatanaka, H.; Kino, T.; Goto, T.; Hashimoto, 
M. J. Am. Chem. Soc. 1987, 109, 5031. Karuso, P.; Kesseler, H.; Mierke, D. F. J. Am. 
Chem. Soc. 1990, 112, 9434. Mierke, D. F.; Schmieder, P.; Karuso, P.; Kessler, H. Helv. 
Chim. Acta 1991, 74, 1027. 
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Table A-8. 1H-NMR (500 MHz, CDCl3) and 13C-NMR (125 MHz, CDCl3) of 2.13b 
(continued). 
 
Carbon 
Number 
1H-NMR data 
FK506 (2.13a) 
(mixture of 
rotamers) 
1H-NMR data 
2.13b (mixture 
rotamers) 
13C-NMR data 
FK506 (2.13a) 
(mixture of 
rotamers) 
13C-NMR data 
2.13b (mixture 
of rotamers) 
6 4.43 & 3.73  (d, 13) 
4.42 & 3.76  
(d, 10) 43.8 & 39.2 43.9 & 39.2 
8 - - 165.8 & 164.6 164.6 
9 - - 196.1 & 192.6 196.1 & 192.6 
10 - - 98.6 & 97.0 98.6 & 97.0 
11 - - 34.5 & 33.6 34.3 & 33.6 
12 - - 32.6 & 32.5 32.7 & 32.5 
13 3.33 (m) 3.37 (m) 73.5 73.6 
14 3.68 (d, 10) 3.85-3.98 (m) 
3.59 (dd, 3, 
10.5) & 3.89 
(dd, 2, 10) 
72.7 & 72.2 73.6 & 73.5 
15 3.52-3.60 (m) 3.49-3.43 (m) 76.5 & 75.1 72.4 & 72.1 
16 - - 32.9 & 35.4 32.9 & 35.4 
17 - - 26.2 26.2 & 26.0 
18 - - 48.5 & 48.3 48.5 & 48.4 
19 - - 138.9 & 139.8 139.8 & 138.9 
20 4.93 & 4.94 (m) 4.98-5.06 (m) 122.6 & 122.4 122.6 & 122.4 
     
21 3.30 & 3.33 (m) 3.35 (m) 52.9 & 52.7 52.8 & 52.7 
22 - - 212.7 & 212.6 212.8 & 212.6 
23 2.1 & 2.7 (m) 2.79 & 2.76  (d, 2.5) 43.8 & 43.2 43.8 & 43.1 
24 3.85-3.98 (m) 3.88-3.95 (m) 70.0 & 68.9 70.2 & 68.9 
25 - - 40.3 & 39.8 40.3 & 39.8 
26 5.32 & 5.19  (d, 2.0) 
5.31 & 5.18       
(d, 2.0) 77.8 & 77.1 
77.8 & overlap 
with solvent 
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Table A-8. 1H-NMR (500 MHz, CDCl3) and 13C-NMR (125 MHz, CDCl3) of 2.13b 
(continued). 
 
Carbon 
Number 
1H-NMR data 
FK506 (2.13a) 
(mixture of 
rotamers) 
1H-NMR data 
2.13b (mixture 
rotamers) 
13C-NMR data 
FK506 (2.13a) 
(mixture of 
rotamers) 
13C-NMR data 
2.13b (mixture 
of rotamers) 
27 - - 132.4 & 131.7 132.5 & 131.9 
28 4.9-5.2 (m) 4.98-5.06 (m) 129.7 & 129.6 129.5 & 129.4 
29 - - 34.9 & 34.8 35.4 & 35.3 
30 - - 34.8 & 34.7 34.6 & 34.3 
31 2.97 (m) 3.17-3.12  (dt, 5.0, 10.0) 84.1 83.2 & 83.1 
32 3.35 (broad s) - 73.6 74.2 
33 - - 31.2 & 31.1 31.9 & 30.7 
34 - - 30.6 (2) 30.0 
35 0.89 & 0.93 1.0-0.82 (m) 16.2 & 16.0 16.2 
36 0.72 & 0.86 1.0-0.82 (m) 20.4 & 19.4 20.4 & 19.4 
37 1.52 & 1.55 1.62 &1.60 (broad s) 15.9 & 15.7 16.0 & 15.8 
38 - - 35.5 & 35.1 85.1 & 35.6 
39 5.7 (m) 5.76-5.65 (m) 135.5 & 135.3 135.5 & 135.3 
40 4.90-5.20 (m) 4.89-5.06 (m) 116.7 116.7 
41 - - 9.8 & 9.5 9.8 & 9.5 
     
42 1.55 & 1.59 1.64 & 1.63 (broad s) 14.2 & 14.1 14.3 & 14.1 
43 3.33 & 3.34 3.39 & 3.38 (broad s) 56.3 & 56.1 56.1 & 55.9 
44 3.24 & 3.30 3.29 & 3.25 (broad s) 57.5 & 56.9 57.6 & 57.0 
45 3.35 3.33 (broad s) 56.6 56.6 
--------- HTFB (2.7a) ------------------- HTFB (2.7a) ---------------- 
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Table A-8. 1H-NMR (500 MHz, CDCl3) and 13C-NMR (125 MHz, CDCl3) of 2.13b 
(continued). 
 
Carbon 
Number HTFB (2.7a) 
1H-NMR data 
2.13b (mixture 
rotamers) 
HTFB (2.7a) 
13C-NMR data 
2.13b (mixture 
of rotamers) 
a - - 125.1 (q, 271.3) 125.6  (q, 275.0) 
b 3.13 (q, 16.0) 3.05-2.98 (m) 29.3 (q, 58.6) 29.4 (q, 21,3) 
c - 4.22-4.15 (m) - - 
d - - 165.9 171.0 
e 4.23 (t, 6.8) 4.44 (t, 6.0) 65.3 64.7 
f 1.84-1.74 (m) 1.82-1.79 28.0 29.4 
g 1.64-1.54 (m) Overlap  25.1 24.8 
h 2.26-2.20 (dt, 2.5, 6.7) 
2.26-2.23 
(dt, 3, 6.5) 18.3 18.0 
i - - 83.9 83.6 
j 1.96 (t, 2.8) Overlap  68.8 68.8 
 
 
Lactimidomycin-HTFB ether (2.14b and 
2.14bʹ′). Lactimidomycin (2.14a) (1.8 mg, 0.0039 
mmol) and rhodium acetate (0.10 mg, 5 mol%) was 
weighted into a flame-dried, round-bottomed flask 
under a nitrogen atmosphere and the solids were 
dissolved in CH2Cl2 (1 mL). Then, a solution of hex-5-ynyl 4,4,4-trifluorobutanoate 
(HTFB, 2.7a) (12.0 mg, 0.047 mmol) in 1 mL of CH2Cl2 was slowly added via a syringe 
pump over a 1 h period. The mixture was allowed to stir at ambient temperature (23 °C) 
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for 1 h. The residue was purified by reverse phase preparative HPLC using Gamini-NX 
3µ C18 110A column, 150 x 4.6 mm (gradient 5→30% CH3CN: H2O, PDA 168-220 
nm) to afford 0.4 mg of a 1:1 mixture of diastereomers 2.14b and 2.14bʹ′  (15% yield). 
Each diastereomer was separated and a small amount of unreacted lactimidomycin was 
recovered. LRMS (MALDI) Calcd for C36H48F3NO8 [M+H]: 678.3254, Found: 
678.3058.  
 
Figure A-1. Preparative HPLC chromatogram for purification of lactimidomycin/HTFB 
(2.14a, 2.14b and 2.14bʹ′). (A) purified 2.14b, (B) purified 2.14bʹ′ , (C) purified 
lactimidomycin (2.14a), (D) crude reaction mixtures. 
 
B 
 C 
A 
D 
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Figure A-2. Total ion count LC/MS chromatogram (positive mode) for purification of 
lactimidomycin/HTFB (2.14b and 2.14bʹ′). (A) crude reaction mixtures, (B) 
lactimidomycin (2.14a), (C) purified 2.14bʹ′, (D) purified 2.14. 
 
 
Figure A-3. LC/MS profiles (positive mode) of purified 12b (A) and purified 2.14bʹ′(B). 
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Table A-9. 1H-NMR (500 MHz, CDCl3) and 13C-NMR (125 MHz, CDCl3) of 2.14bʹ′ 
and 2.14b. 
 
Carbon 
Number 
1H-NMR data 
Lactimidomycin 
(2.14a)9 
1H-NMR data of 2.14b 1H-NMR data of 2.14bʹ′  
2 5.53 (d, 16.0) 5.56 (d, 15.0) 5.56 (d, 16.0) 
3 6.49 (ddd, 16.0, 10.0, 5.0) 
6.45 (m) 6.43 (m) 
6 5.42 (m) 5.43 (m) 5.42 (m) 
7 5.72  (dd, 15.5, 10.5) 
5.70 (dd, 16.0, 10.0) 5.70 (dd, 16.0, 10.0) 
8 6.06 (t, 11.0) 6.08 (t, 10.0) 5.98 (t, 10.0) 
9 5.06 (t, 11.0) 5.10 (t, 10.0) 5.10 (t, 10.0) 
10 3.11 (m) 3.10 (m) 3.10 (m) 
11 5.34 (m, overlap) 5.37 (m) 5.38 (m) 
13 5.34 (m, overlap) 5.37 (m) 5.38 (m) 
14 3.44 (m) 3.38 (m) Overlap with other 
16 2.59 (2H, m) 2.57 (2H, m) 2.57 (2H, m) 
17 4.12 (m) 4.18 (m) 4.10 (m) 
------------ HTFB (2.7a) ------------------------ ------------------------ 
c - 4.80 (dd, 3.5, 8.5) 4.72 (dd, 4.0, 8.5) 
e 4.23 (t, 6.8) 4.22 (t, 6.8) 4.23 (t, 6.8) 
h 2.26-2.20  (dt, 2.5, 6.7) 
2.27 (m) 2.27 (m) 
Only diagnostic protons that are clearly analyzed by 1H-NMR are included. 
 
                                                
9 Koko, S., Yuji, N., Soichiro, t., Nobujiro, K., Masami, H., Toshio, M., Yosuke, S., 
Hideo, K., Masataka, K., and Toshikazu, O. J. Antibiot. 1992, 45, 1433. Ju, J., Seo, J.-
W., Her, Y., Lim, S.-K., and Shen, B. Org. Lett. 2007, 9, 5183. 
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Fumagillol 6-HTFB ether, 2.15b/2.15ʹ′. Fumagillol 
(2.15a) (13.2 mg, 0.047 mmol) and rhodium acetate (1.0 mg, 
5 mol%) were weighed into a flame-dried, round-bottomed 
flask under a nitrogen atmosphere and the solids were 
dissolved in CH2Cl2 (3 mL). A solution of hex-5-ynyl 4,4,4-
trifluorobutanoate (HTFB, 2.7a) (34.98 mg, 0.141 mmol) in 2 mL of CH2Cl2 was slowly 
added via a syringe pump over a 1 h period. The mixture was allowed to stir at ambient 
temperature (23 °C) for 1 h. The solvent was evaporated and the residue was purified by 
preparative TLC on SiO2 (70:30, hexanes:EtOAc) to afford 14.7 mg of a 7:1 mixture of 
diastereomers 2.15b/2.15ʹ′  (63% yield) and 2.8 mg of recovered Fumagillol (21% yield). 
TLC (70:30, hexanes:EtOAc): Rf = 0.49; HRMS (MALDI): Calcd for C26H37O6F3Na 
[M+Na] = 525.2440 m/z, Found [M+Na] = 525.2456 m/z. 
 
Table A-10. 1H-NMR (500 MHz, CDCl3) and 13C-NMR (125 MHz, CDCl3) of 2.15b. 
Carbon 
Number 
1H-NMR data 
Fumagillol 
(2.15a)10 
1H-NMR data of 
2.15b 
(mixture of 
diastereomers) 
13C-NMR data 
Fumagillol 
(2.15a) 
13C-NMR data of 
2.15b (mixture 
of diastereomers) 
1 - - - - 
2 2.93 & 2.52  (d, 4.3) 
2.98 & 2.54 
(d, 4.5) 50.7 50.9 
3 - - 58.5 58.4 
4 1.91 (d, 11.1) 1.71 (m) 47.0 47.1 
5 3.61  (dd, 2.7, 11.1) 
3.57 
 (dd, 2.5, 11.0) 80.9 81.2 
                                                
10 Hanson, F. R.; Elbe, T. E. J. Bacteriol. 1949, 58, 527. Elbe, T. E.; Hanson, F. R. 
Antibiot. Chemother. 1951, 1, 54. 
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Table A-10. 1H-NMR (500 MHz, CDCl3) and 13C-NMR (125 MHz, CDCl3) of 2.15b 
(continued). 
 
Carbon 
Number 
1H-NMR data 
Fumagillol 
(2.15a) 
1H-NMR data of 
2.15b 
(mixture of 
diastereomers) 
13C-NMR data 
Fumagillol 
(2.15a) 
13C-NMR data of 
2.15b (mixture 
of diastereomers) 
6 4.35 (m) 4.33  (dd, 3.5, 9.0) 64.0 64.9 
7 
1.99 (m) & 1.75 
(tdd, 13.9, 2.6, 
4.5) 
2.13 (m) &  
1.79 (m) 26.5 25.7 
8 
2.19 (dt, 4.5, 
13.6) & 0.96 
(ddd, 2.5, 4.5, 
13.6) 
2.18 (m) 28.5 28.9 
9 - - - - 
10 - - 59.8 59.8 
11 2.57 (t, 6.5) 2.62 (t, 5.0) 61.2 60.6 
12 2.41-2.30 (m) & 2.21-2.09 (m) 
2.40-2.35 (m) & 
2.20-2.12 (m) 27.3 27.4 
13 5.19 (tm, 7.4) 5.22 (tm, 7.0) 118.5 118.8 
14 - - 134.9 134.7 
15 1.21 (s) 1.21 (s) 18.0 17.0 
16 1.64 (s) 1.67 (s) 13.9 14.2 
17 1.73 (s) 1.77 (s) 25.7 25.7 
18 3.48 (s) 3.45 (s) & 3.43 (s) 56.5 56.7 
---------- HTFB (3a) ----------------------- HTFB (3a) --------------------
--- 
a - - 125.1  (q, 271.3) 124.5 (q, 110.25) 
b 3.13 (q, 16.0) 2.60-2.57 (m) 29.3 (q, 58.6) 37.6 (q, 56.3) 
c - 4.19 (t, 6.5) & 4.17 (t, 6.5) - - 
d - - 165.9 170.3 
e 4.23 (t, 6.8) 4.24 (m) 65.3 72.9 
f 1.84-1.74 (m) 1.84-1.79 (m) 28.0 29.7 
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Table A-10. 1H-NMR (500 MHz, CDCl3) and 13C-NMR (125 MHz, CDCl3) of 2.15b 
(continued). 
 
Carbon 
Number 
1H-NMR data 
Fumagillol 
(2.15a) 
1H-NMR data of 
2.15b 
(mixture of 
diastereomers) 
13C-NMR data 
Fumagillol 
(2.15a) 
13C-NMR data of 
2.15b (mixture 
of diastereomers) 
g 1.64-1.54 (m) 1.65-1.60 (m) 25.1 24.8 
h 2.26-2.20  (dt, 2.5, 6.7) 
2.29-2.25  
(dt, 3.0, 7.0) 18.3 18.0 
i - - 83.9 83.7 
j 1.96 (t, 2.8) 1.99 (t, 3.0) 68.8 68.8 
 
 
Fumagillol 6-HBPA ether, 2.21/2.21ʹ′. Fumagillol (2.15a) (19.2 mg, 0.068 
mmol) and rhodium acetate (1.5 mg, 5 mol%) were weighed into 
a flame-dried, round-bottomed flask under a nitrogen atmosphere 
and the solids were dissolved in CH2Cl2 (3 mL). A solution of 
hex-5-yn-1-yl 2-(4-bromophenyl)-2-diazoacetate (HBPA, 2.1) 
(65.93 mg, 0.204 mmol) in 2 mL of CH2Cl2 was slowly added via 
a syringe pump over a 1 h period. The mixture was allowed to stir at ambient 
temperature (23 °C) for 1 h. The solvent was evaporated and the residue was purified by 
preparative TLC on SiO2 (70:30, hexanes:EtOAc) to afford 22.8 mg of a 5:1 mixture of 
diastereomers 2.21/2.21ʹ′ (58% yield) and 5.7 mg of recovered Fumagillol (30% yield). 
TLC (70:30, hexanes:EtOAc): Rf = 0.47; HRMS (MALDI): Calcd for C30H39O6BrNa 
[M+Na] = 597.1821 m/z, Found [M+Na] = 597.1806 m/z. 
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Table A-11. 1H-NMR (500 MHz, CDCl3) and 13C-NMR (125 MHz, CDCl3) of 2.21. 
Carbon 
Number 
1H-NMR data 
Fumagillol 
(2.15a) 
1H-NMR data 
2.21 (mixture of 
diastereomers) 
13C-NMR 
data 
Fumagillol 
(2.15a) 
13C-NMR data 
2.21 (mixture of 
diastereomers) 
1 - - - - 
2 2.93 & 2.52 (d, 4.3) 
2.95 & 2.52  
(d, 4.0) 50.7 50.9 & 50.8 
3 - - 58.5 58.5 & 58.4 
4 1.91 (d, 11.1) 2.19 (d, 11.0) 47.0 47.6 & 47.5 
5 3.61  (dd, 2.7, 11.1) 
3.57  
(dd, 2.3, 11.0) 80.9 82.0 & 81.9 
6 4.35 (m) 4.18 (m) & 4.13 (m) 64.0 70.9 & 68.8 
7 
1.99 (m) & 
1.75 (tdd, 13.9, 
2.6, 4.5) 
2.16-2.11(m) & 
1.91-1.88 (m) 26.5 26.5 & 26.2 
8 
2.19 (dt, 4.5, 
13.6) & 0.96 
(ddd, 2.5, 4.5, 
13.6) 
2.18-2.16 (m) & 
2.16-2.11(m) 28.5 29.2 
9 - - - - 
10 - - 59.8 59.9 
11 2.57 (t, 6.5) 2.59 (t, 6.5) 61.2 60.7 
12 
2.41-2.30 (m) 
& 
2.21-2.09 (m) 
2.36-2.30 (m) & 
2.28-2.24 (m) 27.3 27.4 & 27.3 
13 5.19 (tm, 7.4) 5.20 (tm, 7.5) 118.5 118.7 & 118.6 
14 - - 134.9 134.7 
15 1.21 (s) 1.19 (s) & 1.18 (s) 18.0 18.0 & 17.9 
16 1.64 (s) 1.64 (s) & 1.63 (s) 13.9 14.2 & 14.1 
17 1.73 (s) 1.73 (s) & 1.72 (s) 25.7 25.7 
18 3.48 (s) 3.45 (s) & 3.36 (s) 56.5 56.9 & 56.7 
---------- HBPA (2.1) ----------------------- HBPA (2.1) ----------------- 
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Table A-11. 1H-NMR (500 MHz, CDCl3) and 13C-NMR (125 MHz, CDCl3) of 
2.21(continued). 
 
Carbon 
Number HBPA (2.1) 
1H-NMR data 
2.21 (mixture of 
diastereomers) 
HBPA (2.1) 
13C-NMR data 
2.21 (mixture of 
diastereomers) 
     
a - - 119.6 122.5 & 122.4 
b 7.50 (d, 9) 7.48 (d, 8.5) & 7.45 (d, 8.5) 125.6 131.6 & 131.4 
c 7.36 (d, 9) 7.37 (d, 8.5) & 7.35 (d, 8.5) 124.9 128.9 & 128.8 
d - - 132.3 136.5 & 136.1 
e - 5.29 & 2.48 (s) - - 
f - - 164.7 171.2 & 170.2 
g 4.3 (t, 7) 4.10-4.04 (m) 64.8 64.6 & 64.5 
h 1.89-1.79 (m) 1.79-1.67 (m) 28.0 27.5 & 27.4 
i 1.58-1.68 (m) 1.47-1.41 (m) 18.3 17.9 & 17.8 
j 2.26 (dt, 2.5, 7) Overlap  25.1 24.9 & 24.7 
k - - 83.9 83.8 & 83.6 
l 1.97 (t, 2.5) 1.93 (t, 3.0) 69.1 79.3 & 78.9 
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E) Synthesis of FK506-HTFB-Biotin Probe (2.19) by Sharpless-Hüisgen 
Cycloaddition 
 
  CuSO4/ Na Ascorbate (1:10)
t-BuOH/H2O (1:1), 23 oC, 24 h; 60%
FK506
S
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H
H
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H
H
O
H
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H
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A solution of FK506-HTFB (2.13b) (5.5 mg, 0.0054 mmol) in 1.0 mL of dry 
acetonitrile and a stock solution of (+)-Biotin-(PEO)4-N3 (2.17) (93 µL of a 70.0 mM 
stock solution in dry acetonitrile, 0.0065 mmol, Quanta Bio) was mixed in a vial flushed 
with nitrogen and equipped with a magnetic stir bar. The reaction mixture was diluted 
with 1.5 mL of tBuOH/H2O (1:1). A Cu(I) solution was freshly prepared from 2.5 mL of 
an aqueous solution of CuSO4.5H2O (1 M) and 2.5 mL of an aqueous solution of sodium 
ascorbate (10 M). The solutions of CuSO4 and sodium ascorbate were mixed and stirred 
at ambient temperature (23 °C) until the black solution turned light yellow-brown. At 
this point, the Cu(I) solution (6 µL) was immediately added into the mixture of FK506-
HTFB and biotin-azide. The reaction mixture was stirred at ambient temperature for 24 
h. The reaction was then filtered through a cotton plug in a glass pipette to remove solid 
residues and rinsed with 5 mL of EtOAc. The filtrate was concentrated under reduced 
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pressure and purified by preparative TLC (30:70, MeOH:EtOAc) to afford the FK506-
HTFB-biotin probe 2.19 (5.7 mg, 60% yield); TLC (30:70 %v/v of MeOH:EtOAc): Rf = 
0.35; HRMS (MALDI): Calcd for C85H137O24F3N8SNa [M+Na] = 1765.9309, Found 
[M+Na] = 1765.9297. 
 
F) Synthesis of FK506-HBPA-Biotin Probe (2.20) by Sharpless-Hüisgen 
Cycloaddition 
 
  CuSO4/ Na Ascorbate (1:10)
t-BuOH/H2O (1:1), 23 oC, 24 h; 42%
FK506
S
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H
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H
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FK506-HBPA (2.18) was prepared according to a general O-H insertion method 
as described in ref. 10. A solution of FK506-HBPA (2.18) (41.1 mg, 0.0375 mmol) in 
dry acetonitrile (1.0 mL) and a stock solution of (+)-Biotin-(PEO)4-N3 (2.17) (634 µL of 
a 70.0 mM stock solution in dry acetonitrile, 0.0444 mmol, Quanta Bio) were mixed in a 
vial flushed with nitrogen and equipped with a magnetic stir bar. The reaction mixture 
was diluted with 2.0 mL of tBuOH/H2O (1:1). A Cu(I) solution was freshly prepared 
from 2.5 mL of an aqueous solution of CuSO4.5H2O (1 M) and 2.5 mL of an aqueous 
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solution of sodium ascorbate (10 M). The solutions of CuSO4 and sodium ascorbate were 
mixed and stirred at ambient temperature (23 °C) until the black solution turned light 
yellow-brown. At this point, the Cu(I) solution (10 µL) was immediately added into the 
mixture of FK506-HBPA and biotin-azide. The reaction mixture was stirred at ambient 
temperature (23 °C) for 24 h. The reaction was then filtered through a cotton plug in a 
pipette to remove all solid residues and washed with 10 mL of EtOAc. The filtrate was 
concentrated under reduced pressure and purified by preparative TLC (30:70, 
MeOH:Et2O) to afford the FK506-HBPA-biotin conjugate 2.20 (29.1 mg, 42% yield); 
TLC (30:70, MeOH:Et2O): Rf = 0.17; HRMS (MALDI) Calcd for C90H141BrN8O24SNa 
[M+Na] = 1851.8865, Found [M+Na] = 1851.8971. 
 
G) IL-2 Reporter Assay with FK506 Derivatives (2.13b, 2.13bʹ′ , 2.18 and 2.18ʹ′) and 
FK506-Biotin Conjugates (2.19 and 2.20) 
Jurkat T cells (E6.1) from ATCC were transfected with an IL-2 promoter-driven 
luciferase reporter plasmid. After 18 h, the cells were aliquotted into 96-well plates at 
0.5 million cells per well and incubated with FK506 (2.13a), 2.13b, 2.13bʹ′, 2.18, 2.18ʹ′ , 
2.19 and 2.20 with different concentrations for 30 minutes. The cells were then 
stimulated with 40 nM phorbol myristate acetate and 1 mM ionomycin for 6 h. Cells 
were harvested and the luciferase activity was measured. The data were processed with 
Graphpad Prism software. 
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Figure A-4. IC50 value plots of IL-2 activation by phorbol myristyl acetate (PMA) plus 
ionomycin for diastereomeric FK506/HTFB ethers (2.13b/2.13bʹ′), FK506-HPBA ethers 
(2.18/2.18ʹ′), and biotin conjugate 2.19 and 2.20 in the Jurkat T cells.  
 
H) Affinity Chromatography Experiments with FK506-Biotin Conjugates 2.19 and 
2.20 
Jurkat T cells (E6.1) were lysed in a lysis buffer containing 20 mM Tris.HCl, pH 
7.5, 100 mM KCl, 0.5 mM β-mecaptoethanol, 0.1% Triton X-100 and a protease 
inhibitor cocktail (Roche Applied Science, Indianapolis, IN). The lysates were aliquoted 
and incubated with DMSO or FK506 for 30 min, followed by incubation with biotin 
conjugate 16 or 17 for 1 h. The binding proteins of the FK506-biotin conjugates were 
captured with 15 ml streptavidin agarose and resolved on SDS-PAGE gel for silver 
staining or Western blot analysis. 
 
J) ‘Click’ Reaction and Affinity Chromatography Experiments of Fumagillol 
Derivatives 2.15b/2.15ʹ′ , 2.21/2.21ʹ′, 2.22 and 2.23 
HEK293T cells were first incubated with 20 µM of TNP470 (2.23) or DMSO for 
30 min, then continued to incubate with 1 µM of 2.15b/2.15ʹ′ , 2.21/2.21ʹ′, 2.22 or DMSO 
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for 1 h. Cells were harvested and lysed with 100 mM phosphate (pH = 8.0) buffer 
containing protease inhibitor by dounce homogenizer. Cell lysates were subjected to pre-
clear with Strepavidin beads for 1h. The total proteins were diluted to the concentration 
of 2.5 mg/mL. Then, 86 µL of total protein (2.5 mg/mL) was boiled with 0.4% SDS. For 
click chemistry reaction, other reagents were added, which included 25 µM of biotin-
azide 21, 1 mM of Tris(2-carboxyethyl)phosphine hydrochloride (TCEP), 100 µM of 
tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) and 1 mM of CuSO4 to a 
final volume of 100 µL. The mixture was incubated for 1 h at room temperature. 
Streptavidin beads were used to capture the final complex and eluted with 2 x SDS 
sample buffer after extensively washing with washing buffer (100 mM Tris.HCl [pH = 
7.5], 500 mM NaCl, and 0.2% SDS). The eluents were separated by SDS-PAGE for 
western blotting.  
 
K) Proliferation Assay of Fumagillol Derivatives 2.15b/2.15ʹ′ , 2.21/2.21ʹ′, 2.22 and 
2.23 
HUVEC cells were purchased from Lonza and maintained as suggested. HUVEC 
cells were plated into 96-well plate for overnight and treated with compounds 2.15/2.15ʹ′ , 
2.21/2.21ʹ′ , 2.22, and 2.23 with different concentration (0.001, 0.01, 1.0, 10, 100, 1000, 
10000 and 20000 nM) for 18 h. The cells were labeled with 0.5 mci 3H thymidine per 
well for another 6 h and harvested afterwards. The radioactivity of 3H thymidine 
incorporation were measured by MicroBeta and plotted with GraphPad software.  
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Figure A-5. IC50 value plots of fumagillol derivatives 2.15b/2.15bʹ′, 2.21/2.21ʹ′, 2.22 and 
2.23 in HUVEC cells. 
 
L) hMetAP2 Assay of fumagillol derivatives 2.15b/2.15bʹ′ and 2.21/2.21ʹ′  
Eight different concentrations of fumagillol (2.15a) and fumagillol derivatives 
(2.15b/2.15bʹ′  and 2.21/2.21ʹ′) (20, 10, 5, 1, 0.5, 0.1, 0.05 and 0.005 µM) were pipetted 
into a 96-well plate and they were incubated for 20 min at room temperature with an 
assay buffer (40 mM HEPES [pH = 7.5], 100 mM NaCl and 10 µM MnCl2) containing 
250 nM GST-6×His-ThrCS-HsMetAP2 and 0.02 U proline aminopeptidase as the 
coupling enzyme. The enzyme reaction was initiated by adding methionylprolyl-p-
nitroanilide as the substrate (20 µL, 3 mM; such that a final concentration of 600 µM 
was attained in a 100 µL of total reaction volume in each well) and the change in 
absorbance at 405 nm was measured using a microplate reader (BMG Labtech, 
Offenburg, Germany) for a period of 20 min. Reaction progress was computed against 
the data from the wells containing DMSO alone taken for uninhibited reactions. The data 
from four independent experiments were combined and the EC50 values were determined 
by plotting the data using the GraphPad Prism software. 
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Figure A-6. EC50 value plots of fumagillol (2.15a), fumagillol-HTFB 2.15b/2.15bʹ′  and 
fumagillol-HBPA (2.21/2.21ʹ′) from hMetAP2 assay.   
 
Chapter III - Synthesis of β-Lactam Congeners of Orlistat as Fatty Acid Synthase 
Inhibitors 
 
OTBS
O
3.22a
OTBS
SPyC6H13
TBSO O
O
C6H133.28 (+)-3.23a   
(3S,4R)-4-((S)-2-(tert-butyldimethylsiloxy)-hexyl)-3-hexyloxetan-2-one, (+)-
3.23a. To a solution of aldehyde 3.22a (555.6 mg, 2.15 mmol) and thiopyridyl ketene 
acetal 3.28 (1.0 g, 2.87 mmol) in CH2Cl2 (5 ml) at −78 °C was added a solution of SnCl4 
(2.0 mL, 2.0 mmol, 1M in CH2Cl2) slowly over 2 h using syringe pump. After 30 
minutes, the reaction was quenched with pH 7 buffer solution (5.0 mL) and warmed up 
to room temperature. The result mixture was filtrated through a plug of celite and the 
organic layer was separated. The dried (MgSO4) extract was concentrated in vacuo and 
purified by chromatography over silica gel, eluting carefully with 0.3% diethyl ether / 
hexanes, to give β-lactone (+)-3.23a (405.8 mg, 1.05 mmol, 49%) as a colorless oil (dr, 
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6:1). The major isomer: [α]D20 +30.5 (c 1.05, CHCl3); IR (thin film) 2934, 2863, 1827, 
1253, 1063 cm-1; 1H-NMR (500 MHz, CDCl3) δ 4.75 (ddd, J = 2.5, 6.5, 10.5 Hz, 1H), 
3.84-3.89 (m, 1H), 3.63 (dt, J = 7.0, 8.5 Hz, 1H), 1.47-1.55 (m, 3H), 1.24-1.36 (m, 18H), 
0.88-0.91 (m, 14H), 0.071 (s, 3H), 0.068 (s, 3H); 13C-NMR (125 MHz, CDCl3) δ 172.7, 
72.9, 68.6, 52.6, 38.4, 36.8, 32.2, 31.7, 29.3, 27.8, 26.12, 26.07, 26.00, 24.4, 22.8, 22.9, 
18.3, 14.3, -4.2, -4.3; LRMS (ESI+) Calcd for C22H45O3Si (M+H) 385, found 385. 
 
C4H9
O
O
C6H13
TBSO N
O
C6H13
TBSO
BnO
C4H9
(!)-3.31(+)-3.23a  
(3S,4R)-1-(benzyloxy)-4-((S)-2-(tert-butyldimethylsiloxy)-hexyl)-3-hexyl 
azetidin-2-one, (−)-3.31. To a flask with β-lactone (+)-3.23a (197.2 mg, 0.46 mmol) 
was added BnONH2 (123.2 mg, 1.0 mmol). The reaction was warmed to 50 °C for 
overnight. Next, the reaction was diluted with Et2O (5.0 mL) and cooled to 0 °C. To this 
solution was added PPh3 (268.7 mg, 1.0 mmol) and DIAD (208.0 mg, 0.2 mL, 1.0 
mmol). After 30 minutes, the reaction was warmed to room temperature and 
concentrated in vacuo and purified by chromatography over silica gel, eluting with 1% 
EtOAc/hexanes, to give β-lactam (−)-3.31 (111.7 mg, 0.228 mmol, 44%) as a colorless 
oil (dr, 6:1). The major isomer: [α]D20 −37.8 (c 1.11, CHCl3); IR (thin film) 2934, 2854, 
1768, 1466, 1066 cm-1 ; 1H-NMR (500 MHz, CDCl3) δ 7.40-7.45 (m, 5H), 5.0 (d, J = 
11.0 Hz, 1H), 4.96 (d, J = 11.0 Hz, 1H), 3.71-3.76 (m, 1H), 3.31 (ddd, J = 1.5, 4.5, 9.0 
Hz, 1H), 2.55 (dt, J = 2.0, 6.5 Hz, 1H), 1.87 (dt, J = 5.0, 14.0 Hz, 1H), 1.57-1.62 (m, 
2H), 1.48-1.54 (m, 1H), 1.21-1.40 (m, 17H), 0.91-0.95 (m, 4H), 0.89 (s, 10H), 0.06 (s, 
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3H), 0.04 (s, 3H); 13C-NMR (125 MHz, CDCl3) δ 166.9, 135.6, 129.7, 129.2, 128.8, 
78.2, 70.0, 61.4, 52.3, 39.3, 37.1, 32.1, 31.8, 29.5, 28.5, 27.1, 26.1, 25.1, 22.86, 22.80, 
18.27, 14.31, 14.29, -4.2, -4.3; LRMS (ESI+) Calcd for C29H52NO3Si (M+H) 490, found 
490. 
 
N
O
C6H13
TBSO
BnO
C4H9
(!)-3.31
C4H9
N
O
C6H13
HO
BnO
(!)-3.32  
(3S,4R)-1-(benzyloxy)-3-hexyl-4-((S)-2-(hydroxyhexyl)azetidin-2-one, (−)-
3.32. To a solution of β-lactam (−)-3.31 (187.7 mg, 0.38 mmol) in CH3CN at 0 °C was 
added HF (0.46 mL, 48% w/w in H2O). After 20 minutes, the reaction was warmed up to 
room temperature. After 6 h, the reaction was carefully quenched with sat. aq. NaHCO3 
(3.0 mL) and the mixture was extracted with Et2O. The dried (MgSO4) extract was 
concentrated in vacuo and purified by chromatography over silica gel, eluting with 1% 
EtOAc/hexanes, to give β-lactam (−)-3.32 (97.4 mg, 0.259 mmol, 68%) as a colorless oil 
(dr, 6:1). The major isomer: [α]D20 −28.9 (c 0.97, CHCl3); IR (thin film) 3437 (br), 3032, 
2928, 1756, 1460 cm-1; 1H-NMR (500 MHz, CDCl3) δ 7.40-7.46 (m, 5H), 4.99 (d, J = 
11.0 Hz, 1H), 4.95 (d, J = 11.0 Hz, 1H), 3.52-3.61 (m, 1H), 3.37 (ddd, J = 2.0, 5.5, 7.5 
Hz, 1H), 2.54 (ddd, J = 2.0, 6.0, 8.5 Hz, 1H), 1.66-1.70 (m, 4H), 1.26-1.38 (m, 17H), 
0.87-0.91 (m, 6H); 13C-NMR (125 MHz, CDCl3) δ 166.7, 135.4, 129.8, 129.3, 128.9, 
78.4, 69.6, 62.9, 51.8, 40.1, 38.3, 31.80, 31.78, 29.4, 28.6, 27.4, 25.4, 22.85, 22.81, 
14.32, 14.29; LRMS (ESI+) Calcd for C23H38NO3 (M+H) 376, found 376.  
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C4H9
HN
O
C6H13
HO
(!)-3.33
C4H9
N
O
C6H13
HO
BnO
(!)-3.32  
(3S,4S)-3-hexyl-4-((S)-2-hydroxyhexyl)azetidin-2-one, (−)-3.33. To a solution 
of alcohol (−)-3.32 (21.8 mg, 0.06 mmol) in THF (0.9 mL) was added H2O (30 µL). 
Next, this solution was treated with freeze-pump-thawn process at −78 °C (twice) before 
warmed to 0 °C.  A freshly prepared solution of SmI2 (0.07 M in THF) was added to the 
reaction solution dropwise till a persistent deep-blue color formed. After 5 minutes, the 
reaction was quenched with sat. aq. NaHCO3 (2.0 mL), and the mixture was extracted 
with EtOAc (3 x 20 mL). The dried (MgSO4) extract was concentrated in vacuo and 
purified by chromatography over silica gel, eluting carefully with 40% EtOAc/hexanes, 
to give (−)-3.33 (5.5 mg, 0.02 mmol, 35%) as a colorless oil (dr, 6:1). The major isomer: 
[α]D20 −14.5 (c 0.55, CHCl3); IR (thin film) 3423 (br), 3284 (br), 2925, 2851, 1753 cm-1; 
1H-NMR (500 MHz, CDCl3) δ 6.09 (s, 1H), 3.66-3.74 (m,1H), 3.42-3.44 (m, 1H), 2.73-
2,76 (m, 1H), 1.60-1.66 (m, 4H), 1.40-1.48 (m, 2H), 1.25-1.35 (m, 15H), 0.90-0.86 (m, 
6H); 13C-NMR (125 MHz, CDCl3) δ 171.1, 72.0, 57.5, 54.1, 42.2, 38.8, 31.9, 31.8, 29.9, 
29.5, 28.7, 27.5, 25.3, 22.8, 14.32, 14.25; LRMS (ESI+) Calcd for C16H32NO2 (M+H) 
270, found 270.  
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C4H9
N
O
C6H13
O
i-Pr NHCHO
O
(!)-3.34
C4H9
HN
O
C6H13
HO
(!)-3.33
BnO
 
(S)-((S)-1-((2S,3S)-1-(benzyloxy)-3-hexyl-4-oxoazetidin-2-yl)hexan-2-yl) 2-
methan amido-3-methylbutanoate, (−)-3.34. To a solution of alcohol (−)-3.33 (129.5 
mg, 0.34 mmol) in CH2Cl2 (2.0 mL) at room temperature was added DMAP (125.1 mg, 
1.02 mmol), EDCI (151.9 mg. 0.79 mmol) and N-formyl-L-valine (98.4 mg, 0.67 mmol). 
The reaction mixture was stirred for overnight. Then, the reaction was quenched with 
sat. aq. NH4Cl (3.0 mL), and the mixture was extracted with Et2O (3 X 20 mL). The 
dried (MgSO4) extract was concentrated in vacuo and purified by chromatography over 
silica gel, eluting carefully with 20% EtOAc/hexanes, to give ester (−)-3.34 (137.8 mg, 
0.27 mmol, 80%) as a colorless oil: [α]D20 −24.6 (c 1.22, CHCl3); IR (thin film) 3313 
(br), 3032, 2931, 2860, 1764, 1738, 1685 cm-1; 1H-NMR (500 MHz, CDCl3) δ 8.14 (s, 
1H), 7.25-7.34 (m, 5H), 6.06-6.14 (br, 1H), 4.86 (d, J = 11.5 Hz, 1H), 4.83 (d, J = 11.5 
Hz, 1H), 4.74-4.80 (m, 1H), 4.47 (ddd, J = 4.5, 9.5, 11.5, 1H), 2.98-3.04 (m, 1H), 2.34 
(ddd, J = 2, 7.5, 13.5, 1H), 1.79-1.86 (m, 1H), 1.30-1.50 (m, 6H), 1.08-1.25 (m, 17H), 
0.74-0.80 (m, 9H); LRMS (ESI+) Calcd for C29H47N2O5 (M+H) 503, found 503. 
 
C4H9
HN
O
C6H13
O
i-Pr NHCHO
O
(!)-3.24a
C4H9
N
O
C6H13
O
i-Pr NHCHO
O
(!)-3.34
BnO
  
(S)-((S)-1-((2S,3S)-3-hexyl-4-oxoazetidin-2-yl)hexan-2-yl) 2-methanamido-3-
methyl butanoate, (−)-3.24a. To a solution of ester (−)-3.34 (35.2 mg, 0.07 mmol) in 
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THF (2.8 mL) was added H2O (90 µL). Next, this solution was treated with freeze- 
pump-thawn process at −78 oC (twice) before warmed to 0 oC. A freshly prepared 
solution of SmI2 (0.07 M in THF) was added to the reaction solution dropwise till a 
persistent deep-blue color formed. After 5 minutes, the reaction was quenched with sat. 
aq. NaHCO3 (2.0 mL), and the mixture was extracted with EtOAc (3 X 20 mL). The 
dried (MgSO4) extract was concentrated in vacuo and purified by chromatography over 
silica gel, eluting carefully with 50% EtOAc/hexanes, to give β-lactam (−)-3.24a (18.2 
mg, 0.05 mmol, 66%) as a colorless oil: [α]D20 −10.7 (c 0.56, CHCl3); IR (thin film) 
3284 (br), 2925, 2851, 1753 cm-1; 1H-NMR (500 MHz, CDCl3) δ 8.22 (s, 1H), 6.82 (br, 
1H), 6.33 (br, 1H), 5.03-4.97 (m, 1H), 4.60 (dd, J = 5.0, 9.0, 1H), 3.32 (dt, , J = 5.5, 2.5, 
1H), 2.70-2.78 (m, 1H), 2.25-2.19 (m, 1H), 1.94-1.89 (m, 2H), 1.70-1.76 (m, 3H), 1.51-
1.67 (m, 4H), 1.23-1.33 (m, 17H), 0.85-0.09 (m, 6H); LRMS (ESI+) Calcd for 
C22H41N2O4 (M+H) 397, found 397. 
 
An enantiomeric route was also developed for enatiomers of compound 3.31-
3.34. (–)-3.23a [α]D20 –36.8 (c 1.1, CHCl3); (–)-3.31 [α]D20 –28.9 (c 0.97, CHCl3); (–)-
3.33 [α]D20 –14.5 (c 0.55, CHCl3); (–)-3.34 [α]D20 –24.6 (c 1.22, CHCl3); (–)-3.24 [α]D20 
–10.7 (c 0.56, CHCl3). 
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OTBS
O
C10H21 C6H13 SPy
OTBS TBSO
C10H21
O
O
C6H133.38 3.28 (!)-3.23b
+
 
(3R,4S)-4-((R)-2-(tert-butyldimethylsilyloxy)tridecyl)-3-hexyloxetan-2-one (-) 
-3.23b. To a solution of aldehyde 3.38 (342.4 mg, 1.0 mmol) and ketene acetal 3.28 
(527.0 mg, 1.5 mmol) in CH2Cl2 (5.0 mL) at −78 °C was added a solution of SnCl4 (1.5 
mL, 1.5 mmol, 1M in CH2Cl2) slowly over 1 h using syringe pump. After 30 min, the 
reaction was quenched with pH 7 buffer solution (2.5 mL) and warmed up to ambient 
temperature.  The resulted mixture was filtrated through a plug of celite and the organic 
layer was separated. The dried (MgSO4) extract was concentrated in vacuo and purified 
by chromatography over silica gel, eluting carefully with 1% EtOAc/hexanes, to give β-
lactone (–)-3.23b (280 mg, 0.60 mmol, 60%) as a colorless oil (dr, 14:1). The major 
isomer: 1H-NMR (500 MHz, CDCl3) δ 4.76 (ddd, J = 3.0, 6.5, 9.0 Hz, 1H), 3.84-3.90 
(m, 1H), 3.64 (dt, J = 6.5, 8.5 Hz, 1H), 1.74-1.86 (m, 2H), 1.46-1.72 (m, 4H), 1.30 (s, 
26H), 0.86-0.90 (m, 15H), 0.08 (s, 6H); LRMS (ESI+) Calcd for C28H56O3SiLi (M+Li) 
475, found 475.  
 
OH
C10H21
O
O
C6H13
TBSO
C10H21
O
O
C6H13
(!)-3.23b (!)-3.23b'  
(3R,4S)-3-hexyl-4-((R)-2-hydroxytridecyl)oxetan-2-one (–)-3.32bʹ′ : To a 
solution of β-lactone (–)-3.23b (16 mg, 0.034 mmol) in CH3CN at 0 °C was added HF 
(40 µL, 48% w/w in H2O). After 20 min, the reaction was warmed up to room 
temperature  After 6 h, the reaction was carefully quenched with sat. aq. NaHCO3 (1.0 
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mL). After 5 min, the mixture was extracted with Et2O (3 X 20 mL). The dried (MgSO4) 
extract was concentrated in vacuo and purified by chromatography over silica gel, 
eluting with 15% EtOAc/hexanes, to give alcohol (–)-3.32bʹ′  (10 mg, 0.028 mmol, 83%) 
as a colorless oil: [α]D20 –18.8 (c 0.85, CHCl3); IR (thin film) 3425 (br), 2925, 1821 cm-
1; 1H-NMR (500 MHz, CDCl3) δ 4.91 (ddd, J = 2.5, 6.5, 10.5 Hz, 1H), 3.82-3.84 (m, 
1H), 3.67 (dt, J = 6.5, 9.0 Hz, 1H), 1.70-1.88 (m, 2H), 1.50-1.64 (m, 2H), 1.22-1.36 (m, 
28H), 0.86-0.92 (m, 6H); 13C-NMR (125 MHz, CDCl3) δ 172.4, 72.9, 68.3, 52.8, 38.4, 
37.7, 32.2, 31.7, 39.9, 29.88, 29.87, 29.81, 29.7, 29.6, 29.3, 27.7, 25.7, 24.4, 22.9, 22.8, 
14.4, 14.3; LRMS (ESI+) Calcd for C22H42O3Li (M+Li) 361, found 361. 
 
TBSO
C10H21
O
O
C6H13
TBSO
C10H21
N
O
C6H13
BnO
(+)-3.35(!)-3.23b  
(3R,4R)-1-(benzyloxy)-4-((R)-2-(tert-butyldimethylsilyloxy)tridecyl)-3 hexyl 
azetidin-2-one, (+)-3.35. To a flask with β-lactone (−)-3.32b’  (103 mg, 0.22 mmol) was 
added BnONH2 (56 mg, 0.44 mmol).  The reaction was warmed to 50 °C for 16 h.  Next, 
the reaction was diluted with Et2O (2.2 mL) and cooled to 0 °C.  To this solution was 
added PPh3 (115 mg, 0.44 mmol) and DIAD (89 mg, 85 µL, 0.44 mmol).  After 30 min, 
the reaction was warmed up to room temperature and concentrated in vacuo and purified 
by chromatography over silica gel, eluting with 4% EtOAc/hexanes, to give β-lactam 
(+)-3.35 (70 mg, 0.12 mmol, 56%) as a colorless oil: [α]D20 +24.0 (c 1.00, CHCl3); IR 
(thin film) 2925, 2854, 1774, 1465, 1382, 1066 cm-1; 1H-NMR (500 MHz, CDCl3) δ 
7.37-7.43 (m, 5H), 4.97 (d, J = 11.0 Hz, 1H), 4.93 (d, J = 11.0 Hz, 1H), 3.69-3.74 (m, 
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1H), 3.28 (ddd, J = 2.0, 5.0, 9.0 Hz, 1H), 2.53 (dt, J = 1.5, 6.5 Hz, 1H), 1.85 (ddd, J = 
5.0, 6.0, 9.0 Hz, 1H), 1.53-1.64 (m, 2H), 1.48 (ddd, J = 5.0, 9.0, 13.5 Hz, 1H), 1.22-1.38 
(m, 28H), 0.86-0.92 (m, 15H), 0.04 (s, 3H), 0.03 (s, 3H); 13C-NMR (125 MHz, CDCl3) δ 
166.9, 135.7, 129.7, 129.2, 128.8, 78.2, 70.0, 61.5, 52.4, 39.3, 37.1, 32.2, 31.8, 30.0, 
29.9, 29.89, 29.86 (2C), 29.6, 29.5, 28.6, 27.1, 26.1, 25.4, 22.9, 22.8, 18.3, 14. 4, 14.3, -
4.2, -4.1; LRMS (ESI+) Calcd for C35H64NO3Si (M+H) 574, found 574. 
 
TBSO
C10H21
N
O
C6H13
BnO
OH
C10H21
N
O
C6H13
BnO
(+)-3.35 (+)-3.36  
(3R,4R)-1-(benzyloxy)-3-hexyl-4-((R)-2-hydroxytridecyl)azetidin-2-one, (+)-
3.36. To a solution of β-lactam (+)-3.35 (46 mg, 0.08 mmol) in CH3CN at 0°C was 
added HF (96 µL, 48% w/w in H2O). After 20 min, the reaction was warmed up to room 
temperature  After 6 h, the reaction was carefully quenched with sat. aq. NaHCO3 (1.0 
mL), and the mixture was extracted with Et2O (3 X 20 mL). The dried (MgSO4) extract 
was concentrated in vacuo and purified by chromatography over silica gel, eluting with 
20% EtOAc/hexanes, to give alcohol (+)-3.36 (25 mg, 0.054 mmol, 68%) as a colorless 
oil: [α]D20 +26.5 (c 1.13, CHCl3); IR (thin film) 3452 (br), 2923, 2853, 1758, 1456 cm-1; 
1H-NMR (500 MHz, CDCl3) δ 7.36-7.44 (m, 5H), 4.99 (d, J = 11.0 Hz, 1H), 4.95 (d, J = 
11.0 Hz, 1H), 3.54-3.59 (m, 1H), 3.36 (ddd, J = 2.0, 5.5, 9.5 Hz, 1H), 2.52 (ddd, J = 2.0, 
6.5, 10.5 Hz, 1H), 1.77 (br, 1H), 1.64-1.76 (m, 2H), 1.45-1.67 (m, 2H), 1.23-1.40 (m, 
28H), 0.86-0.92 (m, 6H); 13C-NMR (125 MHz, CDCl3) δ 166.7, 135.4, 129.8, 129.3, 
128.9, 78.4, 69.6, 62.8, 51.8, 40.1, 38.2, 32.2, 31.8, 29.9, 29.88, 29.84 (2C), 29.81, 29.6, 
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29.4, 28.6, 27.4, 25.7, 22.9, 22.8, 14.4, 14.3; LRMS (ESI+) Calcd for C29H49NO3Li 
(M+Li) 466, found 466. 
 
OH
C10H21
N
O
C6H13
BnO
(+)-3.36
O
C10H21
N
O
C6H13
NHCHO
O
BnO
(+)-3.37  
(R)-1-((2R,3R)-1-(benzyloxy)-3-hexyl-4-oxoazetidin-2-yl)tridecan-2-yl 2-
methanamidoethanoate, (+)-3.37. To a solution of alcohol (+)-3.36 (23 mg, 0.05 
mmol) in CH2Cl2 (1.0 mL) at room temperature was added DMAP (12.2 mg, 0.1 mmol), 
EDCI (19 mg, 0.1 mmol) and N-formylglycine (10.3 mg, 0.1 mmol).  After 1.5 h, the 
reaction was quenched with sat. aq. NH4Cl (2.5 mL), and the mixture was extracted with 
Et2O (3 X 20 mL). The dried (MgSO4) extract was concentrated in vacuo and purified by 
chromatography over silica gel, eluting with 40% EtOAc/hexanes, to give ester (+)-3.37 
(20 mg, 0.037 mmol, 61%) as a colorless oil: [α]D20 +15.4 (c 1.00, CHCl3); IR (thin 
film) 3322 (br), 2933, 2353, 1754, 1460 cm-1; 1H-NMR (500 MHz, CDCl3) δ 8.23 (s, 
1H), 7.39-7.43 (m, 5H), 6.05 (br, 1H), 4.91-4.98 (m, 3H), 4.08 (dd, J = 5.5, 19.0 Hz, 
1H), 3.94 (dd, J = 5.5, 19.0 Hz, 1H), 3.12-3.16 (m, 1H), 2.45 (dt, J = 1.5, 7.5 Hz, 1H), 
1.92 (ddd, J = 5.0, 8.5, 14.0 Hz, 1H), 1.61 (ddd, J = 4.0, 8.0, 14.5 Hz, 1H), 1.45-1.53 (m, 
2H), 1.20-1.38 (m, 28H), 0.89 (t, J = 7.0 Hz, 6H); 13C-NMR (125 MHz, CDCl3) δ 169.3, 
166.5, 161.1, 135.4, 129.9. 129.4, 128.9, 78.3, 73.5, 61.5, 52.1, 40.2, 36.9, 34.5, 32.1, 
31.8, 29.9, 29.86, 29.84, 29.8, 29.7, 29.6, 29.4, 28.5, 27.3, 25.2, 22.9, 22.8, 14.4, 14.3; 
LRMS (ESI+) Calcd for C32H53N2O5 (M+H) 545, found 545. 
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O
C10H21
N
O
C6H13
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O
BnO
O
C10H21
HN
O
C6H13
NHCHO
O
(+)-3.37 (+)-3.24  
(R)-1-((2R,3R)-3-hexyl-4-oxoazetidin-2-yl) tridecan-2-yl)-2-methan amido 
ethanoate, (+)-3.24. To a solution of ester (+)-3.37 (17 mg, 0.031 mmol) in THF (1.2 
mL) was added H2O (40 µL).  Next, this solution was treated with freeze-pump-thaw 
process at –78 °C (twice) before warmed to 0 °C. A freshly prepared solution of SmI2 
(0.06 M in THF) was added to the above solution dropwise till a persistent deep-blue 
color formed. After 10 min, the reaction was quenched with sat. aq. NaHCO3 (2.5 mL), 
and the mixture was extracted with EtOAc (3 X 20 mL). The dried (MgSO4) extract was 
concentrated in vacuo and purified by chromatography over silica gel, eluting with 80% 
EtOAc/hexanes, to give β-lactam (+)-3.38 (10.5 mg, 0.024 mmol, 77%) as a colorless 
oil: [α]D20 +8.3 (c 0.24, CHCl3); IR (thin film) 3422 (br), 2926, 2353, 1743, 1664, 1465 
cm-1; 1H-NMR (500 MHz, CDCl3) δ 8.28 (s, 1H), 6.44 (s, 1H), 6.30 (br, 1H), 5.02-5.05 
(m, 1H), 4.06 (dd, J = 5.5, 19.5 Hz, 1H), 4.03 (dd, J = 5.5, 19.5 Hz, 1H), 3.37 (dt, J = 
2.0, 5.5 Hz, 1H), 2.75 (dt, J = 1.5, 8.0 Hz, 1H), 1.88-1.96 (m, 2H), 1.57-1.78 (m, 2H), 
1.22-1.36 (m, 28H), 0.90 (t, J = 6.5 Hz, 6H); 13C-NMR (125 MHz, CDCl3) δ 172.0, 
169.6, 169.1, 75.3, 57.6, 53.4, 40.6, 39.8, 35.0, 32.2, 31.8, 29.87, 29.86, 29.8, 29.7, 
29.62, 29.59, 29.5, 28.5, 27.4, 25.3, 22.9, 22.8, 14.4, 14.3; LRMS (ESI+) Calcd for 
C25H47N2O4 (M+H) 439, found 439. 
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An enantiomeric route was also developed for enatiomers of compound 3.35-
3.38. (–)-3.35 [α]D20 –26.0 (c 1.0, CHCl3); (–)-3.36 [α]D20 –27.5 (c 1.7, CHCl3); (–)-3.37 
[α]D20 –21.6 (c 1.0, CHCl3); (–)-3.24 [α]D20 –8.4 (c 0.7, CHCl3). 
 
Chapter IV - Total Synthesis of Spongiolactone  
 
O
O
MeO O
CO2tBu
4.45 4.47  
Vinylogous ester 4.47. To a solution of 1,3 cyclohexadione (15 g, 133.6 mmol) 
in 300 mL of dry DMF was added K2CO3 (22.2 g, 160.3 mmol) and the suspension was 
stirred at room temperature (21 oC) for 10 min. The resulting orange suspension was 
added tert-butyl acrylate (23.3 mL, 160.3 mmol) and stirred at 100oC for 6 h to obtain 
brown suspension. Then, the reaction was cooled to ambient temperature (21 oC) for 1 h. 
Another portion of K2CO3 (22.2 g, 160.3 mmol) was added followed by dimethyl sulfate 
(15.2 mL, 160.3 mmol) and the reaction mixture was stirred at room temperature (21 
oC). After 1 h, the light brown suspension was quenched with pH 7 buffer solution (250 
mL). The organic layer was separated by separatory funnel and the aqueous layer was 
extracted with EtOAc (100 mL x 3). The combined organic layers were washed with 
water (100 mL) and brine (100 mL x 2), dried over anhydrous MgSO4, and concentrated 
in vacuo. Purification of the crude product by flash chromatography on SiO2 eluting with 
hexanes:EtOAc:Et3N (11:8:1) gave 30.5 g (93%) of vinylogous ester 4.47 as a yellow 
oil: Rf = 0.42 (1:1-EtOAc:hexanes); IR (thin film) 3271, 2978, 1729, 1649, 1616, 1371, 
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1163, 1089 cm-1; 1H-NMR (500 MHz, CDCl3) δ 3.79 (s, 3H), 2.55 (t, J = 6.0 Hz, 2H), 
2.53 (t, J = 9.5 Hz, 2H), 2.31 (t, J = 6.0 Hz, 2H), 2.22 (t, J = 8.5 Hz, 2H) 1.94-1.99 (m, 
2H), 1.42 (s, 9H); 13C-NMR (125 MHz, CDCl3) δ 197.7, 172.9, 172.5, 117.6, 79.5, 55.1, 
36.2, 34.1, 28.0(3), 24.7, 20.7, 17.7; HRMS (ESI+) Calcd for C14H22O4Li [M+Li]: 
261.1678. Found: 261.1683. 
 
MeO O
CO2tBu
MeO O
CO2tBu
OBn
4.47 (±)-4.48  
α-Substituted ketone (±)-4.48. To a solution of vinylogous ester 4.47 (17 g, 
66.8 mmol) in 200 mL of toluene was cooled to −78 oC. Lithium hexamethyldisilazide 
(100 mL, 100.3 mmol, 1.0 M in hexanes) was slowly added drop wise. After addition, 
the reaction mixture was immediately moved from −78 oC bath to 0 oC bath and stirred 
for 1 h. Then, the orange solution was cooled to −78 oC again and benzyl chloromethyl 
ether (25.7 mL, 187.2 mmol) was slowly added by syringe pump over an hour period. 
The reaction was stirred at −78 oC for 4 h and allowed to slowly warm up to ambient 
temperature (21 oC) for 8 h. The turbid yellow solution was quenched with pH 7 buffer 
solution (250 mL). The organic layer was separated by separatory funnel and the 
aqueous layer was extracted with EtOAc (100 mL x 3). The combined organic layers 
were washed with brine (200 mL), dried over anhydrous MgSO4, and concentrated in 
vacuo. Purification of the crude product by flash chromatography on SiO2 eluting with 
hexanes:EtOAc:Et3N (15:4:1) gave 21.3 g (85%) of α-substituted ketone (±)-4.48 as a 
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yellow oil: Rf = 0.54 (1:1-EtOAc:hexanes); IR (thin film) 3061, 3031, 2931, 1723, 1613, 
1154 cm-1; 1H-NMR (500 MHz, CDCl3) δ 7.33-7.31 (m, 4H), 4.52 (dd, J = 11.5, 19.75 
Hz, 2H), 3.88 (dd, J = 4.0, 9.5 Hz, 1H), 3.79 (s, 3H), 3.56 (dd, J = 8.0, 9.5 Hz, 1H), 2.68 
(t, J = 5.0 Hz, 1H), 2.65 (t, J = 5.0 Hz, 1H), 2.56-2.47 (m, 4H), 2.29-2.20 (m, 1H), 2.22 
(t, J = 8.0 Hz, 2H), 1.89-1.81 (m, 1H), 1.42 (s, 9H); 13C-NMR (125 MHz, CDCl3) δ 
197.2, 173.0, 172.2, 138.4, 128.3 (2), 127.6 (2), 127.5, 117.5, 79.7, 73.2, 69.8, 55.1, 
45.0, 34.3, 28.1(3), 24.1, 23.8, 18.0; HRMS (ESI+) Calcd for C22H31O5 [M+H]: 
375.2171. Found: 375.2176.  
 
MeO O
CO2tBu
OBn
 (±)-4.48
O
CO2tBu
OBn
 (±)-4.49  
α ,β-Unsaturated ketone (±)-4.49. To a solution of α-substituted ketone (±)-
4.48 (7 g, 18.7 mmol) in 200 mL of dry MeOH was added a white powder of 
CeCl3.7H2O (13.5 g, 37.4 mmol), which was dried at 130 oC for 16h to remove one 
molecule of H2O and stirred at room temperature (21 oC) for 10 min. The resulted 
yellow solution was cooled to −78 oC and NaBH4 (2.83 g, 74.8 mmol) was slowly added. 
The reaction was stirred at −78 oC for 4 h and allowed to slowly warm up to ambient 
temperature (21 oC) for 8 h to obtain the white suspension. Then, the reaction mixture 
was treated with 2N HCl (200 mL) and stirred at room temperature (21 oC) until the 
white suspension turned to a colorless solution. The reaction was extracted with Et2O 
(100 mL x 3). The combined organic layers were washed with brine (100 mL), dried 
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over anhydrous MgSO4, and concentrated in vacuo. Purification of the crude product by 
flash chromatography on SiO2 eluting with hexanes:EtOAc (9:1) gave 5.2 g (81%) of 
α,β-unsaturated ketone (±)-4.49 as a colorless oil: Rf = 0.21 (1:9-EtOAc:hexanes); IR 
(thin film) 3091, 3064, 3031, 2978, 1723, 1675, 1359, 1146 cm-1; 1H-NMR (500 MHz, 
CDCl3) δ 7.38-7.29 (m, 5H), 6.70 (dd, J = 1.5, 2.3 Hz, 1H), 4.53 (dd, J = 12.0, 14.0 Hz, 
2H), 3.44 (ddd, J = 7.0, 6.5, 13.5 Hz, 2H), 2.75-2.69 (m, 2H), 2.54 (t, J = 5.0 Hz, 1H), 
2.51 (t, J = 5.0 Hz, 1H), 2.49-2.45 (m, 1H), 2.39-2.32 (m, 2H), 2.11-2.06 (m, 1H), 1.77-
1.69 (m, 1H), 1.41 (s, 9H); 13C-NMR (125 MHz, CDCl3) δ 199.2, 172.5, 147.0, 138.6, 
138.1, 128.6(2), 127.9, 127.8(2), 80.3, 73.4, 72.9, 37.4, 37.2, 34.5, 28.3(3), 26.2, 25.6; 
HRMS (ESI+) C21H28O4Li [M+Li]: 351.2148. Found: 351.2123. 
 
OtBu
OO
BnO
O
CO2tBu
OBn
 (±)-4.49
 (±)-4.87
 
Alkene (±)-4.87. To slurry of copper (I) bromide-dimethyl sulfide complex (0.75 
g, 2.9 mmol) in 30 mL of dry THF was added HMPA (6.7 mL, 38.3 mmol) and the 
mixture was stirred at room temperature (21 oC) for 5 min. The resulted green solution 
was cooled to −78 oC and 2-methyl-1-propenyl magnesium bromide (115.0 mL, 57.5 
mmol, 0.5 M in THF) was added resulting in a yellow slurry. After stirring for 10 min, a 
solution of α,β-unsaturated ketone (±)-4.49 (6.6 g, 19.2 mmol) and trimethylsilyl 
chloride (6.0 mL, 47.9 mmol) in 10 mL of dry THF was added via syringe pump over 1h 
period. The reaction was stirred at −78 oC for 4 h and allowed to slowly warm up to 
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ambient temperature (21 oC) for 8 h to obtain the black suspension. Then, the reaction 
mixture was quenched with a saturated NH4Cl solution (100 mL) and filtered through a 
Celite with Et2O. The organic layer was separated by separatory funnel and the aqueous 
layer was extracted with Et2O (100 mL x 3). The combined organic layers were washed 
with brine (100 mL), dried over anhydrous MgSO4, and concentrated in vacuo. 
Purification of the crude product by flash chromatography on SiO2 eluting with 
hexanes:EtOAc (19:1) gave 10.8 g (88%; dr, 10:1) of alkene (±)-4.87 as a yellow oil: Rf 
= 0.51 (1:9-EtOAc:hexanes); IR (thin film) 3091, 3067, 3028, 2978, 1732, 1711, 1453, 
1365 cm-1; 1H-NMR (500 MHz, CDCl3) δ 7.35-7.28 (m, 5H), 4.88 (dt, J = 1.5, 10 Hz, 
1H), 4.43 (dd, J = 12.0, 17.0 Hz, 2H), 3.48 (dd, J = 3.0, 9.0 Hz, 1H), 3.23 (dd, J = 7.0, 
9.0 Hz, 1H), 2.42-2.38 (m, 2H), 2.36-2.25 (m, 3H), 2.19 (ddd, J = 2.5, 9.0, 12.0 Hz, 1H), 
2.15-2.08 (m, 1H), 1.86-1.77 (m, 1H), 1.73 (d, J = 1.5 Hz, 3H), 1.68-1.59 (m, 3H), 1.54 
(d, J = 1.5 Hz, 3H), 1.42 (s, 9H); 13C-NMR (125 MHz, CDCl3) δ 211.8, 173.2, 138.5, 
134.2, 128.3(2), 127.5, 127.4(2), 126.7, 79.8, 73.2, 72.6, 53.6, 45.9, 42.6, 41.6, 33.6, 
30.5, 28.2(3), 25.8, 22.1, 18.6; HRMS (ESI+) C25H37O4 [M+H]: 401.2692. Found: 
401.2683. 
 
OH
OO
BnO
(±)-4.56
OtBu
OOTMS
BnO
(±)-4.55  
Alkenyl acid (±)-4.56. Followed the cuprate addition of α,β-unsaturated ketone 
4.49 as explained above, the crude product ((±)-4.55) was directly employed to the next 
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step after work up without purification over SiO2. The crude trimethyl silyl enol ether 
(±)-4.55 (104 mg, 0.22 mmol) was dissolved in 10 mL of dry CH3CN and cooled to 0 
oC. p-toluenesulfonic acid (83 mg, 0.438 mmol) was slowly added. The reaction was 
allowed to warm up to ambient temperature (21 oC) and stirred for 6 h to obtain the 
light-brown solution. The reaction mixture was concentrated in vacuo to afford the 
brown oil. Purification of the crude product by flash chromatography on SiO2 eluting 
with hexanes:EtOAc (7:3) gave 70.2 mg (93%) of alkene (±)-4.56 as a colorless oil: Rf = 
0.50 (1:1-EtOAc:hexanes); IR (thin film) 3339, 3031, 2978, 1732, 1711, 1448, 1362 cm-
1; 1H-NMR (500 MHz, CDCl3) δ 7.35-7.28 (m, 5H), 4.88 (dt, J = 1.0, 10 Hz, 1H), 4.43 
(dd, J = 12.0, 15.5 Hz, 2H), 3.48 (dd, J = 3.0, 9.0 Hz, 1H), 3.23 (dd, J = 6.5, 9.0 Hz, 1H), 
2.49-2.39 (m, 3H), 2.34-2.24 (m, 3H), 2.23-2.18 (ddd, J = 2.5, 9.25, 13.6 Hz, 1H), 1.87-
1.76 (m, 2H), 1.73 (d, J = 1.0 Hz, 3H), 1.71-1.61 (m, 2H), 1.54 (d, J = 1.0 Hz, 3H), No 
O-H proton; 13C-NMR (125 MHz, CDCl3) δ 212.1, 179.1, 138.5, 134.6, 128.5(2), 127.7, 
127.6(2), 126.5, 73.3, 72.6, 53.6, 45.9, 42.7, 41.6, 32.1, 30.5, 25.9, 21.8, 18.7; HRMS 
(ESI+) C21H28O4Li [M+Li]: 351.2148. Found: 351.2143. 
 
OtBu
OO
BnO
OH
OO
BnO
 (±)-4.87  (±)-4.56  
Alkenyl acid (±)-4.56. To a solution of alkene (±)-4.87 (3 g, 7.5 mmol) in 100 
mL of dry CH2Cl2 was cooled to 0 oC. Trifluoroacetic acid (16 mL, 150.0 mmol) was 
slowly added dropwise and the reaction was allowed to slowly warm up to ambient 
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temperature (21 oC) and stirred for 10 h to obtain a brown solution. The reaction mixture 
was concentrated in vacuo to afford black oil. Purification of the crude product by flash 
chromatography on SiO2 eluting with hexanes:EtOAc (7:3) gave 2.4 g (93%) of alkene 
(±)-4.56 as a brown oil: Rf = 0.50 (1:1-EtOAc:hexanes); IR (thin film), 1H-NMR (500 
MHz, CDCl3) and 13C-NMR (125 MHz, CDCl3) were identical to previous explained.  
 
OH
OO
BnO (±)-4.56
OH
OO
BnO
O
(±)-4.51  
Adehyde acid (±)-4.51. To a solution of acid (±)-4.56 (2.0 g, 5.8 mmol) in 
CH2Cl2 (100 mL) and dry MeOH (1.0 mL) was cooled at −78 oC and the ozone was 
bubbled through the mixture for several minutes until the blue color persisted. The 
remaining ozone was removed by bubbling nitrogen through the solution for 10 min. 
Excess dimethyl sulfide (4.5 mL, 58.1 mmol) was added. The mixture was allowed 
slowly warm up to ambient temperature (21 oC) and stirred for 12 h. The solvent was 
evaporated under reduced pressure and the resulting oil was purified by flash 
chromatography on SiO2 eluting with hexanes/EtOAc (1:1) to afford aldehyde acid (±)-
4.51 (1.5 g, 81%) as a colorless oil: Rf = 0.32 (1:1-EtOAc:hexanes); IR (thin film) 3410, 
3037, 2937, 2860, 2724, 1776, 1711, 1456, 1095 cm-1; 1H-NMR (500 MHz, CDCl3) δ 
9.63 (d, J = 4.0 Hz, 1H), 7.36-7.27 (m, 5H), 4.43 (dd, J = 12.0, 22 Hz, 2H), 3.45 (dd, J = 
4.5, 9.5 Hz, 1H), 3.31 (dd, J = 7.0, 9.5 Hz, 1H), 2.73 (ddd, J = 2.5, 9.3, 11.5 Hz, 1H), 
2.54-2.33 (m, 7H), 2.14 (ddd, J = 4.0, 13.1, 8.5 Hz, 1H), 1.91-1.84 (m, 1H), 1.65-1.55 
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(m, 1H), No O-H proton; 13C-NMR (125 MHz, CDCl3) δ 209.7, 200.7, 179.0, 137.7, 
128.6(2), 127.9, 127.8(2), 73.4, 72.5, 59.1, 46.7, 40.6, 38.7, 31.5, 29.2, 22.1; HRMS 
(ESI–) Calcd for C18H21O5 [M-H]: 317.1389. Found: 317.1375. 
 
BnO
O
O
H
H
OH
OO
BnO
O
O
(±)-4.51 (±)-4.60  
Fused tricyclic β-lactone (±)-4.60. To a solution of Mukaiyama’s reagent (1.48 
g, 4.2 mmol) in 30 mL of CH2Cl2 was added triethylamine (1.0 mL, 7.1 mmol) and 
stirred at room temperature (22 oC). The resulting yellow orange solution was added a 
solution of aldehyde acid (±)-4.51 (450 mg, 1.4 mmol) in 10 mL of CH2Cl2 via a syringe 
pump over 1 h period. After addition, the reaction mixture was stirred at room 
temperature (22 oC) for 24 h yielding a dark red solution. The reaction mixture was 
concentrated in vacuo to afford a red-brown oil. Purification of the crude product by 
flash chromatography on SiO2 eluting with hexanes:EtOAc (1:1) gave 0.33 g (78%; dr, 
11:1) of β-lactone (±)-4.60 as a colorless crystal: Rf = 0.66 (1:1-EtOAc/hexanes); IR 
(thin film) 3030, 2928, 2863, 1824, 1717, 1453, 1119 cm-1; 1H-NMR (500 MHz, CDCl3) 
δ 7.37-7.28 (m, 5H), 4.98 (t, J= 3.5 Hz, 1H), 4.53 (dd, J = 12.0, 15.5 Hz, 2H), 3.90 (dd, J 
= 3.5, 8.0 Hz, 1H), 3.63-3.51 (ddd, J = 4.5, 9.5, 43.3 Hz, 2H), 2.82-2.76 (m, J = 5.5, 12.0 
Hz, 1H), 2.45-2.43 (m, 2H), 2.37-2.29 (m, 1H), 2.20-2.14 (m, 2H), 1.89-1.82 (ddd, J = 
8.0, 9.0, 17.0 Hz, 1H), 1.78-1.67 (m, 2H); 13C-NMR (125 MHz, CDCl3) δ 209.2, 170.8, 
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138.1, 128.6(2), 127.9, 127.7(2), 76.1, 73.4, 71.9, 54.5, 51.9, 50.2, 40.6, 37.0, 30.5, 24.8; 
HRMS (ESI+) Calcd for C18H21O4 [M+H]: 301.1440. Found: 301.1435.  
 
 (±)-4.51
OHO
O
CH2Cl2, 23 !C, 24h
N
nPr
Br
OTf
 (S)-HBTM (1 equiv)
 i-Pr2NEt (4 equiv)
(3 equiv)O
OBn OBn
O
H
O
O H
H
H
(+)-4.52
OBn
O
H
O
O H
H
H
4.60
 
Fused tricyclic β-lactone 4.52. To a solution of Mukaiyama’s reagent (1.50 g, 
4.3 mmol) and (S)-HBTM11 (0.76 g, 1.5 mmol) in 30 mL of CH2Cl2 was added N,N-
diisopropylethylamine (1.0 mL, 5.7 mmol) and stirred at room temperature (22 oC). The 
resulting yellow solution was added a solution of aldehyde acid (±)-4.51 (450 mg, 1.4 
mmol) in 10 mL of CH2Cl2 via a syringe pump over 1 h period. After addition, the 
reaction mixture was stirred at room temperature (22 oC) for 24 h yielding a dark red 
solution. The reaction mixture was concentrated in vacuo to afford the red-brown oil. 
Purification of the crude product by flash chromatography on SiO2 eluting with 
hexanes:EtOAc (1:1) gave 42%, dr 1:1 of β-lactone products; 4.60 was obtained 92.5 mg 
(22%; 52%ee) as a colorless crystal and (+)-4.52 was obtained 84.3 mg (20%, 96%ee) as 
a colorless oil: Rf = 0.52 (2:3-EtOAc/hexanes); [α]D20 +26.7° (c 0.23, CHCl3); IR (thin 
film) 2939, 2865, 1826, 1711, 1619, 1423 cm-1; 1H-NMR (500 MHz, CDCl3) δ 7.39-7.31 
(m, 5H), 5.19 (d, J= 3.5 Hz, 1H), 4.52 (dd, J = 12.0, 23.0 Hz, 2H), 3.99 (dd, J = 3.5, 8.0 
Hz, 1H), 3.55 (dd, J = 4.5, 9.5 Hz, 1H), 3.45 (dd, J = 4.5, 9.5 Hz, 1H), 3.07-3.02 (m, J = 
                                                
11 Birman, V. B.; Li, X. Org. Lett. 2008, 10, 1115. 
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7.0, 13.0 Hz, 1H), 2.62 (dd, J = 7.0, 12.0 Hz, 1H), 2.51-2.44 (m, 1H), 2.41-2.39 (m, 1H), 
2.37 (dd, J = 6.5, 13.0 Hz, 1H), 2.15-2.11 (ddd, J = 3.0, 5.5, 10.0 Hz, 1H), 2.02-1.95 (dt, 
J = 8.0, 13.3 Hz, 1H) 1.66-1.61 (m, 2H); 13C-NMR (125 MHz, CDCl3) δ 209.9, 169.8, 
137.8, 128.7(2), 128.1, 127.8(2), 79.0, 73.7, 73.2, 54.9, 49.1, 48.2, 37.1, 33.3, 29.9, 28.9; 
HRMS (ESI+) Calcd for C18H21O4 [M+H]: 301.1440. Found: 301.1426. 
 
 
Figure A-7. Chiral HPLC chromatograms of fused tricyclic β-lactone derived from 
NCAL with (±)-HBTM. Using Chiralpak IA column (Daicel Chemical Industries, 
LTD.), 0.46 x 25 cm, 10% isopropanol in hexanes, 0.9 ml/min; (A) crude reaction 
mixture, (B) purified (±)-4.60, (C) purified (±)-4.52. 
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Figure A-8. Chiral HPLC chromatograms of purified 4.52 derived from NCAL process 
with (R)-HBTM (A) and (S)-HBTM (B). Using Chiralpak IA column (Daicel Chemical 
Industries, LTD.), 0.46 x 25 cm, 10% isopropanol in hexanes, 0.9 ml/min. 
 
OH Cl
4.68 4.69  
Allyl chloride 4.69. To a solution of N-chloro succinimide (7.7 g, 57.5 mmol) in 
CH2Cl2 was cooled at 0 oC and dimethyl sulfide (5.0 mL, 66.7 mmol) was slowly added 
into the reaction mixture. The result white suspension was observed. After 5 min, the 
resulted white suspension was added 3,5,5-trimethylcyclohex-2-enol (4.68) (8.0 mL, 
52.3 mmol) and stirred at 0 oC for 1 h to yield a colorless solution. The reaction mixture 
was concentrated in vacuo to remove all volatiles at 25 oC. Then, the crude product was 
dissolved in 100 mL of pentane and cooled at −10 oC for 3 h. The succinimide, which 
was a byproduct in this reaction, was precipitated. The solid byproduct was removed by 
filtration and the filtrate was washed with cold brine (100 mL), dried over anhydrous 
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B 
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MgSO4, and concentrated in vacuo. The 3-chloro-1,5,5-trimethylcyclohex-1-ene (4.69) 
was obtain as the colorless oil (98%); bp 40-45 oC (5 mmHg). Chloride 4.69 was used 
for the next step without purification and note that 4.69 was decomposed over neutral 
SiO2, neutral Al2O3 and heating above 90 oC. IR (thin film) 3043, 2954, 2869, 1658, 
1459, 820, 796 cm-1; 1H-NMR (500 MHz, CDCl3) δ 5.49-4.48 (m, 1H), 4.65-4.60 (m, 
1H), 1.97-1.92 (m, 2H), 1.69 (s, 3H), 1.66-1.65 (m, 2H), 1.01 (s, 3H), 0.89 (s, 3H); 13C-
NMR (125 MHz, CDCl3) δ 137.6, 122.2, 56.9, 45.9, 43.7, 31.9, 30.9, 26.0, 23.8; LRMS 
(APCI+) Calcd for C9H15Cl [M]: 158.0862. Found: 158.  
 
Cl ZnCl.LiCl
4.69 4.70  
Zincate 4.70: Zinc dust12(6.4 g, 118.0 mmol) and anhydrous LiCl (1.0 g, 23.6 
mmol) were weighted into a flame-dried round-bottomed flask. The solid was dried at 
130 oC (heat gun) under high vacuum for 5 min and cooled down to 23 oC for 1 h. This 
process was repeated 3 cycles. The solid mixtures were covered with 10 mL of dry THF 
and stirred vigorously at 23 oC. The suspension of zinc and LiCl was activated by adding 
1,2 dibromoethane (0.3 mL, 3.5 mmol) and stirred vigorously at 23 oC for 10 min, 
followed by addition of TMSCl (0.15 mL, 1.2 mmol). The resulted suspension was 
generously boiled. The mixture was stirred vigorously for another 30 min to cool down 
to 23 oC, and then the reaction was cooled at 0 oC. A solution of 3-chloro-1,5,5-
trimethylcyclohex-1-ene (4.69) in 5 mL of dry THF was slowly added into the reaction 
                                                
12 Commercially available form Aldrich.  
 201 
mixture via a syringe pump over 2 h. The resulting mixture was stirred vigorously under 
nitrogen atmosphere at 0 oC for 6 h. The zinc suspension was allowed to settle and stored 
at 0 oC. The concentration and the yield were determined by iodolysis.13 Iodine (254.0 
mg, 1.0 mmol) was placed into a dry 10 mL round-bottomed flask equipped with a 
magnetic stir-bar and septum under nitrogen. Dry THF (5 mL) was added. The solution 
of allylic zinc 4.70 was slowly added dropwise with syringe until the red color 
disappeared for 1 min. The volume of the allylic zinc reagent was determined: molarities 
of allylic zinc = 1/volumn of allylic zinc reagent. The concentration of the allylic zinc 
reagent 4.70 was 0.10 mol/l; volume = 16.0 mL; yield: 15%. 
 
OBn
O
O
H
HO
OBn
O
O
H
H
HO
(±)-4.60 (±)-4.71  
Homoallylic alcohol (±)-4.71. To a solution of fused tricyclic β-lactone (±)-4.60 
(312.7 mg, 1.0 mmol) in 10 mL of dry THF was cooled at −78 oC and a solution of 
freshly prepared (3,5,5-trimethylcyclohex-2-en-1-yl)zinc(II) chloride 4.70 (9.5 mL, 1.0 
mmol, 0.11 M in THF) was slowly added. The reaction mixture was stirred at −78 oC for 
1 h. After that, the mixture was quenched with pH 7 buffer solution (50mL) at −78 oC, 
allowed to warm up to ambient temperature (22 oC) for 30 min and filtered through a 
Celite with Et2O. The organic layer was separated by separatory funnel and the aqueous 
layer was extracted with Et2O (50 mL x 3). The combined organic layers were washed 
with brine (50 mL), dried over anhydrous MgSO4, and concentrated in vacuo. 
                                                
13 Krasovskiy, A.; Knochel, P. Synthesis 2006, 5, 890. 
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Purification of the crude product by flash chromatography on SiO2 eluting with 
hexanes:EtOAc (5:1) gave 421.3 g (95%, dr 13:1) of homoallylic alcohol (±)-4.71 as a 
colorless oil: Rf = 0.53 (3:7-EtOAc/hexanes); IR (thin film) 3547, 3028, 2949, 1826, 
1453, 1098 cm-1; 1H-NMR (500 MHz, CDCl3) δ 7.37-7.28 (m, 5H), 5.84 (broad s, 1H), 
5.67 (broad s, 1H), 4.94 (t, J= 3.5 Hz, 1H), 4.52 (dd, J = 12.0, 20.0 Hz, 2H), 3.75 (dd, J 
= 3.5, 8.0 Hz, 1H), 3.50 (d, J = 5.0, 2H), 2.54 (dd, J = 7.0, 14.5 Hz, 1H), 2.17(dd, J = 
5.5, 13.5 Hz, 1H), 2.01-1.96 (m, 1H), 1.85-1.67 (m, 6H), 1.50 (dd, J = 3.0, 12.0 Hz, 1H), 
1.26 (m, 1H), 1.20 (m, 1H), 1.12 (s, 3H), 1.03 (t, J = 7.0, 1H), 0.97 (s, 3H), 0.96 (m, 
3H), O−H proton unobservable; 13C-NMR (125 MHz, CDCl3) δ 209.2, 170.8, 138.1, 
128.6(2), 127.9, 127.7(2), 76.1, 73.4, 71.9, 54.5, 51.9, 50.2, 40.6, 37.0, 30.5, 24.8; 
HRMS (ESI+) Calcd for C27H36O4Li [M+Li]: 431.2774. Found: 431.2781. 
 
OBn
O
O
H
H
HO
OH
O
O
H
H
HO
(±)-4.71 (±)-4.73  
Alcohol (±)-4.73. To a solution of homoallylic alcohol (±)-4.71 (373.7 mg, 0.88 
mmol) in 50 mL of EtOH was added Pd(OH)2 on carbon (75.0 mg, 20% Pd). The 
reaction was stirred under nitrogen atmosphere and connected to high vacuum. Air was 
removed under high vacuum and filled with nitrogen gas. This process was repeated 3 
cycles. A hydrogen balloon was attached to the reaction flask, evacuated one more time 
and removed vacuum line. The heterogeneous solution was stirred vigorously at room 
temperature (22 oC) for 24 h. The reaction was filtered through a pad of Celite with 
Et2O, dried over anhydrous MgSO4, and concentrated in vacuo. Purification of the crude 
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product by flash chromatography on SiO2 eluting with hexanes:EtOAc (2:8) gave 240.1 
mg (81%) of alcohol (±)-4.73 as a colorlrss oil: Rf = 0.24 (1:1-EtOAc/hexanes); IR (thin 
film) 3443, 2951, 2925, 2866, 1821, 1637, 1465, 1388 cm-1; 1H-NMR (500 MHz, 
CDCl3) δ 5.06 (t, J = 4.0 Hz, 1H), 3.81 (dd, J = 4.0, 8.0 Hz, 1H), 3.67 (ddd, J = 5.0, 
11.0, 23.8 Hz, 2H), 2.22 (dd, J = 5.5, 13 Hz, 1H), 1.97-1.91(m, J = 5.5, 12.0 Hz, 1H), 
1.75-1.56 (m, 8H), 1.52-1.47 (m, 4H), 1.40-1.35 (m, 3H), 1.19-1.17 (m, 2H), 1.04 (s, 
3H), 0.99 (s, 3H), 0.88 (m, 3H); 13C-NMR (125 MHz, CDCl3) δ 172.0, 76.5, 66.5, 53.9, 
46.1(2), 44.3, 43.9, 42.1, 39.7(2), 38.8, 36.3, 31.6, 30.9, 28.7, 27.7, 24.9, 21.3, 19.2; 
HRMS (ESI+) Calcd for C20H33O4Li [M+Li]: 337.2379. Found: 377.2386. 
 
OH
O
O
H
H
(±)-4.73
HO
O
O
O
H
H
(±)-4.75
HO
O
 
Ester (±)-4.75. To a solution of alcohol (±)-4.73 (46.7 mg, 0.14 mmol) in 20 mL 
of dry CH2Cl2 was added DMAP (58.5 mg, 0.21 mmol) followed by EDCI.HCl (40.0 
mg, 0.21 mmol). The reaction was stirred at ambient temperature (22 oC) for 10 min 
until all solids well dissolved and isovaleric acid (4.74) (18.5 µL, 0.17 mmol) was 
added. The mixture was stirred for 4 h and quenched with saturated NaHCO3 solution. 
The organic layer was separated by separatory funnel and the aqueous layer was 
extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine 
(50 mL), dried over anhydrous MgSO4, and concentrated in vacuo. Purification of the 
crude product by flash chromatography on SiO2 eluting with hexanes:EtOAc (7:3) gave 
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44.5 mg (75%) of ester (±)-4.75 as a colorless oil: Rf = 0.30 (3:7-EtOAc/hexanes); IR 
(thin film) 3544, 2946, 2925, 1824, 1720, 1465, 1294, 731 cm-1; 1H-NMR (500 MHz, 
CDCl3) δ 4.95 (t, J = 4.0 Hz, 1H), 4.23 (dd, J = 5.0, 11.0 Hz, 1H), 3.97 (dd, J = 6.0, 11.0 
Hz, 1H), 3.83 (dd, J = 4.0, 8.0 Hz, 1H), 2.24 (dd, J = 5.5, 13 Hz, 1H), 2.20 (dd, J = 1.5, 
7.5 Hz, 2H), 2.14-2.07 (m, 1H), 1.98-1.92 (m, J = 5.5, 12.0 Hz, 1H), 1.86-1.79 (m, 1H), 
1.77-1.69 (m, 3H), 1.67-1.56 (m, 2H), 1.52-1.45 (m, 2H), 1.44-1.36 (m, 3H), 1.25 (s, 
2H), 1.20-1.15 (m, 3H), 1.04 (s, 3H), 0.99 (s, 3H), 0.96 (d, J = 1.0 Hz, 3H), 0.95 (d, J = 
1.0 Hz, 3H), 0.88 (m, 3H); 13C-NMR (125 MHz, CDCl3) δ 173.2, 171.7, 77.5, 76.1, 
66.9, 53.9, 46.2, 44.2, 43.8, 43.5, 42.1, 38.8, 36.5, 36.2, 31.6, 31.5, 30.9, 29.8, 28.6, 
27.7, 25.7, 25.1, 22.6, 21.2, 19.2; HRMS (ESI+) Calcd for C25H41O5 [M+H]: 421.2954. 
Found: 421.2945. 
 
OBn
O
H
O
O H
H
H
(+)-4.52
HO
O
O
H
HO
(+)-4.52a
H
H
 
Alcohol (+)-4.54a. To a solution of benzyl ether (+)-4.52 (150.0 mg, 0.50 mmol) 
in 30 mL of EtOH was added Pd(OH)2 on carbon (30.0 mg, 20% Pd). The reaction was 
stirred under nitrogen atmosphere and connected to high vacuum. Air was removed 
under high vacuum and filled with nitrogen gas. This process was repeated 3 cycles. A 
hydrogen balloon was attached to the reaction flask. The heterogeneous solution was 
stirred vigorously at room temperature (22 oC) for 24 h. The reaction was filtered 
through a pad of Celite with Et2O, dried over anhydrous MgSO4, and concentrated in 
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vacuo. Purification of the crude product by flash chromatography on SiO2 eluting with 
hexanes:EtOAc (2:8) gave 43.7 mg (41%) of alcohol (+)-4.54a. Note that alcohol (+)-
4.54a slowly decomposed at room temperature (22 oC). Rf = 0.21 (7:3-EtOAc/hexanes); 
[α]D20 +26.7° (c 0.23, CHCl3); IR (thin film) 3449, 2931, 2867, 1821, 1711, 1643 cm-1; 
1H-NMR (500 MHz, CDCl3) δ 5.20 (d, J = 3.5 Hz, 1H), 4.03 (dd, J = 3.5, 8.0 Hz, 1H), 
3.80 (dd, J = 4.5, 11.0 Hz, 1H), 3.66 (dd, J = 5.5, 11.0 Hz, 1H), 3.07-3.01 (m, J = 7.0, 
13.5 Hz, 1H), 2.61 (dd, J = 6.5, 12.0 Hz, 1H), 2.52-2.45 (m, 1H), 2.40-2.38 (m, 1H), 
2.36 (dd, J = 7.5, 14.0 Hz, 1H), 2.17-2.11 (m, 1H), 2.05-1.97 (dt, J = 8.5, 13.3 Hz, 1H) 
1.67-1.53 (m, 2H), O−H proton unobservable; 13C-NMR (125 MHz, CDCl3) δ 210.1, 
169.9, 78.9, 65.4, 54.9, 49.0, 47.5, 37.0, 34.7, 29.9, 28.5; HRMS (ESI–) Calcd for 
C11H13O4 [M-H]: 209.0814. Found: 209.0821.  
 
HO
O
O
H
HO
O
O
H
HO
(+)-4.52a (+)-4.52c
O
O
 
Ester (+)-4.52c. To a solution of alcohol (+)-4.52a (120.0 mg, 0.57 mmol) in 50 
mL of dry CH2Cl2 was added DMAP (180 mg, 0.87 mmol) followed by EDCI.HCl 
(165.0 mg, 0.87 mmol). The reaction was stirred at ambient temperature (22 oC) for 10 
min until all solids well dissolved and isovaleric acid (0.1 mL, 0.87 mmol) was added. 
The mixture was stirred for 4 h and quenched with saturated NaHCO3 solution. The 
organic layer was separated by separatory funnel and the aqueous layer was extracted 
with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL), 
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dried over anhydrous MgSO4, and concentrated in vacuo. Purification of the crude 
product by flash chromatography on SiO2 eluting with hexanes:EtOAc (7:3) gave 125.8 
mg (81%) of ester (+)-4.52c as a colorless oil: Rf = 0.45 (1:1-EtOAc/hexanes); [α]D20 
+29.2° (c 0.21, CHCl3); IR (thin film) 3544, 2946, 2925, 1824, 1720, 1465, 1294, 731 
cm-1; 1H-NMR (500 MHz, CDCl3) δ 4.95 (t, J = 4.0 Hz, 1H), 4.23 (dd, J = 5.0, 11.0 Hz, 
1H), 3.97 (dd, J = 6.0, 11.0 Hz, 1H), 3.83 (dd, J = 4.0, 8.0 Hz, 1H), 2.24 (dd, J = 5.5, 13 
Hz, 1H), 2.20 (dd, J = 1.5, 7.5 Hz, 2H), 2.14-2.07 (m, 1H), 1.98-1.92 (m, J = 5.5, 12.0 
Hz, 1H), 1.86-1.79 (m, 1H), 1.77-1.69 (m, 3H), 1.67-1.56 (m, 2H), 1.52-1.45 (m, 2H), 
1.44-1.36 (m, 3H), 1.25 (s, 2H), 1.20-1.15 (m, 3H), 1.04 (s, 3H), 0.99 (s, 3H), 0.96 (d, J 
= 1.0 Hz, 3H), 0.95 (d, J = 1.0 Hz, 3H), 0.88 (m, 3H); 13C-NMR (125 MHz, CDCl3) δ 
173.2, 171.7, 77.5, 76.1, 66.9, 53.9, 46.2, 44.2, 43.8, 43.5, 42.1, 38.8, 36.5, 36.2, 31.6, 
31.5, 30.9, 29.8, 28.6, 27.7, 25.7, 25.1, 22.6, 21.2, 19.2; HRMS (ESI+) Calcd for 
C25H41O5 [M+H]: 421.2954. Found: 421.2945.  
 
O
O
H
O
O
O
O
H
O
O
+ H
(±)-4.76 (±)-4.77
O
O
O
H
H
(±)-4.75
HO
O
 
(±)-6,15-bis-epi-spongiolatone ((±)-4.76). To a solution of alcohol (±)-4.75 
(15.0 mg, 0.04 mmol) in 2 mL of dry CH2Cl2 was cooled at 0 oC. The reaction mixture 
was added triethylamine (30 µL, 0.21 mmol) followed by slow addition of thionyl 
chloride (SOCl2) (13 µL, 0.17 mmol). The reaction was allowed to slowly warm up to 
ambient temperature (22 oC) and stirred for 12 h. The mixture was then diluted with 5 
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mL of dry CH2Cl2 and quenched with pH 7 buffer solution. The organic layer was 
separated by separatory funnel and the aqueous layer was extracted with CH2Cl2 (10 mL 
x 3). The combined organic layers were washed with brine (10 mL), dried over 
anhydrous MgSO4, and concentrated in vacuo. Purification of the crude product by 
preparative thin layer chromatography developing twice with hexanes:EtOAc (9:1) gave 
1.6 mg of 6,15-bis-epi-spongiolatone ((±)-4.76) (20% brsm) as a colorless oil and 7.2 mg 
of (±)-4.77 (55% brsm) as a colorless oil, with 2.1 mg of recovered starting material 
((±)-4.75). (±)-4.77; Rf = 0.61 (3:7-EtOAc/hexanes). (±)-6,15-bis-epi-spongiolactone 
((±)-4.76); Rf = 0.61 (3:7-EtOAc/hexanes); IR (thin film) 3064, 2954, 2925, 1821, 1807, 
1637, 1267 cm-1; 1H-NMR (500 MHz, CDCl3) δ 4.97 (t, J = 4.0 Hz, 1H), 4.25 (dd, J = 
5.0, 11.0 Hz, 1H), 4.01 (dd, J = 6.0, 11.0 Hz, 1H), 3.87 (dd, J = 4.0, 8.0 Hz, 1H), 3.27 (d, 
J = 15.0 Hz, 1H), 2.41-2.34 (m, 2H), 2.34-2.27 (m, 1H), 2.21 (dd, J = 1.5, 8.0 Hz, 2H), 
2.14 (dd, J = 6.5, 13.0 Hz, 1H), 2.09 (dd, J = 6.5, 13.0 Hz, 1H), 2.00-1.94 (m, 2H), 1.92-
1.87 (m, 1H), 1.52-1.47 (m, 2H), 1.38-1.32 (m, 2H), 1.31-1.27 (m, 2H), 1.25 (bs, 2H), 
1.03 (s, 3H), 0.97 (s, 3H), 0.95 (s, 3H), 0.86 (s, 3H), 0.78 (s, 3H); 13C-NMR (125 MHz, 
CDCl3) δ 173.2, 171.2, 142.4, 126.8, 75.7, 67.4, 53.6, 50.1, 47.6, 43.5, 39.6, 39.4, 38.2, 
33.2, 33.1, 31.3, 31.2, 29.7, 26.7, 26.8, 25.7, 25.9, 22.4 (2), 20.9; HRMS (ESI+) Calcd 
for C25H38O4Li [M+Li]: 403.2848. Found: 403.2851. 
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Crystal and Molecular Structure Determination 
X-ray Diffraction Laboratory, Department of Chemistry, Texas A&M University 
 
Data Collection: A Leica MZ 75 microscope was used to identify a suitable 
colorless multi-faceted crystal with very well defined faces with dimensions (max, 
intermediate, and min) 0.08 mm x 0.06 mm x 0.03 mm from a representative sample of 
crystals of the same habit. The crystal mounted on a nylon loop was then placed in a 
cold nitrogen stream (Oxford) maintained at 110 K.  A BRUKER GADDS X-ray (three-
circle) diffractometer was employed for crystal screening, unit cell determination, and 
data collection. The goniometer was controlled using the FRAMBO software, v.4.1.05.14 
The sample was optically centered with the aid of a video camera such that no 
translations were observed as the crystal was rotated through all positions. The detector 
was set at 5.0 cm from the crystal sample. The X-ray radiation employed was generated 
from a Cu sealed X-ray tube (Kα = 1.5418 Å with a potential of 40 kV and a current of 
40 mA) fitted with a graphite monochromator in the parallel mode (175 mm collimator 
with 0.5 mm pinholes). 180 data frames were taken at widths of 0.5° with an exposure 
time of 15 seconds. These reflections were used in to determine the unit cell using 
Cell_Now.15 A suitable cell was found and refined by nonlinear least squares and 
Bravais lattice procedures. The unit cell was verified by examination of the h k l 
overlays on several frames of data. No super-cell or erroneous reflections were observed. 
                                                
14 FRAMBO v. 4.1.05  “Program for Data Collection on Area Detectors” BRUKER-
Nonius Inc., 5465 East Cheryl Parkway, Madison, WI 53711-5373 USA 
15 Sheldrick, G. M. “Cell_Now (version 2008/1): Program for Obtaining Unit Cell 
Constants from Single Crystal Data”: University of Göttingen, Germany 
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After careful examination of the unit cell, a standard data collection procedure was 
initiated using omega and phi scans.   
 
Data Reduction, Structure Solution, and Refinement: Integrated intensity 
information for each reflection was obtained by reduction of the data frames with 
SAINTplus.16 The integration method employed a three dimensional profiling algorithm 
and all data were corrected for Lorentz and polarization factors, as well as for crystal 
decay effects. Finally the data was merged and scaled to produce a suitable data set. 
SADABS17 was employed to correct the data for absorption effects. Systematic 
reflection conditions and statistical tests indicated the space group P-1. A solution was 
obtained readily using SHELXTL (SHELXS).5 All non-hydrogen atoms were refined 
with anisotropic thermal parameters. The Hydrogen atoms bound to carbon were placed 
in idealized positions [C–H = 0.96 Å, Uiso(H) = 1.2 x Uiso(C)] and refined using riding 
model. The structure was refined (weighted least squares refinement on F2) to 
convergence.18 X-seed was employed for the final data presentation and structure plots.19  
 
 
 
 
 
 
                                                
16 SAINT (Version 7). “Program for Data Integration from Area Detector Frames”, 
Bruker–Nonius Inc., 5465 East Cheryl Parkway, Madison, WI 53711-5373 USA  
17 Sheldrick, G.M. “SADABS (version 2008/1): Program for Absorption Correction for 
Data from Area Detector Frames”, University of Göttingen, 2008 
18 Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122. 
19 Barbour, L.J.,(2001) "X-Seed (version 2.0): A Software Tool for Supramolecular 
Crystallography" J. Supramol. Chem. 2001, 1, 189-191. 
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Report:   November 02, 2009 
Structure:   DRB_091030_G ((±)-4.60) 
Operator:  Dr. Nattamai Bhuvanesh 
  
 
Figure A-9. Single X-ray structure of (±)-4.60. 
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Table A-12. Crystal data and structure refinement for DRB091030_G ((±)-4.60). 
Identification code  drb1030 
Empirical formula  C18 H20 O4 
Formula weight  300.34 
Temperature  110(2) K 
Wavelength  1.54178 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.9726(9) Å a= 70.138(8)°. 
 b = 10.9573(16) Å b= 88.964(9)°. 
 c = 12.5060(18) Å g = 84.535(9)°. 
Volume 766.16(19) Å3 
Z 2 
Density (calculated) 1.302 Mg/m3 
Absorption coefficient 0.743 mm-1 
F(000) 320 
Crystal size 0.08 x 0.06 x 0.03 mm3 
Theta range for data collection 3.76 to 60.00°. 
Index ranges -6<=h<=6, -12<=k<=12, -14<=l<=14 
Reflections collected 7535 
Independent reflections 2149 [R(int) = 0.0389] 
Completeness to theta = 60.00° 93.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9780 and 0.9429 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2149 / 0 / 199 
Goodness-of-fit on F2 1.020 
Final R indices [I>2sigma(I)] R1 = 0.0393, wR2 = 0.0969 
R indices (all data) R1 = 0.0548, wR2 = 0.1060 
Largest diff. peak and hole 0.136 and -0.218 e.Å-3 
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Table A-13. Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for DRB091030_G ((±)-4.60). U(eq) is defined as one third of the 
trace of the orthogonalized Uij tensor. 
_______________________________________________________________________ 
 x y z U(eq) 
_______________________________________________________________________ 
C(1) 10152(3) 5262(2) 1188(2) 34(1) 
C(2) 8303(3) 4513(2) 1877(2) 30(1) 
C(3) 6851(3) 5832(2) 1396(2) 26(1) 
C(4) 8577(3) 4222(2) 3159(2) 34(1) 
C(5) 8131(3) 5566(2) 3275(1) 27(1) 
C(6) 6200(3) 6243(2) 2408(1) 24(1) 
C(7) 5772(3) 7692(2) 2264(1) 26(1) 
C(8) 5226(3) 7813(2) 3434(1) 30(1) 
C(9) 6963(3) 7053(2) 4368(2) 33(1) 
C(10) 7538(3) 5660(2) 4414(2) 28(1) 
C(11) 3827(3) 8383(2) 1458(1) 28(1) 
C(12) 2464(3) 8936(2) -400(1) 29(1) 
C(13) 2950(3) 8883(2) -1570(2) 27(1) 
C(14) 4986(3) 8341(2) -1839(2) 31(1) 
C(15) 5353(3) 8336(2) -2940(2) 36(1) 
C(16) 3698(4) 8863(2) -3769(2) 37(1) 
C(17) 1653(4) 9385(2) -3493(2) 41(1) 
C(18) 1290(3) 9395(2) -2406(2) 34(1) 
O(1) 8892(2) 6438(1) 820(1) 32(1) 
O(2) 12073(2) 5049(2) 976(1) 49(1) 
O(3) 7526(2) 4728(1) 5289(1) 34(1) 
O(4) 4331(2) 8384(1) 340(1) 29(1) 
______________________________________________________________________
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Table A-14. Bond lengths [Å] and angles [°] for DRB091030_G ((±)-4.60). 
_____________________________________________________  
C(1)-O(2)  1.193(2) 
C(1)-O(1)  1.365(2) 
C(1)-C(2)  1.514(3) 
C(2)-C(4)  1.533(3) 
C(2)-C(3)  1.547(3) 
C(2)-H(2)  1.0000 
C(3)-O(1)  1.497(2) 
C(3)-C(6)  1.515(2) 
C(3)-H(3)  1.0000 
C(4)-C(5)  1.526(2) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-C(10)  1.496(2) 
C(5)-C(6)  1.546(2) 
C(5)-H(5)  1.0000 
C(6)-C(7)  1.532(2) 
C(6)-H(6)  1.0000 
C(7)-C(11)  1.515(2) 
C(7)-C(8)  1.540(2) 
C(7)-H(7)  1.0000 
C(8)-C(9)  1.534(2) 
C(8)-H(8A)  0.9900 
C(8)-H(8B)  0.9900 
C(9)-C(10)  1.514(3) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-O(3)  1.218(2) 
C(11)-O(4)  1.424(2) 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
C(12)-O(4)  1.413(2) 
C(12)-C(13)  1.505(2) 
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Table A-14. Bond lengths [Å] and angles [°] for DRB091030_G ((±)-4.60) (continued). 
_____________________________________________________  
C(12)-H(12A)  0.9900 
C(12)-H(12B)  0.9900 
C(13)-C(18)  1.387(3) 
C(13)-C(14)  1.389(3) 
C(14)-C(15)  1.391(3) 
C(14)-H(14)  0.9500 
C(15)-C(16)  1.381(3) 
C(15)-H(15)  0.9500 
C(16)-C(17)  1.387(3) 
C(16)-H(16)  0.9500 
C(17)-C(18)  1.377(3) 
C(17)-H(17)  0.9500 
C(18)-H(18)  0.9500 
O(2)-C(1)-O(1) 126.59(18) 
O(2)-C(1)-C(2) 137.93(19) 
O(1)-C(1)-C(2) 95.47(14) 
C(1)-C(2)-C(4) 113.12(15) 
C(1)-C(2)-C(3) 84.07(14) 
C(4)-C(2)-C(3) 106.96(14) 
C(1)-C(2)-H(2) 116.1 
C(4)-C(2)-H(2) 116.1 
C(3)-C(2)-H(2) 116.1 
O(1)-C(3)-C(6) 112.02(13) 
O(1)-C(3)-C(2) 88.94(13) 
C(6)-C(3)-C(2) 106.09(14) 
O(1)-C(3)-H(3) 115.5 
C(6)-C(3)-H(3) 115.5 
C(2)-C(3)-H(3) 115.5 
C(5)-C(4)-C(2) 103.13(14) 
C(5)-C(4)-H(4A) 111.1 
C(2)-C(4)-H(4A) 111.1 
C(5)-C(4)-H(4B) 111.1 
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Table A-14. Bond lengths [Å] and angles [°] for DRB091030_G ((±)-4.60) (continued). 
_____________________________________________________  
C(2)-C(4)-H(4B) 111.1 
H(4A)-C(4)-H(4B) 109.1 
C(10)-C(5)-C(4) 119.10(15) 
C(10)-C(5)-C(6) 110.14(14) 
C(4)-C(5)-C(6) 103.63(14) 
C(10)-C(5)-H(5) 107.8 
C(4)-C(5)-H(5) 107.8 
C(6)-C(5)-H(5) 107.8 
C(3)-C(6)-C(7) 120.15(14) 
C(3)-C(6)-C(5) 103.17(13) 
C(7)-C(6)-C(5) 111.14(14) 
C(3)-C(6)-H(6) 107.2 
C(7)-C(6)-H(6) 107.2 
C(5)-C(6)-H(6) 107.2 
C(11)-C(7)-C(6) 112.98(15) 
C(11)-C(7)-C(8) 108.16(14) 
C(6)-C(7)-C(8) 108.58(13) 
C(11)-C(7)-H(7) 109.0 
C(6)-C(7)-H(7) 109.0 
C(8)-C(7)-H(7) 109.0 
C(9)-C(8)-C(7) 113.96(14) 
C(9)-C(8)-H(8A) 108.8 
C(7)-C(8)-H(8A) 108.8 
C(9)-C(8)-H(8B) 108.8 
C(7)-C(8)-H(8B) 108.8 
H(8A)-C(8)-H(8B) 107.7 
C(10)-C(9)-C(8) 112.83(15) 
C(10)-C(9)-H(9A) 109.0 
C(8)-C(9)-H(9A) 109.0 
C(10)-C(9)-H(9B) 109.0 
C(8)-C(9)-H(9B) 109.0 
H(9A)-C(9)-H(9B) 107.8 
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Table A-14. Bond lengths [Å] and angles [°] for DRB091030_G ((±)-4.60) (continued). 
_____________________________________________________  
O(3)-C(10)-C(5) 124.32(16) 
O(3)-C(10)-C(9) 123.08(16) 
C(5)-C(10)-C(9) 112.60(15) 
O(4)-C(11)-C(7) 110.19(14) 
O(4)-C(11)-H(11A) 109.6 
C(7)-C(11)-H(11A) 109.6 
O(4)-C(11)-H(11B) 109.6 
C(7)-C(11)-H(11B) 109.6 
H(11A)-C(11)-H(11B) 108.1 
O(4)-C(12)-C(13) 110.96(14) 
O(4)-C(12)-H(12A) 109.4 
C(13)-C(12)-H(12A) 109.4 
O(4)-C(12)-H(12B) 109.4 
C(13)-C(12)-H(12B) 109.4 
H(12A)-C(12)-H(12B) 108.0 
C(18)-C(13)-C(14) 119.04(17) 
C(18)-C(13)-C(12) 118.38(16) 
C(14)-C(13)-C(12) 122.58(16) 
C(13)-C(14)-C(15) 120.05(18) 
C(13)-C(14)-H(14) 120.0 
C(15)-C(14)-H(14) 120.0 
C(16)-C(15)-C(14) 120.39(18) 
C(16)-C(15)-H(15) 119.8 
C(14)-C(15)-H(15) 119.8 
C(15)-C(16)-C(17) 119.48(18) 
C(15)-C(16)-H(16) 120.3 
C(17)-C(16)-H(16) 120.3 
C(18)-C(17)-C(16) 120.18(19) 
C(18)-C(17)-H(17) 119.9 
C(16)-C(17)-H(17) 119.9 
C(17)-C(18)-C(13) 120.84(18) 
C(17)-C(18)-H(18) 119.6 
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Table A-14. Bond lengths [Å] and angles [°] for DRB091030_G ((±)-4.60) (continued). 
_____________________________________________________  
C(13)-C(18)-H(18) 119.6 
C(1)-O(1)-C(3) 91.34(13) 
C(12)-O(4)-C(11) 110.73(13) 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms. 
 
Table A-15. Anisotropic displacement parameters (Å2x 103) for DRB091030_G ((±)-
4.60). The anisotropic displacement factor exponent takes the form: -2p2[ h2 a*2U11 + 
... + 2 h k a* b* U12 ]. 
_______________________________________________________________________ 
 U11 U22  U33 U23 U13 U12 
_______________________________________________________________________ 
C(1) 32(1)  44(1) 35(1)  -26(1) 3(1)  -6(1) 
C(2) 31(1)  29(1) 37(1)  -17(1) 2(1)  -5(1) 
C(3) 27(1)  26(1) 28(1)  -12(1) 4(1)  -7(1) 
C(4) 39(1)  25(1) 36(1)  -10(1) -2(1)  0(1) 
C(5) 31(1)  24(1) 25(1)  -6(1) 2(1)  -4(1) 
C(6) 28(1)  22(1) 23(1)  -6(1) 4(1)  -6(1) 
C(7) 33(1)  22(1) 23(1)  -5(1) 4(1)  -5(1) 
C(8) 41(1)  24(1) 26(1)  -10(1) 3(1)  -1(1) 
C(9) 43(1)  31(1) 25(1)  -11(1) 3(1)  -1(1) 
C(10) 25(1)  31(1) 26(1)  -5(1) 0(1)  -3(1) 
C(11) 37(1)  23(1) 24(1)  -8(1) 4(1)  -2(1) 
C(12) 32(1)  23(1) 28(1)  -4(1) 2(1)  -3(1) 
C(13) 32(1)  19(1) 26(1)  -5(1) 2(1)  -5(1) 
C(14) 37(1)  25(1) 31(1)  -10(1) 0(1)  -3(1) 
C(15) 42(1)  31(1) 38(1)  -17(1) 8(1)  -4(1) 
C(16) 57(1)  30(1) 28(1)  -13(1) 6(1)  -9(1) 
C(17) 52(1)  40(1) 29(1)  -10(1) -8(1)  -2(1) 
C(18) 36(1)  34(1) 31(1)  -9(1) -1(1)  0(1) 
O(1) 35(1)  34(1) 33(1)  -16(1) 11(1)  -12(1) 
O(2) 31(1)  72(1) 61(1)  -43(1) 9(1)  -8(1) 
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Table A-15. Anisotropic displacement parameters (Å2x 103) for DRB091030_G ((±)-
4.60). The anisotropic displacement factor exponent takes the form: -2p2[ h2 a*2U11 + 
... + 2 h k a* b* U12 ] (continued). 
_______________________________________________________________________ 
 U11 U22  U33 U23 U13 U12 
_______________________________________________________________________ 
O(3) 30(1)  37(1) 28(1)  -1(1) 2(1)  -6(1) 
O(4) 33(1)  30(1) 21(1)  -8(1) -1(1)  2(1) 
 
Table A-16. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 
10 3) for DRB091030_G (4.60). 
_______________________________________________________________________ 
 x  y  z  U(eq) 
_______________________________________________________________________ 
H(2) 7837 3785 1644 37 
H(3) 5582 5851 878 32 
H(4A) 7473 3629 3592 41 
H(4B) 10114 3828 3427 41 
H(5) 9494 6043 3007 32 
H(6) 4804 5826 2728 29 
H(7) 7164 8128 1971 31 
H(8A) 5122 8745 3359 36 
H(8B) 3735 7495 3669 36 
H(9A) 8354 7505 4234 39 
H(9B) 6367 7049 5113 39 
H(11A) 2452 7937 1724 34 
H(11B) 3538 9291 1448 34 
H(12A) 2097 9854 -449 35 
H(12B) 1142 8455 -92 35 
H(14) 6129 7974 -1272 37 
H(15) 6751 7968 -3122 43 
H(16) 3958 8868 -4522 45 
H(17) 499 9738 -4057 49 
H(18) -116 9756 -2225 41 
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Report:   November 18, 2010 
Structure:   DR77 ((±)-4.71) 
Operator:  Dr. Joseph H. Reibenspies 
 
 
Figure A-10. Single X-ray structure of (±)-4.71. 
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Table A-17. Crystal data and structure refinement for dr77 ((±)-4.71). 
Identification code  dr77 
Empirical formula  C27 H36 O4 
Formula weight  424.56 
Temperature  296(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 8.4876(4) Å a= 90°. 
 b = 30.4533(16) Å b= 108.998(3)°. 
 c = 9.6704(5) Å g = 90°. 
Volume 2363.4(2) Å3 
Z 4 
Density (calculated) 1.193 Mg/m3 
Absorption coefficient 0.621 mm-1 
F(000) 920 
Crystal size 2.00 x 0.30 x 0.01 mm3 
Theta range for data collection 5.05 to 60.00°. 
Index ranges -9<=h<=9, -34<=k<=34, -10<=l<=10 
Reflections collected 16694 
Independent reflections 3198 [R(int) = 0.0372] 
Completeness to theta = 60.00° 90.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9938 and 0.3700 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3198 / 0 / 285 
Goodness-of-fit on F2 1.000 
Final R indices [I>2sigma(I)] R1 = 0.0441, wR2 = 0.1087 
R indices (all data) R1 = 0.0537, wR2 = 0.1159 
Extinction coefficient 0.0045(4) 
Largest diff. peak and hole 0.177 and -0.200 e.Å-3 
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Table A-18. Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for dr77 ((±)-4.71). U(eq) is defined as one third of the trace of 
the orthogonalized Uij tensor. 
_______________________________________________________________________ 
 x y z U(eq) 
_______________________________________________________________________ 
O(1) -2339(2) -51(1) 2552(2) 27(1) 
O(2) -4521(2) 427(1) 1818(2) 39(1) 
O(3) 2242(2) 792(1) 1211(1) 25(1) 
O(4) 2684(2) -653(1) 3240(2) 26(1) 
C(1) -1289(2) -85(1) 1571(2) 23(1) 
C(2) -3353(2) 243(1) 1631(2) 27(1) 
C(3) -2443(2) 248(1) 528(2) 23(1) 
C(4) -1423(2) 668(1) 588(2) 21(1) 
C(5) -34(2) 632(1) 2065(2) 19(1) 
C(6) 1572(2) 908(1) 2355(2) 20(1) 
C(7) 2774(2) 774(1) 3863(2) 25(1) 
C(8) 3078(2) 281(1) 4103(2) 26(1) 
C(9) 1457(2) 21(1) 3763(2) 22(1) 
C(10) 379(2) 136(1) 2214(2) 20(1) 
C(11) 1288(2) 1424(1) 2272(2) 24(1) 
C(12) 419(3) 1571(1) 3381(2) 30(1) 
C(13) -666(3) 1985(1) 3017(3) 35(1) 
C(14) -1937(3) 1928(1) 1479(3) 39(1) 
C(15) -1139(3) 1781(1) 391(3) 34(1) 
C(16) 269(3) 1554(1) 744(2) 27(1) 
C(17) 3005(3) 1651(1) 2609(3) 36(1) 
C(18) -1591(4) 2027(1) 4130(3) 50(1) 
C(19) 344(3) 2403(1) 3060(3) 46(1) 
C(20) 1747(3) -466(1) 4080(2) 28(1) 
C(21) 2915(3) -1109(1) 3518(2) 28(1) 
C(22) 4198(2) -1296(1) 2919(2) 27(1) 
C(23) 4541(3) -1745(1) 3091(3) 37(1) 
C(24) 5701(3) -1935(1) 2554(3) 46(1) 
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Table A-18. Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for dr77 ((±)-4.71). U(eq) is defined as one third of the trace of 
the orthogonalized Uij tensor (continued). 
_______________________________________________________________________ 
 x y z U(eq) 
_______________________________________________________________________ 
C(25) 6540(3) -1681(1) 1835(3) 46(1) 
C(26) 6229(3) -1237(1) 1678(3) 39(1) 
C(27) 5079(3) -1045(1) 2233(2) 30(1) 
_______________________________________________________________________ 
 
Table A-19. Bond lengths [Å] and angles [°] for dr77 ((±)-4.71). 
_____________________________________________________  
O(1)-C(2)  1.356(2) 
O(1)-C(1)  1.501(2) 
O(2)-C(2)  1.201(2) 
O(3)-C(6)  1.443(2) 
O(3)-H(3)  0.8200 
O(4)-C(21)  1.415(2) 
O(4)-C(20)  1.427(2) 
C(1)-C(10)  1.507(3) 
C(1)-C(3)  1.537(3) 
C(1)-H(1)  0.9800 
C(2)-C(3)  1.507(3) 
C(3)-C(4)  1.534(3) 
C(3)-H(3A)  0.9800 
C(4)-C(5)  1.531(3) 
C(4)-H(4A)  0.9700 
C(4)-H(4B)  0.9700 
C(5)-C(6)  1.547(3) 
C(5)-C(10)  1.547(2) 
C(5)-H(5)  0.9800 
C(6)-C(7)  1.538(3) 
C(6)-C(11)  1.587(3) 
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Table A-19. Bond lengths [Å] and angles [°] for dr77 ((±)-4.71) (continued). 
_____________________________________________________  
C(7)-C(8)  1.529(3) 
C(7)-H(7A)  0.9700 
C(7)-H(7B)  0.9700 
C(8)-C(9)  1.527(3) 
C(8)-H(8A)  0.9700 
C(8)-H(8B)  0.9700 
C(9)-C(20)  1.518(3) 
C(9)-C(10)  1.520(3) 
C(9)-H(9)  0.9800 
C(10)-H(10)  0.9800 
C(11)-C(16)  1.502(3) 
C(11)-C(17)  1.548(3) 
C(11)-C(12)  1.553(3) 
C(12)-C(13)  1.532(3) 
C(12)-H(12A)  0.9700 
C(12)-H(12B)  0.9700 
C(13)-C(19)  1.528(3) 
C(13)-C(18)  1.530(3) 
C(13)-C(14)  1.537(3) 
C(14)-C(15)  1.494(3) 
C(14)-H(14A)  0.9700 
C(14)-H(14B)  0.9700 
C(15)-C(16)  1.326(3) 
C(15)-H(15)  0.9300 
C(16)-H(16)  0.9300 
C(17)-H(17A)  0.9600 
C(17)-H(17B)  0.9600 
C(17)-H(17C)  0.9600 
C(18)-H(18A)  0.9600 
C(18)-H(18B)  0.9600 
C(18)-H(18C)  0.9600 
C(19)-H(19A)  0.9600 
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Table A-19. Bond lengths [Å] and angles [°] for dr77 ((±)-4.71) (continued). 
_____________________________________________________  
C(19)-H(19B)  0.9600 
C(19)-H(19C)  0.9600 
C(20)-H(20A)  0.9700 
C(20)-H(20B)  0.9700 
C(21)-C(22)  1.503(3) 
C(21)-H(21A)  0.9700 
C(21)-H(21B)  0.9700 
C(22)-C(27)  1.382(3) 
C(22)-C(23)  1.396(3) 
C(23)-C(24)  1.381(3) 
C(23)-H(23)  0.9300 
C(24)-C(25)  1.382(3) 
C(24)-H(24)  0.9300 
C(25)-C(26)  1.378(3) 
C(25)-H(25)  0.9300 
C(26)-C(27)  1.387(3) 
C(26)-H(26)  0.9300 
C(27)-H(27)  0.9300 
C(2)-O(1)-C(1) 90.63(14) 
C(6)-O(3)-H(3) 109.5 
C(21)-O(4)-C(20) 110.64(14) 
O(1)-C(1)-C(10) 112.36(15) 
O(1)-C(1)-C(3) 89.30(13) 
C(10)-C(1)-C(3) 106.75(15) 
O(1)-C(1)-H(1) 115.2 
C(10)-C(1)-H(1) 115.2 
C(3)-C(1)-H(1) 115.2 
O(2)-C(2)-O(1) 126.0(2) 
O(2)-C(2)-C(3) 137.7(2) 
O(1)-C(2)-C(3) 96.26(15) 
C(2)-C(3)-C(4) 113.24(16) 
C(2)-C(3)-C(1) 83.82(15) 
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Table A-19. Bond lengths [Å] and angles [°] for dr77 ((±)-4.71) (continued). 
_____________________________________________________  
C(4)-C(3)-C(1) 107.08(15) 
C(2)-C(3)-H(3A) 116.1 
C(4)-C(3)-H(3A) 116.1 
C(1)-C(3)-H(3A) 116.1 
C(5)-C(4)-C(3) 103.30(15) 
C(5)-C(4)-H(4A) 111.1 
C(3)-C(4)-H(4A) 111.1 
C(5)-C(4)-H(4B) 111.1 
C(3)-C(4)-H(4B) 111.1 
H(4A)-C(4)-H(4B) 109.1 
C(4)-C(5)-C(6) 119.75(15) 
C(4)-C(5)-C(10) 103.79(14) 
C(6)-C(5)-C(10) 110.74(15) 
C(4)-C(5)-H(5) 107.3 
C(6)-C(5)-H(5) 107.3 
C(10)-C(5)-H(5) 107.3 
O(3)-C(6)-C(7) 110.94(15) 
O(3)-C(6)-C(5) 105.80(14) 
C(7)-C(6)-C(5) 107.57(15) 
O(3)-C(6)-C(11) 107.08(14) 
C(7)-C(6)-C(11) 110.67(15) 
C(5)-C(6)-C(11) 114.71(15) 
C(8)-C(7)-C(6) 115.52(16) 
C(8)-C(7)-H(7A) 108.4 
C(6)-C(7)-H(7A) 108.4 
C(8)-C(7)-H(7B) 108.4 
C(6)-C(7)-H(7B) 108.4 
H(7A)-C(7)-H(7B) 107.5 
C(9)-C(8)-C(7) 112.39(16) 
C(9)-C(8)-H(8A) 109.1 
C(7)-C(8)-H(8A) 109.1 
C(9)-C(8)-H(8B) 109.1 
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Table A-19. Bond lengths [Å] and angles [°] for dr77 ((±)-4.71) (continued). 
_____________________________________________________  
C(7)-C(8)-H(8B) 109.1 
H(8A)-C(8)-H(8B) 107.9 
C(20)-C(9)-C(10) 115.49(17) 
C(20)-C(9)-C(8) 112.78(16) 
C(10)-C(9)-C(8) 107.69(15) 
C(20)-C(9)-H(9) 106.8 
C(10)-C(9)-H(9) 106.8 
C(8)-C(9)-H(9) 106.8 
C(1)-C(10)-C(9) 119.14(16) 
C(1)-C(10)-C(5) 104.11(15) 
C(9)-C(10)-C(5) 111.23(15) 
C(1)-C(10)-H(10) 107.3 
C(9)-C(10)-H(10) 107.3 
C(5)-C(10)-H(10) 107.3 
C(16)-C(11)-C(17) 106.89(16) 
C(16)-C(11)-C(12) 110.62(16) 
C(17)-C(11)-C(12) 110.61(17) 
C(16)-C(11)-C(6) 109.90(15) 
C(17)-C(11)-C(6) 108.30(16) 
C(12)-C(11)-C(6) 110.43(15) 
C(13)-C(12)-C(11) 117.65(17) 
C(13)-C(12)-H(12A) 107.9 
C(11)-C(12)-H(12A) 107.9 
C(13)-C(12)-H(12B) 107.9 
C(11)-C(12)-H(12B) 107.9 
H(12A)-C(12)-H(12B) 107.2 
C(19)-C(13)-C(18) 108.78(18) 
C(19)-C(13)-C(12) 112.94(19) 
C(18)-C(13)-C(12) 108.38(18) 
C(19)-C(13)-C(14) 109.30(19) 
C(18)-C(13)-C(14) 109.3(2) 
C(12)-C(13)-C(14) 108.07(17) 
 227 
Table A-19. Bond lengths [Å] and angles [°] for dr77 ((±)-4.71) (continued). 
_____________________________________________________  
C(15)-C(14)-C(13) 112.24(19) 
C(15)-C(14)-H(14A) 109.2 
C(13)-C(14)-H(14A) 109.2 
C(15)-C(14)-H(14B) 109.2 
C(13)-C(14)-H(14B) 109.2 
H(14A)-C(14)-H(14B) 107.9 
C(16)-C(15)-C(14) 123.6(2) 
C(16)-C(15)-H(15) 118.2 
C(14)-C(15)-H(15) 118.2 
C(15)-C(16)-C(11) 124.98(19) 
C(15)-C(16)-H(16) 117.5 
C(11)-C(16)-H(16) 117.5 
C(11)-C(17)-H(17A) 109.5 
C(11)-C(17)-H(17B) 109.5 
H(17A)-C(17)-H(17B) 109.5 
C(11)-C(17)-H(17C) 109.5 
H(17A)-C(17)-H(17C) 109.5 
H(17B)-C(17)-H(17C) 109.5 
C(13)-C(18)-H(18A) 109.5 
C(13)-C(18)-H(18B) 109.5 
H(18A)-C(18)-H(18B) 109.5 
C(13)-C(18)-H(18C) 109.5 
H(18A)-C(18)-H(18C) 109.5 
H(18B)-C(18)-H(18C) 109.5 
C(13)-C(19)-H(19A) 109.5 
C(13)-C(19)-H(19B) 109.5 
H(19A)-C(19)-H(19B) 109.5 
C(13)-C(19)-H(19C) 109.5 
H(19A)-C(19)-H(19C) 109.5 
H(19B)-C(19)-H(19C) 109.5 
O(4)-C(20)-C(9) 111.04(15) 
O(4)-C(20)-H(20A) 109.4 
 228 
Table A-19. Bond lengths [Å] and angles [°] for dr77 ((±)-4.71) (continued). 
_____________________________________________________  
C(9)-C(20)-H(20A) 109.4 
O(4)-C(20)-H(20B) 109.4 
C(9)-C(20)-H(20B) 109.4 
H(20A)-C(20)-H(20B) 108.0 
O(4)-C(21)-C(22) 111.91(16) 
O(4)-C(21)-H(21A) 109.2 
C(22)-C(21)-H(21A) 109.2 
O(4)-C(21)-H(21B) 109.2 
C(22)-C(21)-H(21B) 109.2 
H(21A)-C(21)-H(21B) 107.9 
C(27)-C(22)-C(23) 118.44(19) 
C(27)-C(22)-C(21) 123.16(17) 
C(23)-C(22)-C(21) 118.38(18) 
C(24)-C(23)-C(22) 120.7(2) 
C(24)-C(23)-H(23) 119.6 
C(22)-C(23)-H(23) 119.6 
C(23)-C(24)-C(25) 120.2(2) 
C(23)-C(24)-H(24) 119.9 
C(25)-C(24)-H(24) 119.9 
C(26)-C(25)-C(24) 119.5(2) 
C(26)-C(25)-H(25) 120.2 
C(24)-C(25)-H(25) 120.2 
C(25)-C(26)-C(27) 120.4(2) 
C(25)-C(26)-H(26) 119.8 
C(27)-C(26)-H(26) 119.8 
C(22)-C(27)-C(26) 120.68(19) 
C(22)-C(27)-H(27) 119.7 
C(26)-C(27)-H(27) 119.7 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms. 
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Table A-20. Anisotropic displacement parameters  (Å2x 103) for dr77 ((±)-4.71). The 
anisotropic displacement factor exponent takes the form: -2p2[h2 a*2U11 + ... + 2 h k a* 
b* U12]. 
_______________________________________________________________________ 
 U11 U22  U33 U23 U13 U12 
_______________________________________________________________________ 
O(1) 26(1)  28(1) 32(1)  -2(1) 16(1)  -3(1) 
O(2) 23(1)  46(1) 52(1)  -6(1) 19(1)  3(1) 
O(3) 19(1)  30(1) 27(1)  -1(1) 10(1)  1(1) 
O(4) 33(1)  22(1) 26(1)  4(1) 13(1)  8(1) 
C(1) 26(1)  21(1) 26(1)  -4(1) 14(1)  -1(1) 
C(2) 18(1)  27(1) 35(1)  -7(1) 8(1)  -6(1) 
C(3) 17(1)  27(1) 24(1)  -6(1) 5(1)  -2(1) 
C(4) 18(1)  22(1) 24(1)  -1(1) 7(1)  1(1) 
C(5) 19(1)  19(1) 19(1)  -1(1) 8(1)  2(1) 
C(6) 18(1)  24(1) 21(1)  -2(1) 8(1)  0(1) 
C(7) 18(1)  31(1) 25(1)  -5(1) 5(1)  -2(1) 
C(8) 20(1)  34(1) 21(1)  2(1) 5(1)  6(1) 
C(9) 23(1)  25(1) 22(1)  2(1) 11(1)  6(1) 
C(10) 18(1)  20(1) 24(1)  -2(1) 10(1)  1(1) 
C(11) 28(1)  22(1) 25(1)  -2(1) 11(1)  -3(1) 
C(12) 40(1)  23(1) 32(1)  -2(1) 16(1)  -4(1) 
C(13) 49(1)  20(1) 46(2)  -3(1) 29(1)  0(1) 
C(14) 39(1)  25(1) 54(2)  4(1) 18(1)  4(1) 
C(15) 42(1)  23(1) 35(1)  3(1) 9(1)  0(1) 
C(16) 35(1)  20(1) 29(1)  1(1) 14(1)  -4(1) 
C(17) 35(1)  30(1) 44(2)  -3(1) 11(1)  -10(1) 
C(18) 72(2)  26(1) 68(2)  -4(1) 46(2)  3(1) 
C(19) 64(2)  22(1) 61(2)  -6(1) 33(2)  -4(1) 
C(20) 30(1)  29(1) 29(1)  5(1) 14(1)  7(1) 
C(21) 29(1)  21(1) 31(1)  2(1) 6(1)  1(1) 
C(22) 25(1)  24(1) 27(1)  -1(1) 1(1)  3(1) 
C(23) 39(1)  25(1) 47(2)  2(1) 14(1)  2(1) 
C(24) 49(2)  26(1) 64(2)  1(1) 20(1)  13(1) 
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Table A-20. Anisotropic displacement parameters (Å2x 103) for dr77 ((±)-4.71). The 
anisotropic displacement factor exponent takes the form: -2p2[h2 a*2U11 + ... + 2 h k a* 
b* U12] (continued). 
_______________________________________________________________________ 
 U11 U22  U33 U23 U13 U12 
_______________________________________________________________________ 
C(25) 46(2)  38(1) 62(2)  -3(1) 27(1)  12(1) 
C(26) 39(1)  37(1) 47(2)  3(1) 21(1)  5(1) 
C(27) 33(1)  23(1) 32(1)  1(1) 8(1)  4(1) 
 
Table A-21. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 
10 3) for dr77 ((±)-4.71). 
_______________________________________________________________________ 
 x  y  z  U(eq) 
_______________________________________________________________________ 
H(3) 3210 711 1576 30 
H(1) -1256 -376 1153 27 
H(3A) -3068 140 -451 28 
H(4A) -968 677 -211 26 
H(4B) -2096 928 549 26 
H(5) -520 708 2824 22 
H(7A) 3837 917 4006 30 
H(7B) 2338 885 4607 30 
H(8A) 3697 176 3483 31 
H(8B) 3752 229 5112 31 
H(9) 877 132 4417 27 
H(10) 1031 71 1568 24 
H(12A) -273 1330 3502 37 
H(12B) 1275 1617 4318 37 
H(14A) -2768 1714 1518 47 
H(14B) -2502 2206 1161 47 
H(15) -1656 1853 -587 41 
H(16) 655 1468 -12 32 
H(17A) 3610 1517 2036 55 
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Table A-21. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 
10 3) for dr77 ((±)-4.71) (continued). 
_______________________________________________________________________ 
 x  y  z  U(eq) 
_______________________________________________________________________ 
H(17B) 3624 1618 3629 55 
H(17C) 2845 1957 2370 55 
H(18A) -2277 2285 3918 74 
H(18B) -798 2050 5097 74 
H(18C) -2278 1773 4074 74 
H(19A) 1233 2419 3976 69 
H(19B) -368 2654 2959 69 
H(19C) 799 2399 2273 69 
H(20A) 2344 -508 5113 34 
H(20B) 683 -615 3850 34 
H(21A) 1864 -1259 3078 33 
H(21B) 3264 -1159 4565 33 
H(23) 3982 -1919 3573 44 
H(24) 5918 -2235 2676 55 
H(25) 7309 -1810 1460 56 
H(26) 6793 -1065 1198 47 
H(27) 4898 -743 2142 36 
_______________________________________________________________________ 
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NMR spectra 
O
O
F3C
hex-5-yn-1-yl 4,4,4-trifluorobutanoate (2.7a-2)  
 
 
 
 
1H-NMR (500 MHz) of hex-5-yn-1-yl-4,4,4-trifluorobutanoate (2.7a-2) in CDCl3 
 
 
 
13C-NMR (125 MHz) of hex-5-yn-1-yl-4,4,4-trifluorobutanoate (2.7a-2) in CDCl3 
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O
O
F3C
OPh
hex-5-yn-1-yl 2-benzoyl-4,4,4-trifluorobutanoate (2.7a-3)  
 
 
 
 
1H-NMR (500 MHz) of hex-5-yn-1-yl 2-benzoyl-4,4,4-trifluorobutanoate (2.7a-3)  
in CDCl3 
 
 
 
 
13C-NMR (125 MHz) of hex-5-yn-1-yl 2-benzoyl-4,4,4-trifluorobutanoate (2.7a-3)  
in CDCl3 
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N2
O
O
2.7a (HTFB)
F3C
 
 
 
1H-NMR (500 MHz) of hex-5-ynyl 2-diazo-4,4,4-trifluorobutanoate (2.7a, HTFB) 
 in CDCl3 
 
 
13C-NMR (125 MHz) of hex-5-ynyl 2-diazo-4,4,4-trifluorobutanoate (2.7a, HTFB)  
in CDCl3 
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19F NMR (300 MHz) of hex-5-ynyl 2-diazo-4,4,4-trifluorobutanoate (2.7a, HTFB)  
in CDCl3 (Trifluoroacetic acid was used as a standard; -76.55 ppm) 
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hex-5-yn-1-yl 3,3,3-trifluoropropanoate (2.7b-2)  
 
 
 
 
1H-NMR (500 MHz) of hex-5-yn-1-yl 3,3,3-trifluoropropanoate (2.7b-2) in CDCl3 
 
 
 
 
13C-NMR (125 MHz) of hex-5-yn-1-yl 3,3,3-trifluoropropanoate (2.7b-2) in CDCl3 
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hex-5-yn-1-yl 2-cyanoacetate (2.7c-2)  
 
 
 
 
1H-NMR (500 MHz) of hex-5-yn-1-yl 2-cyanoacetate (2.7c-2) in CDCl3 
 
 
 
 
13C-NMR (125 MHz) of hex-5-yn-1-yl 2-cyanoacetate (2.7c-2) in CDCl3 
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1H-NMR (500 MHz) of hex-5-ynyl 2-cyano-2-diazoacetate (2.7c) in CDCl3 
 
 
 
 
13C-NMR (125 MHz) of hex-5-ynyl 2-cyano-2-diazoacetate (2.7c) in CDCl3 
 239 
N3
O
OH
2-(4-azidophenyl)acetic acid (2.7d-2)  
 
 
 
 
1H-NMR (500 MHz) of 2-(4-azidophenyl)acetic acid (2.7d-2) in CDCl3 
 
 
 
 
13C-NMR (125 MHz) of 2-(4-azidophenyl)acetic acid (2.7d-2) in CDCl3 
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hex-5-yn-1-yl 2-(4-azidophenyl)acetate (2.7d-3)
 
1H-NMR (500 MHz) of hex-5-yn-1-yl 2-(4-azidophenyl)acetic acid (2.7d-3) in CDCl3 
 
 
 
 
13C-NMR (125 MHz) of hex-5-yn-1-yl 2-(4-azidophenyl)acetic acid (2.7d-3) in CDCl3 
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1H-NMR (500 MHz) of hex-5-ynyl 2-(4-azidophenyl)-2-diazoacetate (2.7d) 
in CDCl3 
 
 
 
13C-NMR (125 MHz) of hex-5-ynyl 2-(4-azidophenyl)-2-diazoacetate (2.7d) 
in CDCl3 
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1H-NMR (500 MHz) of gibberellic acid methyl ester 3-HTFB ether (2.8a) in CDCl3 
 
1
3C-NMR (125 MHz) of gibberellic acid methyl ester 3-HTFB ether (2.8a) in CDCl3 
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1H-NMR (500 MHz) of gibberellic acid methyl ester 13-HTFB ether (2.9a) in CDCl3 
 
 
13C-NMR (125 MHz) of gibberellic acid methyl ester 13-HTFB ether (2.9a) in CDCl3 
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1H-NMR (500 MHz) of gibberellic acid methyl ester 13-2.7d ether (2.8d) in CDCl3 
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1H-NMR (500 MHz) of brefeldin A 13-HTFB ether (2.4b) in CDCl3 
 
 
13C-NMR (125 MHz) of brefeldin A 13-HTFB ether (2.4b) in CDCl3 
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1H-NMR (500 MHz) of brefeldin A 13-HTFB ether (2.4bʹ′) in CDCl3 
 
 
13C-NMR (125 MHz) of brefeldin A 13-HTFB ether (2.4bʹ′) in CDCl3 
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1H-NMR (500 MHz) of paclitaxel 2’-HTFB ether (2.11b/2.11bʹ′) in CDCl3 
 
 
13C-NMR (125 MHz) of paclitaxel 2’-HTFB ether (2.11b/2.11bʹ′) in CDCl3 
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1H-NMR (500 MHz) of ephedrine 2-HTFB ether (2.12b/2.12bʹ′) in CDCl3 
 
 
 
13C-NMR (125 MHz) of ephedrine 2-HTFB ether (2.11b/2.11bʹ′) in CDCl3 
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1H-NMR (500 MHz) of FK506 32-HTFB ether (2.13b/2.13bʹ′) in CDCl3 
 
13C-NMR (125 MHz) of FK506 32-HTFB ether (2.13b/2.13bʹ′) in CDCl3 
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1H-NMR (500 MHz) of Lactimidomycin 7-HTFB ether (2.14b and 2.14bʹ′) in CDCl3 (a) 
purified 2.14bʹ′; (b) purified 2.14b; (c) recovered lactimidomycin (2.14a); (d) 
lactimidomycin (2.14a) 
a                
 
 
b               
 
c              
 
 
d 
~ 2 mg reaction 
 251 
O
OMe
O
O
F3CH2C
O
O
2.15/2.15'
H
 
 
1H-NMR (500 MHz) of fumagillol 6-HTFB ether (2.15/2.15ʹ′) in CDCl3 
 
 
 
13C-NMR (125 MHz) of fumagillol 6-HTFB ether (2.15/2.15ʹ′) in CDCl3 
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1H-NMR (500 MHz) of FK506-HTFB-Biotin Probe (2.19) 
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1H-NMR (500 MHz) of FK506-HBPA-Biotin Probe (2.20) 
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1H-NMR (500 MHz) of fumagillol 6-HBPA ether (2.21/2.21ʹ′) in CDCl3 
 
13C-NMR (125 MHz) of fumagillol 6-HBPA ether (2.21/2.21ʹ′) in CDCl3 
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MeO O
CO2tBu
4.47  
 
1H-NMR (500 MHz) of vinylogous ester 4.47 in CDCl3 
 
 
13C-NMR (125 MHz) of vinylogous ester 4.47 in CDCl3 
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MeO O
CO2tBu
OBn
 (±)-4.48  
 
1H-NMR (500 MHz) of α-Substituted ketone (±)-4.48 in CDCl3 
 
 
13C-NMR (125 MHz) of α-Substituted ketone (±)-4.48 in CDCl3 
 
 257 
O
CO2tBu
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 (±)-4.49  
 
1H-NMR (500 MHz) of α,β-Unsaturated ketone (±)-4.49 in CDCl3 
 
13C-NMR (125 MHz) of α,β-Unsaturated ketone (±)-4.49 in CDCl3 
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1H-NMR (500 MHz) of Alkene (±)-4.77 in CDCl3 
 
13C-NMR (125 MHz) of Alkene (±)-4.77 in CDCl3 
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1H-NMR (500 MHz) of Alkenyl acid (±)-4.56 in CDCl3 
 
 
13C-NMR (125 MHz) of Alkenyl acid (±)-4.56 in CDCl3 
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1H-NMR (500 MHz) of Aldehyde acid (±)-4.51 in CDCl3 
 
 
13C-NMR (125 MHz) of Aldehyde acid (±)-4.51 in CDCl3 
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1H-NMR (500 MHz) of Fused tricyclic β-lactone (±)-4.60 in CDCl3 
 
13C-NMR (125 MHz) of Fused tricyclic β-lactone (±)-4.60 in CDCl3 
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1H-NMR (500 MHz) of Fused tricyclic β-lactone (+)-4.52 in CDCl3 
 
13C-NMR (125 MHz) of Fused tricyclic β-lactone (+)-4.52 in CDCl3 
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Cl
4.69  
 
1H-NMR (500 MHz) of 3-chloro-1,5,5-trimethylcyclohex-1-ene 4.69 in CDCl3 
 
 
13C-NMR (125 MHz) of 3-chloro-1,5,5-trimethylcyclohex-1-ene 4.69 in CDCl3 
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1H-NMR (500 MHz) of Homoallylic alcohol (±)-4.71 in CDCl3 
 
13C-NMR (125 MHz) of Homoallylic alcohol (±)-4.71 in CDCl3 
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1H-NMR (500 MHz) of Alcohol (±)-4.73 in CDCl3 
 
13C-NMR (125 MHz) of Alcohol (±)-4.73 in CDCl3 
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1H-NMR (500 MHz) of Ester (±)-4.75 in CDCl3 
 
 
13C-NMR (125 MHz) of Ester (±)-4.75 in CDCl3 
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1H-NMR (500 MHz) of 6,15-Bis-epi-spongiolactone (±)-4.76 in CDCl3 
 
13C-NMR (125MHz) of 6,15-Bis-epi-spongiolactone (±)-4.76 in CDCl3 
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(±)-4.77  
 
1H-NMR (500 MHz) of spongiolactone derivative (±)-4.77 in CDCl3 
 
13C-NMR (125 MHz) of spongiolactone derivative (±)-4.77 in CDCl3 
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